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Abstract 
Alpha toxin is expressed by Clostridium perfringens during necrotic enteritis infection of chickens 
and causes great cellular damage in its active conformation. This project focussed on designing 
constructs with modifications to the gene sequence that resulted in inactivation of the toxin 
whilst retaining the immunogenicity of the native toxin. Three constructs were designed: plcInv, 
deletion of a section of the catalytic domain that inactivates the active site; plc104, the highly 
immunogenic carboxyl domain of the alpha toxin; and plc2, a multiple point mutagenesis 
designed to inactivate two key amino acids in the active site. Purification of the proteins 
demonstrated that plc2 had superior expression and was more stable than plcInv deletion 
protein.  These constructs were tested as both purified proteins and cloned to be expressed 
constitutively from an attenuated vaccine strain STM1, a Salmonella enterica serovar 
Typhimurium vaccine approved for poultry usage, using a hemolysin secretion system vector.  
 
As purified protein vaccines, the plc2 construct provided partial protection from gas gangrene 
infection in mice; while the other constructs elicited good humoral responses they did not induce 
a significant delay of disease onset. In mice, the delivery of these constructs via STM1 did not 
result in protection from gas gangrene challenge. In chicken immunogenicity trials the responses 
elicited by the STM1 delivered constructs were determined to be non-specific and cross-reactive 
with the STM1 vector. In the presence of pre-existing immunity to the most commonly isolated 
commensal, Salmonella enterica serovar Sofia, the vaccines and constructs did result in lower 
responses for the extracellularly delivered construct.  
 
In conclusion, these constructs based on the alpha toxin when delivered by STM1 were not 
effective immunogens in eliciting specific protective responses to gas gangrene challenge in mice 
and did not elicit strong responses in the immunogenicity trials in chickens. This failure to induce 
high antigen-specific responses does not preclude the use of the hemolysin system in STM1 as a 
 ~ xx ~ 
 
vaccine delivery system with a more immunogenic antigen. Ideally the most effective way to 
investigate these responses would be in a necrotic enteritis chicken model as this would 
determine if the responses are indeed ultimately protective.  
 
 ~ CHAPTER 1 ~ 
LITERATURE REVIEW 
1.1 Introduction 
Globally, the burden of disease and infection is diverse and inescapable. It is a shared affliction for 
all humanity and one that is constantly moderated by better hygiene, enhanced education, and 
improved vaccines and drug treatments. In terms of disease management, it is always more 
beneficial to prevent a disease or infection from occurring than to treat and cure it.  The 
development of vaccines is dependent on the knowledge of: what pathogen causes the disease; 
how it establishes itself in the host; how the host’s innate and cell-mediated immunity responds 
to pathogens; and how it maintains ongoing protection after the disease using antibodies. Whilst 
there are many successful vaccines currently available, there are still no registered vaccines for 
the two most prevalent global diseases – malaria and human immunodeficiency virus (HIV). 
Although we have made enormous progress in medicine over the last 300 years since the practice 
of vaccination first began, there are still diseases that are killing millions of people globally which 
desperately require a vaccine. Furthermore, there is a multitude of diseases that affect the 
veterinary sector- these are costly and cause animal suffering. This review will explore the 
progression from empirical vaccines to the more recent novel vaccines and how recent 
advancements can be used to combat two poultry diseases: necrotic enteritis and salmonellosis 
caused by Clostridium perfringens and Salmonella species, respectively.   
 
1.2 A brief history of vaccination 
The first crude attempt at disease control was the procedure of variolation where the inoculated 
person stood a good chance at surviving both the procedure and later exposure to the pathogen. 
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Variolation consisted of directly transferring the infection from a sick person to a healthy person, 
through direct contact or by infectious matter such as pus, saliva or blood (Dinc and Ulman, 
2007). This form of vaccination is believed to have begun in either ancient China or India, but was 
only brought to the United Kingdom by the wife of a British diplomat, Lady Wortley-Montagu in 
1721 (Figure 1.1 A) (Dinc and Ulman, 2007). 
 
 Lady Wortley-Montagu had observed that harem girls in Constantinople had pox-free faces which 
was attributed to them being variolated, hence she had her son variolated in Istanbul in 1718 
(Figure 1.1B) to save him from experiencing what she had as a young adult – smallpox. Later she 
also variolated her daughter in London; however this was only after she had confirmed that it did 
not result in death or disease in eleven orphans and six convicted murderers from Newgate 
Prison (Dinc and Ulman, 2007). Lady Wortley-Montagu was so impressed that she implored her 
surgeon, Dr Charles Maitland, to learn the technique and demonstrate it to the Royal British 
Court (Stewart and Devlin, 2006). After this demonstration, 200 upper-class members of British 
society - including members of the royal family – were subjected to the procedure, and in 1729 a 
further 897 more inoculations were performed with only 17 deaths post-procedure which is an 
insignificant number compared to the smallpox mortality at the time (Dinc and Ulman, 2007).  
 
Even though Lady Wortley-Montagu was severely criticised for bringing the procedure to Britain, 
it was slowly implemented throughout the United Kingdom over the following years, and in 1757 
a young boy named Edward Jenner would be variolated against smallpox (Dinc and Ulman, 2007).  
This ultimately saved countless lives from smallpox; the most devastating disease of the time. 
However there were two issues with variolation: 1) it could impair the patient or even kill them if 
the dosage was incorrect or if they were not physically fit enough to withstand the infection, and 
2) whilst the patient would be protected from further infections they would become contagious 
as they were having a true progression of the disease (Bazin, 2003).  
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A) 
 
B) 
 
 
Figure 1.1: Historical depictions of Lady Mary Wortley-Montagu. 
A) Lady Mary Wortley-Montagu was responsible for variolation being introduced from Turkey to 
Britain. B) She had her son variolated in Istanbul by an old wise Turkish woman and her Embassy 
surgeon, Dr Charles Maitland in 1718. Figure obtained from (Dinc and Ulman, 2007).  
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Although variolation was popular, in the English countryside there were many rumours that if you 
had a case of cowpox you were protected from the deadly smallpox, subsequently a farmer 
named Benjamin Jesty inoculated his wife and two sons with cowpox. Even though his wife 
became very ill, she and the whole family survived and went on to survive many exposures to 
smallpox. This transpired a full 20 years before scientist Jenner began his experiment with a boy 
called James Phipps (Pead, 2003). It is believed that Jenner was also aware of the rumours of 
cowpox protecting against smallpox, and that was the inspiration for his experiment, resulting in 
him being the first to document that a person infected with cowpox would survive subsequent 
exposure to smallpox (Stewart and Devlin, 2006). This technique evolved into using cow 
inoculums as the vaccine, which did provide immunity to smallpox although not to the same 
degree as natural disease or variolation. This discovery was heralded as the new age of vaccines 
and instigated new research into other common diseases. 
 
 A couple of centuries later, medicine would again make another huge step forward with the 
separate works of scientists Louis Pasteur and Robert Koch and the publication of germ theory. 
The most famous of these works would be Pasteur’s and his attenuation of the bacteria 
Pasteurella multocida, which causes fowl cholera by exposing the cultures to air and room 
temperature for extended periods of time (Bordenave, 2003). He proved that whilst the bacteria 
were avirulent, they provided full protection from the virulent strain of the bacteria, which was a 
revolutionary idea at the time. Pasteur also went on to attenuate the rabies virus by passage 
through rabbits (Bazin, 2003). Koch, on the other hand, would discover the bacterial agents of 
anthrax, tuberculosis and cholera whilst also compiling postulates with fellow scientist Jacob 
Henle that would transform the world of microbiology (Kaufmann and Schaible, 2005). All of 
these discoveries led to the development of immunology and non-empirical vaccines.  
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The first whole cell vaccine was produced by Salmon and Smith in 1886 and was based on a 
Salmonella strain that was killed by heat and injected into pigeons to provide immunity (Bazin, 
2003). Around the same time, others were looking at bacterial components and methods to 
purify them. This was the beginning of traditional vaccine methodology. During this era there 
were many great innovations in the field of immunology and vaccinology, such as the discovery of 
toxins and the consequent inactivation of toxins by heat and formalin, killed vaccines, adjuvants, 
sub-unit or acellular vaccines, tissue culture and live attenuated vaccines. With the establishment 
of molecular biology and genetic engineering in the late 1950s, a new era began where vaccine 
development no longer needed to be empirical and bacterial components could be produced 
artificially or even in vivo by unrelated vectors.  
 
1.3 Vaccines in the modern era 
1.3.1  What makes a good vaccine?  
The traditional definition of a vaccine is one that protects against a particular (or group of) 
infectious agent(s), however these days there are many vaccines that could be designated as 
therapeutic agents against diseases such as cancer (Bergman et al., 2006), although the goal is 
still to prevent illness. The global market for vaccines is estimated to be around US$8 billion per 
year whilst the cost to develop each vaccine from concept to commercialism is around US$300—
800 million (Plotkin, 2005). The reason for the high expenditure is that each vaccine has to be 
rigorously tested before commercial release and the average time it takes to fully develop a 
vaccine is between 15 and 20 years (Arntzen et al., 2005). A successful vaccine is measured by its 
effectiveness, its spectrum of protection, the duration of immunity and the strength of 
immunological memory that it induces. Secondary considerations of a good vaccine are its 
stability, ease of administration and storage, achievable mass production and its toxicity.  The 
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most recent and highly publicised vaccine is the quadvalent human papillomavirus vaccine against 
cervical cancer, marketed as Gardasil®, which prevents the premalignant disease that leads to 
cervical cancers and fulfils all the above criteria of being a successful vaccine (Govan, 2008).  
 
Biotechnology is a rapidly developing area which allows continued improvement into the 
exploration of antigens suitability as vaccine candidates. Choosing the right antigen is a core 
decision in the development of a vaccine candidate as some antigens that are immunogenic in 
vivo may not elicit long term protection. The same antigen may also vary in structure and 
sequence between strains, limiting its usefulness. Some antigens are also hard to express and 
purify on a large scale which is required for mass production (Mora et al., 2003). This is where 
novel vaccine methodology hopes to improve how vaccines are made and administered; this will 
be examined subsequently. The most common areas of vaccine design are shown in Figure 1.2. 
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Figure 1.2: Traditional and novel vaccinology.  
Traditional vaccinology is represented by killed vaccines, live attenuated vaccines and subunit 
vaccines. Novel vaccinology is represented by live carriers which deliver heterologous antigens 
and reverse vaccinology which screens genomes for potential antigens. Figure from (Scarselli et 
al., 2005) 
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1.3.2  Routes of administration 
1.3.2.1  Subcutaneous vaccination and intramuscular routes 
The oldest technique for vaccination is that of subcutaneous delivery via scarification and one of 
the newest techniques is intramuscular injection (Bazin, 2003). Whilst the intramuscular route of 
vaccination is quite standard today in developed countries, it is an inconvenient method of 
application as it requires sterile needles and syringes, and usually a medical physician to 
administer it. This is the major drawback of vaccines that rely on intramuscular injections to be 
effective.  In one study, a viral vectored vaccine was found to elicit stronger systemic and 
detectable mucosal responses via a single intramuscular injection than if it was applied via the 
oral route. The oral route proved to stimulate suboptimal T-cell responses and did induce a higher 
level of mucosal antibody than the intramuscular route (Lin et al., 2007).  
 
1.3.2.2  Nasal and oral routes 
Nasal and oral administration routes of a vaccine are desirable as they are non-invasive, painless, 
not required to be sterile and do not require a physician for administration. This final point is 
most important as it is one of the reasons that Third World countries have the lowest level of 
immunisations in the world (Costantino et al., 2007). Nasal immunisation would place the vaccine 
in contact with the large surface of the nasal mucosa which consists of the nasal-associated 
lymphoid tissue (NALT), which can lead to both humoral and cellular immune responses (Zuercher 
et al., 2002; Costantino et al., 2007). The most well-known nasal vaccine is FluMist®; a live cold-
adapted influenza virus. It can be given as one or two doses from a syringe sprayer, is licensed for 
use in the U.S.A. for persons aged 5–50 and has shown high efficacy from its inception (Plotkin, 
2005; Costantino et al., 2007). However one of the detriments of a nasal vaccine is that an 
unpleasant taste and nasal discomfort can occur often discouraging repeated use (Atmar et al., 
2007).  
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Oral administration is a practical method of application if it can be achieved without diminishing 
the effectiveness of the vaccine and immunity can be achieved with a single dose.  The objective 
of oral vaccines is to mimic a natural infection and provide mucosal immunity. Orally delivered 
vaccines can induce suboptimal T-cell responses with high levels of mucosal antibody than the 
intramuscular route; however the vaccine must be very stable as it will have to survive the acidic 
environment of the stomach before it reaches the M cells of the intestinal wall where it can be 
processed by antigen presenting cells (APCs) (Lin et al., 2007).  
 
1.3.3  Adjuvants 
Adjuvants are defined as compounds that influence the immune system into mounting a Th1 or 
Th2 response and whilst doing so, greatly enhances the magnitude of immune response against 
the antigen (Marciani, 2003). They are an important aspect of vaccines due to their tendency to 
make an ineffective antigen become effective. It is vital that adjuvants have the following 
properties as a components of vaccines – a non-toxic nature or have minimal toxicity at the 
dosage to elicit effective adjuvanticity; able to stimulate a strong humoral and/or T-cell immune 
response; provide good immunological memory or long-term protection; not induce 
autoimmunity; are non-mutagenic, non-carcinogenic, non-teratogenic and non-pyrogenic; and be 
stable under broad ranges of storage time, temperature and pH levels (Marciani, 2003). The most 
popular adjuvants are aluminium-based and were first described and published in 1926 (Glenny 
et al., 1926). The only adjuvant that is currently licensed for human use is aluminium hydroxide, 
also known as alum (Davies and Flower, 2007). It is well established that aluminium adjuvants 
stimulate the production of IgE and a Th2 immune profile, yet for some diseases this would not 
be adequate protection against pathogens as a Th1 response would be required (Lindblad, 2004).  
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Adjuvants are used to lengthen the dissemination time of the antigen from the site of injection 
which allows the antigen to be released over a prolonged period improving the effectiveness of 
the vaccine. This feature is called the depot effect and is observed with most aluminium-based 
adjuvants (Lindblad, 2004). Other methods in which adjuvants improve the immune response are 
to form complexes with the antigen and to target the vaccine towards specific receptors. For 
example, the use of mannose in the adjuvant is recognised by pattern recognition receptors 
(PRRs) that initiate endocytosis and antigen processing (Stahl and Ezekowitz, 1998).  The use of 
pathogen-associated molecular patterns (PAMPs) such as lipopolysaccharide (LPS) and CpG-DNA, 
and of synthetic low-MW imidazoquinolines in adjuvants, all trigger innate immune responses 
that lead to a Th1 or Th2 response in the vaccinated person (Marciani, 2003). Other adjuvants 
consist of cytokines (Cheng et al., 2007) and glycolipids (Singh et al., 1999; Ko et al., 2005) and 
other immunomodulators (Morrow et al., 2004) that bind to highly specific receptors on T cells 
which activate them.  
 
1.3.4   Political and global aspects of vaccine usage 
When a vaccine is designed, it is assumed that if it proves effective it will be used in countries 
around the world to vaccinate the population; however this is not always the case. Within each 
country there are government agencies, industry and community health advocates, and outside 
agencies such as the World Health Organization (WHO) that will make recommendations for 
vaccination strategies.  Often this process will result in a successful vaccination strategy such as 
the global eradication of smallpox (Stewart and Devlin, 2006), but it can also lead to confusion 
and scepticism in the chosen strategy. One such example was the choice of pertussis vaccine for a 
national vaccination campaign in the Netherlands.   
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Originally, the Dutch government chose to use a whole cell vaccine based on the Bordetella 
pertussis bacterium, however after speculation that the vaccine could cause brain damage, 
alternative vaccines were sought. At this time, acellular vaccines comprising three to five bacterial 
components were being used by many countries in Europe as they were comparable in protection 
to the whole cell vaccines and appeared to have minimal side effects (Blume and Zanders, 2006). 
Over the course of seven years, the debate over the new vaccine became very convoluted as 
many government agencies, drug companies and consumer groups presented opposing studies 
and evidence. There was also external pressure from neighbouring countries and global non-
profit groups including WHO and UNICEF for the Dutch government to make a decision.  
Concurrently, many parents had lost faith in the old vaccine strategy; hence an epidemic of 
pertussis ensued.  To combat the growing epidemic the Dutch government chose an acellular 
vaccine which was used in primary vaccinations in 2005, however the Health Minister advised 
that this decision was not based on recommendations and evidence provided by the Dutch Health 
Council, but on the need to appease parents and re-establish their confidence in the vaccine 
strategy (Blume and Zanders, 2006). By contrast in areas where any disease is endemic and the 
health system is overwhelmed, often the vaccination strategy proposed by governing bodies will 
be accepted by the population and acquiesced as mandatory (Chalmers, 2006).  
 
1.4 Traditional vaccine methodology 
The early development of vaccines focused on using killed organisms, inactivated toxins or 
modified organisms, but currently there are many different approaches to vaccine development, 
which will be examined subsequently. As these approaches were empirical in design, these types 
of vaccines — whilst being successful — are now viewed as being traditional vaccines. These can 
be divided into three different types: a) killed vaccines; b) attenuated vaccines; and c) sub-unit 
vaccines (Table 1.1). 
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1.4.1  Killed vaccines  
A killed or ‘inactivated’ vaccine is developed by the pathogen being grown and then being made 
inactive by means of heat, chemical or radiation treatment and was the basis of most vaccines 
until the 1980s. This results in the pathogen being unable to cause disease whilst providing the 
immune system with stimulation via its normal antigenic epitopes on its cell surface. One major 
disadvantage of this approach is that, whilst these vaccines are immunogenic, they do not 
replicate in vivo limiting the spectrum of the immunity acquired as the agent is incapable of going 
through its normal antigenic variation over the course of the infection. This results in decreased 
immunity and a requirement of booster shots to maintain immunity (Moylett and Hanson, 2003). 
Another disadvantage of this vaccine type is that during the inactivation process the antigenic 
epitopes can be modified resulting in a less efficacious vaccine (Tano et al., 2007). Despite these 
limitations, killed vaccines are commonly used today with the typhoid, Salk poliomyelitis and 
seasonal influenza vaccines still being administered (Bazin, 2003; Palese, 2006).  
 
1.4.2   Attenuated vaccines 
Among the more efficacious of the traditional vaccines are the attenuated ones. In this case, a 
pathogen is subjected to altered growth conditions, is passaged through a host or is genetically 
modified to eliminate its virulence, yet retaining its ability to replicate albeit at a greatly reduced 
rate.  These vaccines are more successful at eliciting a robust lifelong immunity than other 
traditional vaccines. This can be attributed to their ability to cause an asymptomatic infection 
which stimulates both the humoral and cellular branches of the immune system.  
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Table 1.1: Types of traditional vaccines (adapted from (Griffin, 2002)). 
Types of vaccine Target micro-organism Type of Immunity 
Killed   
Bacterial Salmonella, Yersinia, Leptospires IgG 
Virus Polio, Influenza IgG 
Attenuated   
Bacterial Salmonella, Tuberculosis (BCG) IgA, CMI 
Virus Mumps, Measles, Polio, Rubella IgA, CMI 
Sub-unit   
Bacterial Clostridial, Fusiformis — toxoids, 
Haemophilus influenzae type B 
IgG 
Virus Foot and Mouth Disease Virus —
capsid 
IgG 
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However this ability to replicate carries the greatest risk as the vaccine can persist in immune-
compromised persons or the elderly due to limited immune responses. A benefit to these 
vaccines is they express their own immunogenic antigens which stimulate the immune system 
strongly thereby negating the need for an adjuvant to be used (Loessner et al., 2008). The most 
commonly used attenuated vaccine is the MMR vaccine which protects children worldwide 
against measles, mumps and rubella and with subsequent boosters provides lifelong immunity 
(Vandermeulen et al., 2007). Attenuated vaccines have further progressed into carrier vaccines 
where they can deliver heterologous antigens (Bachtiar et al., 2003; Lotter et al., 2008; Schoen et 
al., 2008). For live carrier vaccines that deliver multiple heterologous antigens, there is a risk that 
the host immune system will dampen the immune response to the heterologous antigens by 
misdirecting the immune response against the carrier (Berzofsky et al., 2004). 
 
1.4.3  Subunit vaccines  
Traditionally, it was thought that the only way to protect against a disease was to use the whole 
organism to vaccinate the host. However it was elucidated that specific parts of the organisms, 
when purified or isolated, proved to be immunogenic. These components could be the capsule, 
the flagella or even an outer membrane protein of the cell wall. These types of vaccines are 
known as subunit vaccines or acellular vaccines. These vaccines are not able to cause the disease 
and in comparison to whole cell killed vaccines they are not as efficacious. This is both an 
advantage as they are safe for immune-compromised patients and a disadvantage as they do not 
elicit long-term immunity and will often require multiple vaccinations to maintain immunity 
(Schmitt et al., 2008). An advantage of this type of vaccine is that it can be engineered to protect 
against various strains of the organism. An example of a successful subunit vaccine is the 
Haemophilus influenzae type b (HiB) conjugate vaccine which consists of a polysaccharide-protein 
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conjugate. This vaccine has eliminated or significantly reduced this disease in children in regions 
of South America (Ribeiro et al., 2007; Franco-Paredes et al., 2008) and Africa (Adegbola et al., 
2005; Muganga et al., 2007) where it was once endemic. In the UK, the success of this vaccination 
program was compromised by a highly publicised paper (which has now been retracted) that 
linked autism to early childhood vaccination which lead to a rise in HiB infections as parents chose 
not to vaccinate; however subsequent booster campaigns by the NHS has seen a reduction in 
infection rates again (Ladhani et al., 2008).  
 
1.5 Novel vaccine methodology 
1.5.1  In silico screening 
In silico screening is a recent technique that has only become accessible to scientists in the last 25 
years due to the increasing power of computers and the sequencing of complete genomes. In 
silico screening is based on the use of algorithms to search genomes. A potential use is to search 
for putative antigens termed reverse vaccinology (Mora et al., 2003). There are four main 
processes to screening genomes for putative antigens: 1) a primary screen for coding regions; 2) 
all open reading frames (ORFs) are detected and used for homology searches using such 
programs as BLASTx and BLASTn; 3) examine if the potential antigen has not been characterised; 
and 4) identify the cellular location of the potential antigen. A major advantage of this technique 
is the efficient exploration of all ORFs in a genome. The primary disadvantage of in silico screening 
for reverse vaccinology is that the algorithms are sometimes unable to predict whether the 
protein is intracellular or extracellular, as extracellular proteins tend to be more immunogenic. 
The first published use of in silico screening, in terms of reverse vaccinology, was the 
identification of vaccine candidates for Neisseria meningitidis serogroup B meningococcus (Pizza 
et al., 2000). Pizza and colleagues identified 570 genes for possible surface-exposed antigens of 
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which 350 were successfully cloned and expressed. Of these characterised proteins, 85 were 
found to be surface-exposed and 22 were able to induce an antibody response (Pizza et al., 2000). 
This technique has also been used for other organisms such as Streptococcus pneumoniae 
(Wizemann et al., 2001), Porphyromonas gingivalis (Ross et al., 2001) and Chlamydia pneumoniae 
(Montigiani et al., 2002).  
 
Other uses of in silico screening are: B cell and T cell epitope prediction based on forecasting 
peptide fragments that can be presented by T cells using BIMAS or EpiDirect programs; predicting 
the surface region of antigens that will bind to antibodies using  ePitope or Discotope programs; 
screening proteins that have IgE epitopes that lead to allergies and sensitivities using AlgPred or 
AllerPredict programs; in cancer vaccinology, algorithms can show proteins that might have an 
effect on tumour growth; and adjuvant hunting using Immunogrid where small proteins are 
screened against cell receptors and ligands to see if they can elicit an immune response (Mora et 
al., 2003). 
 
1.5.2  Plant-based oral vaccines 
One of the most novel and innovative fields of current vaccine experimentation is the exploration 
of plant-derived vaccines and antibodies. This revolves around the production of antigens or 
antibodies within the stems or leaves of a plant. The main advantage of this technique is that 
plants can perform post-translational modifications, opposed to other systems such as bacteria 
that are unable to. Other advantages include minimised risk of contamination from human 
pathogens, the elimination of purification steps for food based vaccines, convenient storage, the 
elimination of health professionals if the vaccine can be given orally, and a renewable source of 
the vaccine (Arntzen et al., 2005; Shams, 2005; van der Laan et al., 2006). The first scientific 
report describing the potential of plant-derived vaccines was the expression of a Hepatitis B 
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surface antigen in a transgenic tobacco plant (Mason et al., 1992). There are three major 
strategies to induce plants to express foreign antigens – stable genetic transformation of the 
nuclear genome, stable transformation of the chloroplast genome, or transient expression using 
viral vectors. However these three strategies differ in how much protein is expressed and to 
which plant species the strategy can be applied (Arntzen et al., 2005). The majority of these 
studies have been carried out in model tobacco plants but the longer term usefulness of these 
transgenics is limited due to the high alkaloid content which would not pass vaccine regulations 
for orally delivered vaccines (Arntzen et al., 2005; van der Laan et al., 2006). One persistent 
concern regarding plant-derived vaccines is that the antigen is ingested like food proteins, which 
could lead to tolerance of the antigen and thus would not provide protection against infection 
(van der Laan et al., 2006). However there has been recent articles reporting that when given 
orally, plant derived vaccines induce both mucosal and humoral immunity (Hale et al., 2006; 
Youm et al., 2007). Another significant aspect of plant-derived vaccines is the production of 
antibodies in transgenic plants, first reported in 1989, where plants expressing either single 
gamma or kappa immunoglobulin chains were crossed to yield tobacco plant progeny in which 
both chains were expressed simultaneously (Hiatt et al., 1989). This production of antibody could 
be used as an edible prophylaxis vaccine after exposure to infectious gastrointestinal pathogens 
to which standard vaccines do not exist.  
   
1.5.3  Synthetic peptides 
Synthetic peptides are another enhancement of traditional sub-unit vaccines. Whilst sub-unit 
vaccines focussed on reproducing whole proteins as the antigen, synthetic peptides focussed in 
on small regions of the antigens that were presented by T-cells. This epitope-based strategy relies 
on confirmation that the epitope is immunogenic and the peptide being able to elicit a strong cell-
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mediated immune response (van der Burg et al., 2006). Delivery of a large dose of peptides leads 
to a larger magnitude immune response as they will activate a greater number of lymphocytes. 
 
Synthetic peptides are easily produced, stable, deficient of oncogenic potential and are free of 
bacterial or viral contaminating substances (Jiang et al., 2006; van der Burg et al., 2006). The first 
reports of this type of vaccine occurred in 1991 where a peptide provided protection from a viral 
challenge (Kast et al., 1991; Schulz et al., 1991). Since then there have been many improvements 
which have increased the efficacy of these peptides such as the modification of peptides to 
improve its binding efficiency to major histocompatibility complex (MHC). Another is to include 
multiple peptide epitopes that induce both CD8+ and CD4+ T-cell activity which results in a 
stronger immune response. Promiscuous overlapping synthetic peptides are one application that 
uses multiple peptides. The peptides are designed to represent sequential portions of a known 
antigen which subsequently elicits both CD4+ and CD8+ immune responses as both types of 
epitopes are represented (Jiang et al., 2006). One difficulty associated with synthetic peptides is 
their short nature, in vivo they are automatically exposed to the indigenous proteases which may 
render the peptide inert if cleavage occurs. One way to avoid this scenario is to make the peptide 
longer but consequently it will reduce its ability to bind to MHC. However it has been found that 
although the peptide loses its binding ability, it will still be taken up and processed by dendritic 
cells which will result in an immune response (van der Burg et al., 2006). An advantage of 
synthetic peptides is that multiple peptides can be administered to protect against a multitude of 
antigens; but they must be coupled with the right adjuvant that will attract APCs to the site of 
injection. Currently, two synthetic peptide vaccines are being tested in Phase I trials against 
malaria (Hermsen et al., 2007; Peduzzi et al., 2008). 
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1.5.4   DNA vaccines 
DNA vaccines differ from traditional vaccines as they do not consist of a protein or a cell 
component but only the DNA that encodes an immunogenic antigen within a plasmid vector. The 
plasmid can be administered by injection, gene gun, electroporation or aerosol delivery, upon 
which the host’s immune cells, usually dendritic cells, will sample the plasmid and express the 
encoded antigens. These antigens are then degraded by the cell into peptides and presented via 
MHC class I and class II molecules depending on the mode of administration and the cell type. 
From this, both antibody and cellular responses can be induced (Forde, 2005). 
 
The first reported use of a plasmid DNA vaccine outside of trial or experimental conditions was in 
2003 and was a desperate attempt to save an endangered species from extinction (Bouchie, 
2003). The vaccine was for the highly endangered California condors against the lethal West Nile 
virus. West Nile virus had emerged in New York in 1999 and spread to 41 out of the 50 US states 
killing birds from 138 species in a matter of years. It was believed that if the virus spread to 
California, the remaining 200 or so condors would face extinction. The US Centers for Disease 
Control and Prevention expedited the manufacture of an experimental vaccine and permitted the 
condors to be vaccinated with it (Bouchie, 2003). The DNA vaccine expressed West Nile virus pre-
membrane/membrane and envelope proteins.  The vaccinated condors were monitored and it 
was observed that the DNA vaccination stimulated protective immunity in adults, nestlings and 
newly hatched chicks. Following two intramuscular vaccinations, the condors demonstrated 
excellent neutralising antibodies 60 days post-vaccination with a continued increase until 
approximately one year post-vaccination.  It was also noted that the birds did not show any 
unusual behaviours, health changes or side effects post-vaccination (Chang et al., 2007). The first 
two DNA vaccines for veterinary use were granted US approval in 2005 for West Nile virus vaccine 
for horses and haematopoietic necrosis vaccine for farm-reared Atlantic salmon (Chalmers, 2006).  
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1.6 Veterinary vaccines 
Veterinary vaccines have slightly different objectives to those of human vaccines. They share the 
same aim of prevention and control of infectious agents with one major difference. In veterinary 
vaccinology, reducing the cost of food production whilst maintaining animal welfare is paramount 
as disease results in great economic losses (Shams, 2005). These vaccines have different but more 
stringent requirements such as they do not induce local reactions diminishing the value of the 
food product, induce long term and stable herd immunity, and vaccine-initiated infections can be 
differentiated from naturally acquired infections, known as marker vaccines. Most current 
licensed veterinary vaccines are killed or inactivated types such as porcine reproductive and 
respiratory syndrome virus (Zuckermann et al., 2007) or live modified vaccines such as foot and 
mouth virus (Mason et al., 1997). Another avenue of veterinary vaccines being developed is that 
of fertility controls, where the vaccines can either increase or inhibit ovulation in females (Rangel 
et al., 2005; Medan et al., 2006), which could be useful in times of drought or food shortages. In 
most cases, commercial veterinary vaccination is purely available to sustain the health of the 
animal so that premium price is ensured after slaughter.  
 
1.7 Diseases in the poultry industry 
1.7.1  Salmonella infections  
Chickens are extremely susceptible to Salmonella infections in the first days of life and prevention 
of infection post-hatch is the primary and most important objective of poultry vaccine 
researchers worldwide. It is very important to control the amount of Salmonella harboured in the 
gut of chickens for several reasons; firstly chicken is an important source of affordable protein 
around the world, (Zhang-Barber et al., 1999) as on average, Americans alone consume 234 
eggs/person/year (Babu et al., 2004). Secondly, the global poultry meat and egg industry is worth 
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more than US$2 billion annually (Collier et al., 2008) and responsible for many jobs 
internationally. In Australia, the gross value of egg production in 2007-08 was A$463 million (ABS, 
2009) with egg consumption fluctuating between 129 – 140 eggs/person/year between 1998 and 
2000 highlighting the significance of the local poultry industry (ABS, 2000; Bell, 2001). Vaccination 
against Salmonella in poultry is important both for the poultry’s health and also for reducing 
contamination of the food chain later on. 
 
There are over 2400 different Salmonella serovars but only a few will infect poultry, causing 
septicaemia and rapid mortality in flocks (Zhang-Barber et al., 1999).  The risk of this occurring 
can be severely reduced by stringent cleaning measures and by identifying risk factors that 
increase the horizontal and vertical spread of Salmonella. There are three stages in avian systemic 
salmonellosis. The first is the invasion of the gastrointestinal tract with the second being the 
establishment of a systemic infection resulting in Salmonella invading the circulating 
macrophages and disseminating to the internal organs for further replication. The third stage of 
infection is dependent on the level of Salmonella replication that occurs in the organs. There are 
three possible outcomes: 1) uncontrolled replication in the organs that leads to a systemic 
infection ending in mortality; 2) levels of replication are moderate and a persistent infection will 
result with the chicken becoming a carrier; and 3) the replication does not outpace the immune 
system’s ability to clear the infection and the chicken recovers (Barrow et al., 1990; Zhang-Barber 
et al., 1999; Chappell et al., 2009).  
 
In poultry, Salmonella Gallinarum and Salmonella Pullorum produce severe systemic disease with 
limited faecal excretion (Barrow, 2007), so the risk of carcass contamination at slaughter is 
minimal and does not cause food poisoning in humans (Zhang-Barber et al., 1999).  These host 
specific serotypes can be vaccinated against in poultry. However Salmonella Enteritidis and 
Salmonella Typhimurium, both host non-specific serotypes, can cause transient infections in 
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poultry which colonise the gastrointestinal tract of the chicken and enter the human food chain 
potentially causing food poisoning (Zhang-Barber et al., 1999). The main routes of human 
infection are from the ingestion of meat from colonised or contaminated carcasses or eggs 
infected from colonised ovaries or by Salmonella-contaminated faeces during laying (Barrow et 
al., 1990). 
 
Salmonella Enteritidis is the most commonly found serovar in poultry and can cause systemic 
infections in young chicks and laying hens accompanied by prolonged faecal shedding (Suzuki, 
1994; Zhang-Barber et al., 1999; Barrow, 2000). The typical route of poultry infection is when 
Salmonella is ingested by the chicken.  It then passes through the acidic environment of the crop, 
where the acid adaptation mechanisms are initiated that help the Salmonella survive the 
subsequent passage through the proventriculus, the gizzard and eventually the gastrointestinal 
tract (Chappell et al., 2009). During the initial infection symptoms can include depression, 
anorexia, diarrhoea, and reduced egg production in layers and can lead to high mortality in young 
chicks of up to 21% (Gorham et al., 1991; Suzuki, 1994).  If the chicken is unable to clear the 
infection it will become a persistent carrier of the organism and expose the rest of the flock to the 
infection.  
 
After the initial infection, S. Enteritidis will colonise the large blind ceca, which are the largest 
secondary lymphoid organs in chickens, which branch off the distal ileum just before the colon 
(Chappell et al., 2009).  Once the caeca are colonised in the chicks that survive, they will 
constantly shed S. Enteritidis in the faecal matter (Suzuki, 1994). Upon dissection these persistent 
carriers of S. Enteritidis will have the organism recovered from the heart, liver, spleen, caeca, yolk 
sac, ovary, oviduct, peritoneum, eggs and intestines (Suzuki, 1994). In older layers that have had a 
sub-clinical infection there are often deformed, shrunken, discoloured and/or congested ovaries 
and ovules with malformed follicles (Suzuki, 1994). These dissections occurred at typical market 
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age at 42 days showing that the risk to humans of ingesting contaminated meats is quite high if 
the carcasses are not examined carefully during slaughter (Gorham et al., 1991; Suzuki, 1994). 
Through the colonisation of the oviduct, which is dictated by the induction of multiple genes on 
the virulence plasmid, S. enterica can directly contaminate eggs through the shell and can be 
found in both the yolk and the albumen (Gantois et al., 2008). 
 
Ingestion of Salmonella-contaminated materials is the key cause of these infections and often it is 
the ingestions of their own faecal matter by chickens that leads to infection. A study of 74 poultry 
farms over the course of a year found that S. enterica serovar Enteritidis was the only persistent 
serotype found in flocks and that environmental contamination with this serovar increased 
significantly over time (Wales et al., 2007). Interestingly, all of the flocks were vaccinated against 
Salmonella with the majority being vaccinated using either a live S. Enteritidis vaccine with or 
without a live Salmonella Typhimurium component, an inactivated S. Enteritidis vaccine with 
Salmonella Typhimurium or a live Salmonella Gallinarum that provided cross-protection against S. 
Enteritidis. They had also been administered with an oral competitive exclusion treatment, 
however these flocks still showed signs of being persistent carriers (Wales et al., 2007). Wildlife 
vectors such as rodents and flies (Mian et al., 2002; Garber et al., 2003) had also introduced 
Salmonella into poultry farms and were found to be an indicator of the Salmonella status of the 
chickens. During sampling, when the rodent faecal matter and the flies tested negative for the 
presence of Salmonella, the flock tested negative as well and the reverse was found that if the 
result was positive, the flock would also be positive (Wales et al., 2007).  
 
The reduction of Salmonella-colonisation in the poultry industry is a major objective although the 
costly and time-consuming measures are not often embraced by the industry. Control and 
reduction of Salmonella in flocks can be achieved through sophisticated housing measures, 
constant surveillance on feed quality, strict and regular hygiene management and administration 
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of competitive exclusion and vaccine measures in chicks (Zhang-Barber et al., 1999). As the 
poultry industry often uses high density housing and have a high output, it has been found that 
continuously used housing which have multi-aged flocks living in them were heavily contaminated 
with Salmonella (Wales et al., 2007). A modification that has the potential to limit the 
accumulation of Salmonella in this scenario is to organise a break in the rearing of the chicks in 
the henhouse to allow proper decontamination of the cages and the associated fixtures.  Regular 
and thorough cleaning is of the utmost importance to reduce horizontal transmission within 
flocks.  The physical removal of the organic matter, the thorough and regular application of 
disinfectants, strict rodent control and constant surveillance of risk factors such as continuous use 
of henhouses and older flocks all contribute to reduction of carriage rates (Wales et al., 2007).   
 
The second modification that would reduce the proliferation of Salmonella is changing the density 
of which the chickens are housed and the housing itself. Chickens are sensitive to change and 
stresses can often make the infection worse such stresses include vaccinations, transfer of birds, 
cold wet weather and rearing at a high density (Suzuki, 1994; Zhang-Barber et al., 1999). If the 
poultry farms made their henhouses more insulated and reared at a lower density, there could be 
a reduction in prevalence of Salmonella. A distinct seasonal pattern for environmental 
contamination is seen quite clearly among the free range flocks than the caged flocks, supporting 
the fact that stress of cold weather and wildlife vectors can cause an increase in Salmonella 
excretion (Wales et al., 2007). However these modifications are costly and rearing at a lower 
density directly affects the poultry farm’s ability to earn income.  
 
As poultry is consumed on such a regular basis, most countries have taken steps to regulate the 
poultry industry to minimise health impacts on the public. In Australia, this began in the 1990s 
when changes were made to the regulation of poultry hygiene, with Australian Standards and 
meat processors who were required to operate a Hazard Analysis and Critical Control Points 
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(HACCP) program introduced (Sumner et al., 2004).  Since the implementation of these standards 
the microbiological status of poultry has improved with human pathogens such as S. 
Typhimurium, along with non-pathogenic strains such as S. Sofia, being isolated less often in meat 
samples (Sumner et al., 2004).  The only controversy with these changes is that they were made 
to reduce the incidence of salmonellosis in the human population; however statistics in the 
decade after the introduction indicated the numbers of infections have remained stable over the 
last decade rarely changing from 5000—6000 cases per annum (Baker et al., 1998; Sumner et al., 
2004). This can be attributed to three possible causes – 1) the failure of retail food suppliers to 
follow health regulations whilst serving patrons, 2) inadequate handling and storage of food 
products in the home and 3) non-food sources of contamination such as contaminated water and 
contact with pets/farm animals faecal matter (Sumner et al., 2004). Improvement in clinical 
diagnosis and reporting may also contribute to the consistent annual trend.  
 
In the European Union (EU), in order to regulate their poultry industry, legislation was introduced 
at the beginning of 2009 with the aim to reduce the prevalence of S. Enteritidis and S. 
Typhimurium to 1% or less in all broiler and layer flocks by the end of 2011 (Cooper, 2008). In the 
UK, the current overall rate is 8% whilst in other parts of the EU the overall Salmonella prevalence 
can range from 0% in Sweden to 68% in Hungary with an average of 24% with the EU (Cooper, 
2008). In their most recent report, the European Food Safety Authority have advised that even 
with the preceding recommendations 15 member states have already been able to get their 
Salmonella prevalence to below the reduction target of 1% laid down by the new EU legislation 
(EFSA, 2009).  
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1.7.2 Clostridium perfringens, gas gangrene and necrotic enteritis 
1.7.2.1  Clostridium perfringens and the alpha toxin 
The genus Clostridium contains bacteria that are Gram-positive, obligately anaerobic, spore-
forming bacilli (Hatheway, 1990) and the first clostridia species, Clostridium butyricum, was 
identified by Louis Pasteur in 1861 (Rekha and Gopalan, 2007). They can be differentiated from 
Bacillus species by their lack of catalase activity and are ubiquitously found in soil, sewage, 
decaying biological matter and the intestinal tracts of humans and other animals (Smith and 
Gardner, 1949; Hatheway, 1990). Of this genus the most omnipresent is Clostridium perfringens 
which has previously been known as Bacillus aerogenes capsulatus and C. welchii after one of its 
discoverers, William H. Welch (Hatheway, 1990). Clostridium perfringens produces five different 
types of major toxins (A-E) of which the alpha (α), beta (β), epsilon (ε) toxins are prevalent 
(McDonel, 1980).  Each strain of C. perfringens causes different disease as they express differing 
toxins in differing quantities, with Type A strains producing large amounts of alpha toxin whilst 
lacking expression of the other major toxins (Petit et al., 1999).  Type A strains of C. perfringens 
are often responsible for causing gas gangrene and food borne illnesses in humans and livestock 
(Hatheway, 1990). 
 
Characterisation of the alpha toxin showed that it was a phospholipase C which was the first time 
that a toxin had been shown to be enzymatic (Macfarlane and Knight, 1941). Alpha toxin is a zinc-
metallo-phospholipase which has two domains, the first amino-terminus domain (N-domain) 
composed of α-helices and the carboxyl-domain (C-domain) composed of β sheets (Naylor et al., 
1998). Alpha toxin is a potent toxin with a MLD <0.1 µg/mouse (Naylor et al., 1998) which is 
attributed to the fact that alpha toxin can hydrolyse phospholipids and lyses erythrocytes from 
various species (Titball et al., 1999). Crystallographic analysis of the alpha toxin has elucidated 
that the putative active site is situated within a cleft that has three essential zinc ions held in 
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place by the N-terminus tryptophan residue, a glutamic acid residue, two aspartic acid residues 
and five histidine residues (Figure 1.3) (Naylor et al., 1998). 
 
Gene analysis of the alpha toxin gene, known as plc or cpa, has shown that the gene is highly 
conserved between isolates from diseased chickens. Despite that conservation, there are 28 
different published types of alpha toxin genes and studies have shown that there is no correlation 
between PFGE type, plc sequence type, health status of the host chickens and level of alpha toxin 
production (Abildgaard et al., 2009). The differences between these sequences were shown to be 
just single base substitutions resulting in synonymous changes that did not significantly alter the 
encoded proteins (Sheedy et al., 2004; Abildgaard et al., 2009). 
 
Of the C. perfringens strains that can induce lesions, the production of alpha toxin is quite 
variable and similar levels can be produced by normal gut isolates that do not cause disease 
making it likely that certain C. perfringens strains engage in host-specific interactions that lead to 
disease (Timbermont et al., 2009). Effects on mammalian cells has shown that at high 
concentrations, alpha toxin leads to the disruption of the plasma membrane whilst at low 
concentrations it disrupts phospholipid metabolism and several signal transduction processes 
such as diacylglycerol generation, protein kinase C activation, calcium mobilisation and activation 
of arachidonic acid metabolism (Flores-Díaz et al., 2004). All of these effects go on to cause 
inhibition of neutrophils in infected tissues and can cause thrombotic events that enhance the 
anaerobic conditions that C. perfringens thrive in (Flores-Díaz et al., 2004).  
 
1.7.2.2  Gas gangrene in humans to necrotic enteritis in poultry 
Gas gangrene is an acute and critical infection caused by clostridial species, C. perfringens being 
the most frequently isolated from gangrenous wounds (Flores-Diaz and Alape-Giron, 2003).  
Observations of this disease can be found in the oldest editions of our modern journals with one 
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dating back as far as 1914 where it was noted that gas gangrene was caused by wound 
contamination with “street mud” (Dudgeon, 1914). Another early report of gas gangrene came 
from army doctors who had experience with shrapnel wounds in the First World War (Bowlby and 
Rowlands, 1914). Bowlby and Rowlands isolated a bacillus from such wounds and found that 
when a guinea pig was inoculated with it, gangrenous cellulitis occurred. They also noted that of 
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Figure 1.3: Tertiary structure and mode of action of alpha toxin. 
A) Protein model of alpha toxin showing the two domains. B) Mode of membrane destruction by 
alpha toxin. Figure taken from Sakurai et al. (2004).   
A) 
B) 
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all the organisms isolated from these wounds were anaerobic spore-bearers.  The development of 
the disease was observed to appear in a few days or even a few h depending on the severity of 
the injury sustained by the soldier. Symptoms included severe pain caused by swelling, 
discolouration of the skin to green then black (Figure 1.4), an overpowering smell coming from 
the offending limb and death due to cardiac failure (Bowlby and Rowlands, 1914; Stevens, 2000). 
Typical incubation times for gas gangrene is less than 24 h after trauma but extremes such as 1 
hour to 6 weeks have been reported in civilian cases (Rekha and Gopalan, 2007). The description 
of this disease has altered very little over the course of the last 95 years, and unfortunately 
neither has the treatment.  
 
Treatment of gas gangrene during the First World War included making incisions into the affected 
areas, flushing them with hydrogen peroxide and removing any contaminating materials in the 
wound, and as a last resort, amputation, which was the most successful treatment (Bowlby and 
Rowlands, 1914). Currently, treatment consists of aggressive use of antibiotics, most often 
penicillin and clindamycin in combination (Brook, 2008); debridement surgery where longitudinal 
incisions are made throughout the deep fascia to assist with drainage (Schwartz, 1978; Brook, 
2008) leading to surgical amputation in 15% to 20% of cases (Rekha and Gopalan, 2007); and if 
diagnosed soon enough hyperbaric oxygen therapy (Mortensen, 2008).  However as the necrosis 
can spread at a speed of up to 15 cm/h, hyperbaric oxygen therapy is a rather controversial 
treatment (Mortensen, 2008). It has been known that well perfused tissue is resistant to infection 
and can help inhibit the spread (Schwartz, 1978; Mortensen, 2008) and that the thousand-fold 
increase in oxygen saturation in the infected tissue leads to a bactericidal effect and improved 
wound healing (Brook, 2008). However to date there has been no controlled studies of the 
treatment leading to much speculation that it is not a suitable treatment for such a rapidly 
developing disease (Brook, 2008). One of the most promising aspects of this treatment is that it 
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Figure 1.4: Patient with gas gangrene affecting her left leg after a laceration to her foot.  
Characteristic darkening of the skin during gas gangrene with swelling apparent around the ankle. 
Figure from Rekha and Goplan (2007).  
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can inhibit formation of toxins and at a pO2 of 250 mmHg, there is no production of toxins by the 
C. perfringens (Mortensen, 2008) which may limit cellular damage and prevent shock. 
 
The relationship between the toxins that C. perfringens express and the progression of gas 
gangrene has not been fully elucidated and early treatments found that antitoxin treatments 
were ineffective as a prophylaxis (Schwartz, 1978). Toxin filtrates of C. perfringens were tested to 
see if signs of gangrene could be induced and it was observed that the filtrates could alter the 
epinephrine-sensitivity in the blood vessels and inhibit phagocytosis at the site of infection, a 
unique characteristic of gas gangrene (Ganley et al., 1955). As alpha toxin is the predominant 
toxin produced by C. perfringens Type A strains (Petit et al., 1999), it was a natural progression to 
explore said toxin as a vaccine candidate against gas gangrene especially as it exhibits myotoxic 
activity, induces platelet aggregation, affects leukocyte proliferation and leads to a rapid 
reduction in arterial pressure (Stevens, 2000; Flores-Diaz and Alape-Giron, 2003). Later, alpha 
toxin was purified in recombinant form and shown to induce myonecrosis and many 
histopathological signs of gas gangrene when injected intramuscularly in mice (Bunting et al., 
1997). The C-terminus domain of the alpha toxin was found to be an efficacious vaccine against 
challenge with lethal doses of either alpha toxin or C. perfringens in a gas gangrene mouse model 
(Williamson and Titball, 1993). These studies indicated that the alpha toxin was a virulence factor 
in the development of gas gangrene (Williamson and Titball, 1993; Bunting et al., 1997). Recently, 
it was reported that the C. perfringens alpha toxin was able to stimulate gas gangrene when 
expressed in a C. septicum background further confirming that it is an important virulence factor 
in gas gangrene (Kennedy et al., 2009). 
 
Another important disease caused by C. perfringens Type A, and occasionally Type C, is necrotic 
enteritis which occurs in poultry and other avian species worldwide (Parish, 1961; Songer, 1996). 
The disease is characterised by a sudden increase in flock mortality without any clear indications 
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of illness, however development of wet litter can sometimes be an early warning sign. At 
necropsy, the small intestinal mucosa will have large necrotic lesions (Figure 1.5a) and in the 
severest cases the whole mucosa will show extensive necrosis of the lumen (Figure 1.5b)(Parish, 
1961; Van Immerseel et al., 2009). There are two forms of the disease, clinical and sub-clinical, 
where in both there is chronic damage to the mucosa affecting weight gain and feed-conversion 
ratios (Kaldhusdal et al., 2001). Sub-clinical disease is very common and occurs in flocks with 
neither substantially increased mortality nor an increased number of ill birds. Sub-clinical disease 
is only detected upon discovery of lesions on either the intestines or liver which condemns the 
carcass at slaughter and can increase condemnations from 0.5% of the flock to 1.5% which 
translates to a large loss in production value (Kaldhusdal and Lovland, 2000). As the global poultry 
industry is estimated to be greater than US$2 billion annually (Collier et al., 2008) this production 
loss can translate into millions of dollars in loss of revenue every year. It has also been associated 
with increased feed-conversion ratio and retarded growth rate (Lovland and Kaldhusdal, 2001). 
Necrotic enteritis reached epidemic proportions in Scandinavia in 1995 when the proportion of 
affected flocks rose to between 25–40% after the withdrawal of antimicrobial growth promoters 
from feed (Kaldhusdal and Lovland, 2000). 
 
Although the pathogenesis of necrotic enteritis is not fully elucidated, it is known that toxigenic 
strains of C. perfringens displace the normal non-necrotic enteritis strains in the gut of broiler 
chickens and actively inhibit their re-establishment by producing substances such as bacteriocins 
(Barbara et al., 2008). It has been found that competitive exclusion against C. perfringens can 
reduce mortality. One study showed that giving affected birds doses of lactic-acid producing 
bacterial strains (Lactobacillus acidophilus, Enterococcus faecium, Lactobacillus platarum and 
Pediococcus acidilactici) lowered mortality from 60% to 30% (Hofacre et al., 2003) and also 
reduced colonisation rates of S. Typhimurium (van der Sluis, 2003). 
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Figure 1.5: Necrotic lesions of the lumen in broilers suffering from severe necrotic enteritis. 
A) Patches of lesions throughout the intestine; B) Severe extensive necrosis of the lumen surface 
(picture from Van Immerseel et al., 2009).  
  
A) 
B) 
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Experimentally, necrotic enteritis has been very difficult to reproduce as high pre-experiment C. 
perfringens colonisation of commercial birds and spontaneous disease interferes with the validity 
of the results obtained (Kaldhusdal et al., 1999). Having high numbers of C. perfringens in the 
broiler chickens gut is not sufficient to induce necrotic enteritis even when the broiler has 
predisposing factors such as mucosal damage caused by coccidial pathogens (Collier et al., 2008) 
and a diet high in protein (Timbermont et al., 2009). It has also been found that strains isolated 
from broilers suffering from necrotic enteritis have different virulence factor that may be 
required to induce the disease whereas strains that come from healthy broilers lack them 
although they have not all been characterised (Engstrom et al., 2003; Timbermont et al., 2009). 
Contradicting these reports, a study by Gholamiandekhordi and colleagues (2006) discovered that 
production of alpha toxin in vitro does not show a positive correlation with the disease status of 
the flock (Gholamiandekhordi et al., 2006). 
 
1.7.2.3  Virulence factors in necrotic enteritis 
Whilst the role of alpha toxin has been accepted as an important virulence factor in gas gangrene, 
its role in necrotic enteritis is still being debated. Throughout the literature, there are many 
contrasting studies that have reached differing views on how to approach necrotic enteritis. The 
three main hypothesises will be examined here. The first hypothesis is that alpha toxin is involved 
in pathogenesis of necrotic enteritis and should not be discounted as a vaccine candidate. The 
second is that alpha toxin is not essential to the development of necrotic enteritis and that there 
are other more efficacious immunogens that should be investigated.  Finally the third is just 
emerging and is based on the idea that there may not be just one main factor in necrotic enteritis 
but multiple ones acting synergistically. As a result of this continuing debate all groups that are 
looking into a successful vaccine agree that necrotic enteritis is a multifactorial disease which has 
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increased in areas where antimicrobial growth promoters have been banned from use (Van 
Immerseel et al., 2009).   
 
One of the first studies that linked alpha toxin to necrotic enteritis showed that intestinal lesions 
could be induced by administrating C. perfringens culture supernatant (Al-Sheikhly and Truscott, 
1977), however the supernatant was not pure alpha toxin hence the relationship could not be 
definitively established.  In a later report, germ-free chickens inoculated with a dose of purified 
alpha toxin died and upon necropsy, intestinal damage was observed that was consistent with 
necrotic enteritis (Fukata et al., 1988). These two articles appear to have laid the foundation of 
the hypothesis that alpha toxin was a virulence factor involved in intestinal damage of necrotic 
enteritis.  
 
Consequently, researchers focused on collecting isolates from chickens suffering from necrotic 
enteritis to show that alpha toxin was essential to the disease. Upon characterisation of isolates 
taken from healthy flocks and those affected by necrotic enteritis, one study reported that “alpha 
toxin was produced in significantly larger amounts by isolates from birds with necrotising enteritis 
than by isolates from birds without the disease, regardless of bird species” (Hofshagen and 
Stenwig, 1992). This claim supported the theory that alpha toxin was involved in the pathogenesis 
and many subsequent reports demonstrated success in using the toxin as a vaccine. Immunisation 
with alpha toxoid followed with boosting with active toxin offered the best protection and 
induced epitope-specific neutralising antibodies (Kulkarni et al., 2007). Recombinant alpha toxin 
has also been reported as generating a strong IgG response when administrated subcutaneously 
which gave partial protection from whole organism challenge with C. perfringens  (Cooper et al., 
2009).  
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One of the most recent articles to support the argument that alpha toxin should not be dismissed 
as a virulence factor reported that protective responses against necrotic enteritis was induced 
using a Salmonella vaccine expressing the carboxyl-terminus domain of the alpha toxin (Zekarias 
et al., 2008). Suppression of active growth of C. perfringens in broth culture by the serum 
acquired from these vaccinated chickens indicated that alpha toxin may be retained on the cell 
wall which reiterates that it is an important immunogen in this disease. This group found that 
their vaccine when administered orally induced toxin-neutralising antibodies, reduced lesion 
development and increased weight gain in the broiler chickens challenged with C. perfringens 
(Zekarias et al., 2008).  Delivery of the alpha toxin carboxyl-terminus domain using Bacillus subtilis 
endospores administered orally or nasally has also induced protective immune responses against 
alpha toxin challenge (Hoang et al., 2008). 
 
So why is there still debate over the role of alpha toxin? Firstly, in immunisation studies, a 
naturally occurring mutant strain of C. perfringens which expressed a non-toxic alpha toxin 
variant, lacking enzymatic, haemolytic and lethal activity, induced protective immune responses 
against wild-type alpha toxin challenge in a murine model (Schoepe et al., 2006). Another study 
reported that two out of four avirulent alpha toxin deficient mutants were able to protect birds 
against experimental necrotic enteritis which showed that there are other immunogens 
important to pathogenesis (Thompson et al., 2006). Finally a virulent alpha toxin mutant was 
shown to produce necrotic enteritis in an experimental chicken model (Keyburn et al., 2006).  All 
these studies further supported the idea that alpha toxin may not be the sole virulence factor 
because if it was crucial to pathogenesis, these particular mutant strains would not have been 
able to confer immunity. Furthermore, as stated previously, in contradiction to Hofshagen and 
Shenwig’s study from 1992, a group reported that they demonstrated no apparent correlation 
between the disease status of the flock and the amount of alpha toxin produced by the isolates as 
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in vitro expression of alpha toxin did not vary between normal flora isolates and disease isolates 
(Gholamiandekhordi et al., 2006). 
 
Keyburn and colleagues focused on other immunogens when they could not reproduce necrotic 
enteritis using other Type A strains of C. perfringens even though they also expressed alpha toxin 
as well (Keyburn et al., 2006). The most recently reported toxin that has been identified by this 
group is NetB which is a pore-forming toxin that displayed cytotoxic activity in tissue culture 
assays and has been found in C. perfringens type A strains isolated from chickens suffering from 
necrotic enteritis (Keyburn et al., 2008).  When a NetB mutant was tested for virulence it was 
unable to produce necrotic enteritis in an experimental model, however, during classification of 
the isolates from necrotic enteritis infected chickens four were found to be NetB negative yet 
were still able to cause necrotic enteritis in the experimental model (Keyburn et al., 2008) 
showing that like alpha toxin, NetB may not be an essential nor critical virulence factor. 
Furthermore, when non-Australian C. perfringens isolates were tested for the NetB gene, it was 
present in both strains isolated from healthy chickens and those suffering from necrotic enteritis 
(Martin and Smyth, 2009). There were also strains recovered directly from lesions in affected 
birds that were NetB negative (Martin and Smyth, 2009) adding to the evidence against NetB as 
an essential virulence factor. 
 
For more than 20 years, the majority of necrotic enteritis research has focused on the alpha toxin. 
Recently, there have been reports of other immunogens that have shown potential as vaccine 
candidates. Intramuscular immunisation with other C. perfringens secreted proteins such as 
pyruvate:ferredoxin oxidoreductase (PFOR), glyceraldehyde-3-phosphate dehydrogenase, 
fructose 1,6-biphosphate aldolase (FBA) and hypothetical protein (HP) all conferred protection to 
mild challenge whilst FBA and HP protected against a moderate challenge (Kulkarni et al., 2007) 
These results suggest that there may be a synergistic relationship between multiple secreted 
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proteins in the pathogenesis of necrotic enteritis. Subsequently, these secreted proteins were 
also tested in Salmonella vectored vaccines and shown to induce significant protective immune 
responses (Kulkarni et al., 2008). Metalloproteinases and collagenolytic enzymes are soon to be 
investigated as vaccine candidates as it is proposed that they may have a major role in early 
lesion development (Olkowski et al., 2008).  
 
1.8 Salmonella vaccination in livestock 
1.8.1  Current strategies to protect against Salmonella 
Vaccination is the simplest way to reduce bacterial carriage rates in animals. In livestock this is of 
particular importance as many of them become food products and have the potential to elicit 
food poisoning in humans. In other cases, infections by Salmonella can provoke unnecessary 
complications in rearing and farming. In swine, Salmonella enterica serovar Choleraesuis is a 
highly invasive, host-adapted pathogen that lead to sepsis, pneumonia, enterocolitis and hepatitis 
resulting in significant economic losses in the swine industry (Ku et al., 2005). In rare cases, it can 
also result in intestinal infections and infective aneurysms in humans after ingestion of 
contaminated products (Chiu et al., 2005). This strain has become a focus of researchers due to 
its increasing antibiotic resistance to conventional livestock prophylaxis attributed to its many 
pseudogenes which complement lateral gene acquisition for improved virulence and broader 
antibiotic resistance (Chiu et al., 2005). Homologous protection against Salmonella enterica 
serovar Choleraesuis in swine has been tested using S. Choleraesuis phoP and rpoS mutants. This 
study showed that the S. Choleraesuis mutants were successful at proliferating within the primary 
intestinal macrophages, were able to competitively exclude the wild type strain of S. Choleraesuis 
from the pigs and induced good humoral immune responses (Domínguez-Bernal et al., 2008). 
Recently the same group has shown that the S. Choleraesuis phoP and rpoS mutants are 
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successful at delivering DNA vaccines using a model epitope to the intestinal immune system in 
mice (Bartolomé et al., 2010). 
 
Although the primary product derived from sheep is wool, not food products, vaccination against 
specific strains of Salmonella serovars are currently being investigated. One such strain is 
Salmonella enterica subspecies enterica serovar Abortusovis, an ovine-restricted serovar which 
causes contagious late-term abortions in ewes mainly in Europe and Western Asia (Cagiola et al., 
2007). Killed vaccines have been effective against this disease (Pardon et al., 1990) and most 
affected ewes usually abort once then mount a successful immune response against the disease, 
which may be linked to a IFN-γ mediated immune response (Cagiola et al., 2007). Use of a live 
attenuated S. Typhimurium as a single dose vaccination reduced the abortion rate in ewes from 
33.4% in the unvaccinated to ≤ 0.1% in over 100,000 deliveries when compared to inactivated 
vaccines (Linde et al., 1992).  
 
Cattle are another livestock that require vaccination against Salmonella species. Persistent 
colonisation with Salmonella species in calves decreases their appetite resulting in lower feed: 
weight ratios and higher costs for the farmers (Dueger et al., 2003). Salmonella enterica serovar 
Typhimurium lacking DNA adenine methylase has been used to induce both early and late 
protective responses in calves to protect them from becoming carriers (Dueger et al., 2003). 
Cross-protection against S. enterica Dublin has also been shown (Mohler et al., 2006) as well as S. 
enterica serovar Newport which is important as it has become multi-drug resistant and is an 
emerging relevant pathogen in cattle (Mohler et al., 2008).  
 
Poultry is one of the biggest reservoirs of Salmonella (Zhang-Barber et al., 1999) and reducing 
carriage rates has been an ongoing objective. Over the past decade the UK has seen a large 
decline in salmonellosis outbreaks since the implementation of the Lion Code Egg scheme which 
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requires compulsory vaccination against S. Enteritis, strict quality control and independent 
auditing of its eggs (reviewed by (Gormley et al., 2011)). Successful vaccination has been achieved 
using both killed and live Salmonella vaccines. The existing commercial live Salmonella vaccines 
have exhibited an ability to induce significant CD8+ T cell and IgA responses that resulted in 
almost no Salmonella being detected in the caecum where they normally colonise (Carvajal et al., 
2008). In one study the use of a live attenuated Salmonella vaccine resulted in more effective 
clearance of S. Enteritidis in chickens than the killed vaccine. This was attributed to an increased 
cell-mediated response which lead to reduced shedding of the organism and stronger responses 
upon re-exposure (Babu et al., 2004). A recent study used a bivalent killed vaccine in laying hens 
which significantly reduced vertical egg transmission of S. enterica serovars Enteritidis, 
Typhimurium and Gallinarum biovar Pullorum (Okamura et al., 2007). The evolution of live 
vaccines continues and is now focusing on making them multivalent by delivering heterologous 
antigens. 
 
1.8.2  Heterologous antigen presentation via Salmonella vectors 
Pioneer studies into heterologous antigen presentation using Salmonella species as carriers were 
conducted in the early 1980s by Formal and colleagues. The first used the existing attenuated 
typhoid vaccine, Salmonella typhi Ty2la to present the form I antigen from Shigella sonnei which 
conferred protection against both infections when tested in mice (Formal et al., 1981). This 
system where the heterologous antigen is actually expressed by the vector demonstrated to be 
an effective system. Upon further investigation Salmonella was validated as an obvious choice in 
regards to delivering heterologous antigens ensuing from its ability to transfer expression 
plasmids to host cells even though the bacteria were unable to escape the phagocytic vacuole 
(Darji et al., 1997). This is the basis of most modern day DNA vaccines that are not expressed but 
just carried by the Salmonella vector.  Salmonella can also persist in dendritic cells and are usually 
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sampled directly from the intestinal lumen by dendritic cells after ingestion (Rescigno et al., 2001) 
indicating heterologous antigens delivered orally would be presented to the immune system 
earlier.  
 
Most of the attenuated strains used in early vaccine research were auxotrophic strains in which 
essential genes for synthesis of purine (pur), aromatic acids (aro) or guanidine (gua) had been 
deleted or mutated. These mutations gave the desired attenuation of the strain whilst 
maintaining its immunogenicity.  Early research was most promising, for example, the 
administration of an attenuated aroA mutant Salmonella Typhimurium carrying an eukaryotic 
expression plasmid encoding the listerial protein, listeriolysin, was given orally and strong 
cytotoxic and helper T cell production were elicited after the first dose (Darji et al., 2000).  Further 
investigation demonstrated that the heterologous antigen delivered could be detected in Peyer’s 
patches and the spleen several days after the vaccination with the attenuated Salmonella even 
though the expression plasmid was lost soon after administration. It was also evident that 
although this loss occurred, mice that were immunised four times orally were protected against a 
lethal challenge of Listeria monocytogenes (Darji et al., 2000). Although the transference of the 
plasmid to the host nucleus occurs very early on, stabilisation of the plasmid in vitro and in vivo is 
still one critical criteria of a successful live carrier and this can be achieved by using low copy 
number plasmids in the Salmonella vector (Loessner et al., 2008). Another application that has 
been applied to Salmonella vaccines is to have the expression vector as a single copy in vitro but 
upon administration becomes a multicopy plasmid. This has been achieved by having two 
promoters in the plasmid, trfA and sifA, but only sifA is activated upon invasion of the cell and is 
able to dictate both expression and plasmid amplification (Loessner et al., 2008).  
 
The strength of heterologous antigen expression determines the efficacy of a successful live 
carrier vaccine.  However as protein expression places a burden on the metabolic status of the 
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carrier, this can lead to a loss of virulence and reduced viability, which decreases the immune 
response (Loessner et al., 2008). Early investigations into using the Salmonella Type I (ATP-binding 
cassette) secretion system to express heterologous antigens demonstrated that it had a low 
secretion capability, complicated genetic regulation and structural limitations of the secreted 
antigen, which all hinder in vivo delivery and uptake affecting immunogenicity of the antigen 
hence it is unsuitable for heterologous antigen expression (Hahn and von Specht, 2003). 
Salmonella pathogenicity islands are of importance in terms of carrier vaccines as their Type III 
secretion system can be exploited to reduce metabolic burden of the heterologous antigen and 
deliver it to the host cells (Cheminay and Hensel, 2008). The Salmonella Type III system has been 
demonstrated to deliver heterologous antigens to the host-cell cytosol which results in MHC class 
I-restricted immune responses which is useful against viral infections (Rüssmann et al., 1998).  
 
Another aspect of using a carrier to deliver an antigen is how antigen accumulates in the cell as 
the magnitude of the immune response is affected by inefficient presentation to the immune 
system. Hence, many studies have shown that when an antigen is successfully secreted extra-
cellularly the immune response to the antigen can be as much as 104 times higher than when the 
antigen is accumulated in the cytoplasm of the carrier bacterial cell (Boyle et al., 1997; Kang and 
Curtiss, 2003). In one study, the expressed amount of recombinant Streptococcus pneumoniae  
PspA was similar in both Salmonella vaccines despite one being localised in the cytoplasm and the 
other being secreted (Kang and Curtiss, 2003). Another study which used an aro-attenuated 
Salmonella vaccines as a vector successfully protected against plague by expressing the V antigen 
from Yersinia pestis (Garmory et al., 2003). It has also been found that specific immune responses 
triggered against the heterologous antigen are often masked by the dominant immune response 
to the Salmonella vector antigens (Hahn and von Specht, 2003). Another limitation of 
experimental infection trials is the use of a large challenge dose, often 109 CFU, which may not 
reflect the normal conditions under which an animal would be exposed to Salmonella over the 
CHAPTER 1
 
 
~ 44 ~ 
 
course of its lifetime (Zhang-Barber et al., 1999). This means that some poultry vaccines are 
deemed failures even though they may protect against low infectious doses which is typical in 
horizontal spread of Salmonella in flocks.  
 
There have been studies published that have utilised heterologous antigen presentation from a 
live Salmonella vector with the final application to be applied to livestock. Anthrax in cattle is one 
such target.  One study showed that using a vector expressing Bacillus anthracis protective 
antigen protected mice against aerosolised B. anthracis spores when they were vaccinated orally 
(Stokes et al., 2007) and has previously protected against subcutaneously delivered spore 
challenge (Coulson et al., 1994). Using Salmonella as a delivery system for DNA vaccines has also 
proven successful against viral infections in chickens.  Delivery of a hemagglutinin DNA vaccine 
against H9 avian influenza virus was administered to specific pathogen free (SPF) chickens 
followed by a killed avian influenza vaccine, this combination provided complete protection from 
intranasal H9N2 challenge (Pan et al., 2009). It is thought that the stabilised mucosal DNA vaccine 
coupled with a boost by a conventional killed vaccine provided enough stimulation for both a 
strong and persistent humoral and cellular immune response (Pan et al., 2009).  
 
As examined earlier, selected C. perfringens secreted proteins as well as alpha toxin have been 
delivered in Salmonella vectored vaccines (Kulkarni et al., 2008; Zekarias et al., 2008). Both 
studies used an attenuated ΔpabA and ΔpabB  Salmonella Typhimurium with a chromosomal 
deletion of the aspartate B-semi-aldehyde dehydrogenase asd which is complemented with a 
asd+ plasmid which ensures that the plasmid is steadily maintained and expression upheld when 
induced (Kulkarni et al., 2008). The first assessed the immunogenicity of three immunogens 
(PFOR, HP and FBA) each secreted under a lacI promoter (Kulkarni et al., 2008) whilst  the second 
used the carboxyl-terminus domain of the alpha toxin under various promoters (Zekarias et al., 
2008). Both studies achieved partial protection against challenge with C. perfringens and good 
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levels of specific antibodies against Salmonella antigens (Kulkarni et al., 2008; Zekarias et al., 
2008). Both of these groups suggest that better expression of foreign antigens from the selected 
Salmonella vectors will lead to better induction of immune responses.  
 
1.9 Concluding remarks 
Vaccine development has progressed dramatically over the past couple of hundred years, from 
initial variolation techniques (Dinc and Ulman, 2007) to the latest DNA vaccination methods 
(Chang et al., 2007).  There have been many successes such as the smallpox vaccines (Stewart and 
Devlin, 2006) and the recent HPV vaccines (Govan, 2008).  The pursuit of an efficacious vaccine to 
induce protection against multiple diseases would be of enormous value to the poultry industry. 
Many studies have shown that using attenuated vectors to deliver heterologous antigens will 
induce significant immune responses to both the vector and to the heterologous antigen (Darji et 
al., 2000; Bachtiar et al., 2003; Garmory et al., 2003; Cheminay and Hensel, 2008; Kulkarni et al., 
2008; Zekarias et al., 2008).  Over the past decade, even with many conflicting reports about 
alpha toxin as an essential virulence factor, there has been progress in the elucidation of the 
pathogenesis and aetiology of necrotic enteritis. By utilising the best vector technologies and by 
selecting immunogenic antigens, necrotic enteritis could be eliminated from the poultry industry 
globally saving millions of dollars in product and improving the lives of poultry.  
1.10 Rationale of the project 
 
Live attenuated Salmonella vaccines are already established in the field of modern medicine for 
both human and veterinary use. As they are usually delivered in the same manner in which a 
natural infection would occur, the subsequent immune responses are often protective and 
targeted at specific points of the natural infection. In order to take advantage of this immune 
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targeting, an established Salmonella Typhimurium vaccine (STM1) which has been used in the 
livestock industry to prevent salmonellosis in poultry (Coloe et al., 1995) was chosen as the carrier 
vector. Previously, STM1 was demonstrated to have the ability to express a model heterologous 
antigen, ovalbumin. Upon vaccination in mice, the dendritic cells not only up took the STM1 but 
was able to stimulate CD8+ cells specific to the dominant ovalbumin epitope, SIINFEKL and 
mucosal IgA responses (Bachtiar et al., 2003). It is these characteristics that have lead to STM1 
being used in the current study. For the heterologous antigen, the alpha toxin from C. perfringens 
was chosen as it had been shown to be a stable immunogenic antigen when purified fragments 
had been used to vaccinate mice against gas gangrene (Williamson and Titball, 1993). Pre-existing 
immunity to heterologous and homologous Salmonella strains has been reported to not impede 
the efficiency of this vaccine in mice when delivering a model heterologous antigen, ovalbumin 
(Saxena et al., 2009). 
 
The objectives of this project focused on creating alpha toxin variants which retain their 
immunogenicity but lose their toxicity. Several forms of variants were made and tested in various 
animal trials. The effectiveness of STM1 expressing these variants was evaluated in both mice and 
chickens. The efficacy of the STM1 expressing variants was also determined when the chickens 
had prior colonisation with Salmonella enterica serovar Sofia, which is Australia’s most commonly 
isolated commensal Salmonella serovar. 
 ~ CHAPTER 2 ~ 
GENERAL MATERIALS AND METHODS 
2.1 General procedures 
All chemicals used were of analytical laboratory reagent grade. All glassware, media and solutions 
were sterilised by autoclaving at 121°C (15 lbs/in2) for 20 min unless otherwise stated. All 
solutions were prepared with deionised water obtained from a Millipore Milli-Q® water system 
(mH2O) (Liquipure, Melbourne, Australia) excluding media, which was prepared with distilled 
water (dH2O). Glassware was washed with Pyroneg detergent (Diversey-Lever, Pty. Ltd., 
Australia), rinsed twice with tap water, and then twice with deionised water.  
 
Solutions were dispensed using the Finnpipette® digital pipette range (Thermo Labsystems) which 
included a 0.5-10 μL, 5.0-40 μL, 20-200 μL, 200-1000 μL, 1-5 mL, 5-10 mL digital pipette and a 50-
300 μL multi-channel pipette.  Volumes of 1.5 mL or less were centrifuged with the Eppendorf 
microcentrifuge 5415C or 5415D. Greater volumes of up to 50 mL were separated by 
centrifugation in a Beckman Allegra 21R centrifuge. Volumes of up to 200 mL were separated by 
centrifugation in a Beckman J2-21 M/E centrifuge. All products of less than 2 g were weighed on a 
Sartorius analytical top loading balance. Reagents of greater than 2 g were weighed on an ISSCO 
model 300 top loading balance. Media containing supplements were autoclaved and cooled to 
55°C before the addition of the supplement(s). All media was prepared using aseptic technique or 
in a lamina flow cabinet and stored at 4°C until required. 
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2.2 General chemicals and equipment 
2.2.1   Equipment and reagents 
ABI Prism BigDye Terminator Cycle 
Sequencing Ready Reaction kit: Perkin-Elmer 
Corp., USA. 
Anaerogen gas pack: Oxoid, England. 
Balances: 
Analytical balance: Sartorius Gottingen, 
Germany. 
Balance (0.1-500 g): U-Lab, Australia. 
BALB/c mice (female): Animal Resource 
Centre, Canningvale, Western Australia. 
Centricon ultracentrifugal devices: Millipore, 
USA. 
Centrifuges: 
Eppendorf 5414C and 5414D bench top 
centrifuges: Eppendorf Geratebau, Germany 
Beckman Allegra. 21R Centrifuge Beckman 
Coulter, USA. 
Beckman J2-21 M/E Super Centrifuge 
Beckman Coulter, USA. 
Centrifuge tubes: 
1.5 mL Eppendorf centrifuge tubes. Treff AG, 
Switzerland. 
10 mL centrifuge tubes Sarstedt, Germany. 
50 mL centrifuge tubes Greiner 
Labortechnik, Germany. 
200 mL autoclavable centrifuge bottles 
Nalgene Nunc International, USA. 
Chromatography paper (0.18 mm thick): 
Whatman, England. 
Cover slips: Mediglass, Australia. 
Cryovials (1.8 mL): Nalgene Company, USA. 
Dry block heater: Ratek, Australia. 
Electrophoresis power supply: 
PowerPac 300 Biorad Laboratories, USA. 
EPS 3000xi BioRad Laboratories, USA. 
EPS600 Amersham Pharmacia LKB, Sweden. 
Electrophoresis units - 
DNA: 
(a) Mini gel (GNA-100) Pharmacia LKIB, 
Sweden. 
Protein: 
(a) Mini Protean III gel system BioRad 
Laboratories, USA. 
Electroporation cuvettes: 0.2 cm cuvettes 
chilled at -20°C before use, BioRad 
Laboratories, USA. 
Filters: Acrodisc 0.2 μm and 0.45μm, Pall, 
USA. 
Gel Doc image system: BioRad Laboratories, 
USA. 
Geneclean® kit: QBIOgene, USA. 
Microplate reader (96-well) MR7000: 
Dynatech (now Dynex), USA. 
Microscopes: 
Light microscope (CH2) Olympus Optical Co., 
Japan. 
Inverted microscope Olympus, Japan. 
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Microscope slides: LOMB Scientific Co., 
Australia. 
Microtitre plate (96-well, flat bottom): Nunc, 
Denmark. 
Needles (19, 21, and 26 gauge): Terumo Pty, 
Ltd., Australia. 
Nitrocellulose membrane (Trans-Blot®) 0.2 
μm: BioRad Laboratories, USA. 
PCR machines: 
GeneAmp2400 PCR system PerkinElmer, 
USA. 
PCR Express gradient thermal cycler: 
Thermohybaid, UK. 
Petri dishes: BioLab, Australia. 
pH meter: Hanna, U-lab, Australia. 
Platform shaker: Ratek, Australia. 
Pulse controller & Gene pulser apparatus: 
BioRad Laboratories, USA. 
QIAprep® spin miniprep kit: QIAGEN, 
Australia. 
Syringe (1, 5, 10, 20, and 60 mL): Terumo 
Pty, Ltd, Australia. 
Trans-blot electrophoretic transfer cell 
(mini): BioRad Laboratories, USA 
Transilluminator (UV): Novex, Australia. 
Waterbath: Ratek, Australia. 
2.2.2   Materials 
2.2.2.1  General media 
Luria-Bertani (LB) broth: 0.5% (w/v) yeast extract (Oxoid, England), 1% (w/v) tryptone (Oxoid, 
England), 0.5% (w/v) sodium chloride (BDH chemicals, UK). 
Luria-Bertani (LB) agar: 0.5% (w/v) yeast extract (Oxoid, England), 1% (w/v) tryptone (Oxoid, 
England), 0.5% (w/v) sodium chloride, 1.0% (w/v) bacteriological agar (Oxoid, England). 
Columbia agar (CA): 3.9% (w/v) Columbia agar base (Oxoid, England). 
Cooked meat medium (CMM): 1.0 g granules of dehydrated CMM (Oxoid, England) were added 
to bottles and filled to 10 mL with dH2O. 
Sheep blood agar (SBA): CA cooled to 55°C and supplemented with 5% (v/v) defibrinated sheep 
blood (Oxoid, England). 
CHAPTER 2
 
~ 50 ~ 
 
Nagler plate: CA supplemented with 10% egg yolk solution (v/v). The egg yolk was first mixed 
with saline in a 1:1 ratio and centrifuged at 5,500 x g for 10 min. The supernatant was used for 
preparation of the plates. 
Thioglycollate broth: 2.9% (w/v) of thioglycollate (alternative) (Oxoid, England) broth was 
prepared and boiled to completely dissolve the medium. Ten millilitre aliquots were dispensed 
into 20 mL bottles. 
 
2.2.2.2  General solutions 
β-mercaptoethanol: electrophoresis purity (Biorad Laboratories, USA). 
λ-DNA marker: A solution of 0.1 μg/μL digested λ-DNA was prepared by incubating 20 μg λ-DNA 
(Promega, Australia), 18 μL Buffer H (Promega, Australia), 10U Pst1 (Promega, Australia) and 
mH2O up to 180 μL, at 37°C overnight. The digestion was ceased by heating at 65°C for 15 min and 
twenty microlitres of 11x DNA loading buffer was then added. The marker was stored at -20°C 
and 10 μL aliquots used on a DNA agarose gel. 
Acrylamide/bisacrylamide solution: A 40% (w/v) prepared solution containing 38.67% (w/v) ultra 
pure acrylamide and 1.33% (w/v) bisacrylamide (Australia Scientific, Australia). 
Agarose: 1% (w/v) DNA grade agarose (Progen Industries, Australia) in 1x TAE buffer, dissolved by 
heating in a microwave. 
Ammonium persulphate (APS): 10% (w/v) ammonium persulphate (Sigma-Aldrich, Germany) 
stored at 4°C. 
Ampicillin: 100 mg/mL ampicillin (CSL, Australia), filter sterilised. 
BCIP/NBT solution for detection of alkaline phosphatase antibodies: 0.48 mM 5-bromo-4-
chloro-3-indolyl phosphate (BCIP) and 0.51 mM nitro blue tetrazolium (NBT) (Amresco, USA). 
Binding buffer: 25 mM Tris (Astral Scientific), pH 8.0, 0.5 M NaCl (BDH), 60 mM imidazole (Sigma-
Aldrich). 
Blocking solution (ELISA): 5% skim milk in PBST. 
CHAPTER 2
 
~ 51 ~ 
 
Bovine serum albumin fraction V (BSA): 1 mg/mL (Sigma-Aldrich, Germany), stored at -20°C. 
Bradford reagent: 100 mg Coomassie Brilliant G-250 (Sigma-Aldrich, Germany) dye was dissolved 
in 50 mL 95% (v/v) ethanol, then mixed with 100 mL 85% (v/v) phosphoric acid, and brought up to 
1 L with dH2O. The solution was stored at 4°C, and filtered through a 0.45 μm filter before use. 
Bromophenol blue: 1% bromophenol blue (BDH, USA) (w/v). 
Calcium chloride (CaCl2): 1 M CaCl2 (BDH, USA) filter sterilised. 
Cell lysis buffer: 25 mM Tris, pH 8.0, 0.5 M NaCl, 50 mM imidazole. Lysozyme (4mg/mL) was 
added to the buffer immediately prior to use. 
Chloroform: 100% (v/v) chloroform (BDH, USA). 
Chloroform: Isoamyl (CI): 96% (v/v) chloroform (BDH, USA), 4% (v/v) isoamyl alcohol (BDH, USA). 
CIAP Stop buffer: 10 mM Tris-HCl (pH 7.5), 1 mM EDTA (Sigma-Aldrich) (pH 7.5), 200 mM NaCl 
(BDH, USA), 0.5% SDS (BDH, USA). 
Coating buffer: 0.016 M Na2CO3, 0.034 M NaHCO3, pH 9.6. 
Coomassie blue destain solution: 10% (v/v) ethanol (BDH, USA) and 10% (v/v) glacial acetic acid 
(BDH, USA). 
Coomassie blue stain solution: 0.1% (w/v) Coomassie brilliant blue R-250 (Sigma-Aldrich), 50% 
(v/v) methanol (BDH, USA), 10% (v/v) glacial acetic acid (BDH, USA). 
Detection buffer: 100 mM Tris, 100 mM NaCl, pH9.5 
Dextran: 10 mg/mL stored at -20°C (Sigma-Aldrich, Germany) 
DNA loading buffer 11.: 10% (w/v) ficoll (Sigma-Aldrich, Germany), 50% (v/v) glycerol (BDH, USA), 
0.5% (w/v) Orange G (Sigma-Aldrich, Germany), 1% (w/v) SDS (BDH, USA), 10 mM EDTA (BDH, 
USA), 50 mM Tris (pH 8.0). 
dNTPs (deoxynucleotide triphosphates): 25 mM each of dATP, dGTP, dTTP and dCTP (Bioline, 
Denmark) 
Elution Buffer: 25 mM Tris, pH 8.0, 0.5 NaCl, 200 mM imidazole. 
Ethanol: 70% (v/v), 95% (v/v), 100% (v/v) analytic ethanol (BDH, USA). 
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Ethidium bromide (EtBr): A stock solution of 10 mg/mL EtBr (BM). This solution was not 
autoclaved. 
Ethylenediaminetetra-aetate (EDTA) buffer: 0.25 M EDTA (BDH, USA), pH 8.0. 
Folin’s reagent: Folin & Ciocalteaus reagent (BDH, USA) diluted 1:1 in mH2O, stored at 4°C away 
from light. 
Formaldehyde: Formaldehyde (37% w/v) was purchased from Sigma-Aldrich, Germany and used 
at a final concentration of 0.4% (w/v). 
Glycerol: 100%, 50% (v/v) glycerol (BDH, USA). 
Hydrochloric acid: 32% (w/v) (Ajax Chemicals Ltd., Australia). 
Hydrogen peroxide (H202): 30% (w/v) H2O2 (BDH, USA). 
Imidazole: A 5 M Imidazole stock solution (Sigma-Aldrich, Germany) was prepared and filtered 
through a 0.45 μm filter. 
Isopropanol: Propan-2-ol (BDH, USA). 
Isopropyl-β-D-thiogalactopyranoside (IPTG) 1 M stock: 0.2 g/mL IPTG (Astral Scientific, 
Australia), filter sterilised. One millilitre aliquots were stored at -20°C. 
Lowry reagent A: 2% (w/v) sodium carbonate (BDH, USA), 0.4% (w/v) sodium hydroxide (BDH, 
USA), 0.16% (w/v) sodium potassium tartrate (Sigma-Aldrich, Germany) and 1% (w/v) SDS. 
Lowry reagent B: 4% (w/v) copper sulphate (Ajax Chemicals Ltd., Australia) 
Magnesium chloride: BDH, USA  
Methanol: 100% (v/v) (BDH, USA). 
Nickel Sulphate (0.2 M): Nickel sulphate (2.6 g) (BDH, USA) was dissolved in 50 mL of mH2O. 
Phenol (saturated): Supplied by Astral Scientific, Australia. 
Phenol/chloroform-isoamyl: A ratio of 25:24:1 (BDH, USA) of phenol, chloroform and isoamyl 
alcohol. 
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Phosphate-buffered saline (PBS): 1 tablet Dulbecco’s A PBS (Oxoid, England) in 100 mL mH2O 
(sodium chloride 0.8%, potassium chloride 0.02%, disodium hydrogen phosphate 0.115% 
potassium dihydrogen phosphate 0.02%). 
PBST: PBS and 0.05% (v/v) Tween 20 (polyoxyethylene sorbitan monolaurate, Sigma-Aldrich, 
Germany). 
Plasmid isolation solution I: 50 mM glucose (Sigma-Aldrich, Germany), 10 mM EDTA (BDH, USA), 
25 mM Tris-HCl (pH 8.0, Amresco, USA). Lysozyme (4 mg/mL) was added immediately prior to 
use. 
Plasmid isolation solution II: 1% (w/v) SDS (BDH, USA), 0.2 M NaOH (BDH, USA). 
Plasmid isolation solution III: 60 mL of 5 M potassium acetate (BDH, USA) (final concentration 3 
M), 11.5 mL glacial acetic acid (BDH, USA) (final concentration 5 M) and 28.5 mL mH2O. 
Protein lysis buffer 1: 25 mM Tris, pH 8.0, 0.5 M NaCl, 50 mM imidazole. Lysozyme (1 mg/mL) 
was added to the solution just before use. 
Saline: 0.85% sodium chloride (BDH, USA). 
SDS loading buffer (5x): 60 mM Tris (pH 6.8), 25% (v/v) glycerol (BDH, USA), 2% (w/v) SDS (BDH, 
USA), 14.4 mM β-mercaptoethanol (BioRad Laboratories, Australia), 0.1% (w/v) bromophenol 
blue (Sigma- Aldrich, Germany). 
SDS-PAGE Separating gel (12.5%): 375 mM Tris. HCl (pH 8.8), 0.1% w/v SDS , 12.5% v/v bis 
acrylamide with setting agents added prior to pouring: 0.06% w/v ammonium persulfate, 0.03% 
v/v TEMED. 
SDS-PAGE Stacking gel (4.5%): 125 mM Tris. HCl (pH 6.8), 0.1% (w/v) SDS and 4.5% bis acrylamide 
with setting agents added prior to overlaying of separating gel: 0.06% (w/v) ammonium 
persulfate and 0.03% (v/v) TEMED. 
SDS running buffer stock (10x): 0.25 M Tris, 1.92 M glycine (BDH, USA), 1% (w/v) SDS (BDH, USA). 
The pH was adjusted to 8.3. 
Skim milk: Bonlac Foods Limited, Australia. 
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Sodium acetate: 3 M (BDH, USA), pH 4.6. 
Sodium chloride: 5 M stock solution of sodium chloride. 
Sodium dodecyl sulphate (SDS): 10% (w/v) SDS (BDH, USA). 
Sodium hydroxide (NaOH): 10 M stock solution (BDH, USA). 
Sulphuric acid (H2SO4) (TMB stop solution): 1.0 M sulphuric acid (BDH, USA). 
TCA: 100% (w/v) Trichloroacetic acid 
TE buffer x10: 100 mM Tris (BM), 10 mM EDTA (Amresco), pH 8.0. 
TEMED (N,N,N.,N.-tetramethylethylenediamine): Electrophoresis purity (BioRad Laboratories, 
Australia). 
Tetramethylbenzidine (TMB): TMB substrate reagent A (BD Biosciences, USA) and TMB substrate 
reagent B (BD Biosciences, USA) were mixed in a ratio of 1:1 and used within 10 min.  
Transfer buffer: 25 mM Tris (Amresco, USA), 192 mM glycine (BDH, USA), 20% (v/v) methanol 
(BDH, USA). 
Tris (hydroxymethyl) aminomethane (Tris): 2 M stock solution (BDH, USA) 
Tris-Acetate buffer (TAE) x 50: 2 M Tris, 1 M acetic acid, 0.1 M EDTA. 
Tris buffered saline (TBS): 25 mM Tris, 0.18 M sodium chloride, pH 7.4. 
Trypan Blue stain: Purchased from Sigma (0.4%) (w/v) 
Tryptone: Oxoid, England. 
TST: 10 mM Tris (pH 7.4), 150 mM NaCl (BDH, USA) and 0.05% (v/v) Tween 20 (polyoxyethylene 
sorbitan monolaurate, Sigma-Aldrich, Germany). 
Wash Buffer (IMAC): 25 mM Tris, pH 8.0, 0.5 M NaCl, 60 mM imidazole. 
Western blot substrate solution (for HRP antibodies): Chloro-1-naphthol (30 mg) (Sigma-Aldrich, 
Germany) was dissolved in 10 mL methanol (BDH, USA), brought up to 50 mL with TBS, mixed 
with 30 μL hydrogen peroxide (H2O2) and used immediately for the development of Western 
blots probed with horseradish peroxidase (HRP) conjugates. 
Whole cell lysis buffer: 0.1 M Tris, 2% (v/v) SDS and 15% (v/v) glycerol, pH 6.8. 
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2.2.2.3  Enzymes 
All enzymes were used with their supplied buffer according to manufacturer’s instructions, and 
were stored at -20°C unless otherwise stated. 
DNA polymerase, Expand Long Template PCR system: 5U/μL (Roche, Germany). 
DNA polymerase, Pfu: 3U/μL (Promega, USA). 
DNA polymerase, Platinum Taq: 5U/μL (Invitrogen, USA) 
Restriction enzymes: See Table 2.4 
Calf intestinal phosphatase (CIAP): 10U/μL (Promega, USA), stored at 4°C. 
DNase I bovine pancreas: A stock of 10U/μL was prepared from a lyophilised vial of DNase 
(Sigma-Aldrich, Germany). 
RNase solution: 10 mg/mL ribonuclease 1A bovine pancreas (Pharmacia, Australia). For DNase 
free RNase, the RNase solution was boiled for 30 min. 
Lysozyme solution 1: 20 mg/mL lysozyme (BM) in EDTA buffer, prepared at use. 
DNA Ligase (T4): 10U/μL (Boehringer Mannheim, Germany). 
 
2.2.2.4  Antibodies 
Horse anti-α-toxin polyclonal antisera (gas-gangrene antisera): CSL, Australia 
Rabbit anti-chicken IgA-HRP: Sapphire Bioscience, Australia 
Rabbit anti-horse IgG (H+L)-HRP: ICN, USA 
Goat anti-chicken IgG-HRP: Sapphire Bioscience, Australia 
Goat anti-mouse IgG-HRP: ICN, USA 
Rabbit anti-horse IgG (H+L)-alkaline-phosphatase: Sigma-Aldrich, Germany. 
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2.3 Microbiological methods 
2.3.1  Bacterial strains, plasmids and recombinant proteins 
developed throughout the study 
The description of all the bacterial strains used throughout this study is listed in Table 2.1. A 
description of all plasmid vectors developed throughout the study is listed in Table 2.2. 
 
2.3.2   Bacterial storage 
E. coli and Salmonella strains were stored at -70°C in 50% glycerol. C. perfringens strains were 
stored at -70°C in a solution containing 10% skim milk, 1% tryptone, and 10 mM Tris, pH 7.5. 
 
2.3.3   Culture conditions 
All E. coli and Salmonella strains were grown on solid microbiological media under aerobic 
conditions at 37°C for 16 h. In instances where broth cultures were used, the strains were grown 
aerobically at 37°C for 16-20 h on a Ratek orbital shaker set at 120 rotations per min. All 
clostridial species grown on solid agar were placed in airtight jars and an anaerobic environment 
was maintained with an Anaerogen gas pack (Oxoid, England) containing ascorbic acid as the 
active component. Clostridia species were grown at 37°C for 16-20 h.  
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Table 2.1: Bacterial strains used in this study. 
Bacterial strain Genotype/Description Source 
Clostridium perfringens   
60 Type A NE isolate from a chicken 
Escherichia coli Genotype/Description Source 
TOP10F’ F´(lacIq, Tn10(TetR)) mcrA (mrr-
hsdRMS-mcrBC) 80lacZ M15 
lacX74 recA1 araD139 (ara-
leu)7697 galU galK rpsL (StrR) 
endA1 nupG 
Invitrogen, Australia 
BL21 F- ompT hsdSB(rB
-mB
-) gal dcm 
(DE3) 
Invitrogen, Australia 
DH5 F’/endA1, hsdR17(r
-
Km
+
K), subE44, 
thi-1, recA1, gyrA (NalR), relA1, 
(lacZYA-argF)U169 
(m80lacZM15) 
(Hanahan, 1983) 
Salmonella spp  Genotype/Description Source 
Salmonella Typhimurium 
LT2-9121 
leu hsdL trpD2 rpsL120 ilv52 
metE551 metA22 hsdA hsdB 
Prof. P. Reeves, Department of 
Microbiology, The University of 
Sydney 
Salmonella Typhimurium 
STM1 
ΔaroA- Δserc- RMIT University 
Salmonella Typhimurium 
82/6915 
Wild type Inv+ (Alderton et al., 1991) 
Salmonella enterica 
serovar Sofia 
Wild type Bt8 Dr. Margaret McKenzie, 
Inghams Enterprises Pty Ltd., 
Springwood, Queensland 
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Table 2.2: Plasmid vectors used in this study. 
Plasmid Description/Genotype Source/Reference 
pCR2.1 3.9 kb PCR cloning plasmid, AmpR, KmR, lacZ  Invitrogen 
pCRplc 1.24 kb amplified fragment from C. perfringens strain 
61 containing the complete plc with a 6xCAT (coding 
for 6xHis) at the 5’ end, cloned into pCR2.1 using TA 
cloning 
Dr Xenia Gatsos 
pCRplc2 Two point mutation with two base changes at each 
of sites 84 (D→A) and 96 (H→S). 
This study 
pCRplcInv Inverse amplified and self-ligated pCRplc (with 
nucleotides 250-309 of plc deleted) 
Dr Xenia Gatsos 
pRSETA 2.9 kb protein expression plasmid: AmpR, N-terminus 
6xHis, T7 promoter 
Invitrogen 
pRplc104 DNA sequence coding for the C-terminus of plc 
(nucleotides 882-1243) cloned into the PstI and EcoRI 
sites of pRSETA 
Dr Xenia Gatsos 
pMOhly1 11.9 kb protein expression plasmid containing the 
E. coli hemolysin secretion system. Genes of interest 
are ligated into a truncated hlyA’, immediately 
upstream of the C-terminus secretion signal and 
downstream of the initiation codon. 
Dr I. Gentschev 
pMO104 DNA sequence coding for the C-terminus of plc 
(nucleotides 882-1243) in the hlyA’ expression gene 
in pMOhly1 
This study 
pMOInv Full plc sequence with deletion of nucleotides 250-
309 inserted into hlyA’ expression gene in pMOhly1 
This study 
pMNInv plc (deletion of nucleotides 205-309) with additional 
deletion of internal signal peptide (nucleotides 1-84) 
inserted into hlyA’ expression gene in pMOhly1 
 
This study 
pMOplc2 Full plc2 inserted into pMOhly1 vector 
 
This study 
pMNplc2 plc2 with additional deletion of internal signal 
peptide (nucleotides 1-84) 
 
This study 
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Broths for clostridial cultivation were used immediately, once cooled from sterilisation. If not 
used immediately, day old broths were boiled for ten min prior to C. perfringens inoculation to 
remove any dissolved oxygen. 
 
2.4 Methods of DNA analysis 
2.4.1   Alkaline lysis plasmid extraction (miniprep) 
Plasmids used in restriction digests were purified by using the alkaline lysis method described in 
Current Protocols in Molecular Biology (Ausubel, et al., 1994). One and a half millilitres of an 
overnight culture was placed in a microfuge tube and the cell pellet collected by centrifugation at 
16,000 x g for 2 min. The pellet was resuspended in 100 μL of plasmid isolation solution I and left 
at room temperature for 5 min followed by cell lysis using 200 μL of plasmid isolation solution II. 
The solution was placed on ice for 5 min followed by the addition of 150 μL ice cold plasmid 
isolation solution III to precipitate chromosomal DNA and protein. The precipitate was separated 
by centrifugation at 16,000 x g for 10 min at 4°C and the supernatant transferred to a new 
microfuge tube. Fifty microlitres of PCI was added to the tube and mixed by vortex. The upper 
aqueous phase was collected by centrifugation at 16,000 x g for 2 min and mixed with 50 μL of CI. 
The solution was mixed by vortex and pelleted by centrifugation as above. The aqueous phase 
was collected and 2 volumes of 96% ethanol added to precipitate the plasmid DNA. Plasmid DNA 
was pelleted by centrifugation at 16,000 x g for 5 min, the supernatant decanted and the pellet 
air-dried before the addition of 40 μL 10 mM Tris, pH 8.0 and stored at -20°C. 
 
2.4.2   Plasmid extraction for DNA sequencing 
Plasmid DNA required for sequence determination was purified using the QIAprep® spin miniprep 
kit as per the manufacturer’s instructions. 
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2.4.3   Extraction of DNA from agarose 
DNA was excised from the agarose gel and extracted using the GeneClean® kit according to the 
manufacturer’s instructions. 
 
2.4.4   Agarose gel electrophoresis 
Ten microlitres of PCR or extracted DNA product and 2.0 μL of 11x DNA loading buffer were 
combined and separated on a 1-2% DNA grade agarose gel in a minigel or midigel unit filled with 
1x TAE buffer. A current of 100 V was applied to the gel, and the DNA fragments separated for 1 
h. The gel was then stained in a 3 μL/mg EtBr bath for 5 min, followed by a 20 min destaining 
period in running tap water. 
 
The DNA products were visualised with an UV illuminator and photographed using the Geldoc 
imaging system (BioRad Laboratories). Sizes of DNA fragments were estimated by the addition of 
lambda (λ) DNA previously digested with PstI (λ-PstI) to the gel prior to electrophoresis. A 
diagram of the λ-DNA sizes is located in Appendix 1. 
 
2.4.5   Spectrophotometric quantification of DNA 
The Shimadzu UV-160 Spectrophotometer was used to determine the optical density (OD) of a 
solution of DNA at a wavelength of 260 nm, which is the optimal wavelength for nucleic acids. 
Protein contamination was detected by an OD reading at 280 nm. An OD ratio of DNA/protein 
was then used to measure the quality of the DNA. Ratios of 1.8-2.0 indicated good quality DNA 
(Sambrook and Russell, 2001). An OD of 1 corresponded to 50 μg/mL double stranded DNA and 
the amount of DNA present was determined using this standard. 
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2.4.6  DNA gel electrophoresis quantification of DNA 
Lambda-DNA previously digested with PstI was separated on an agarose gel along with sample 
DNA fragments. The quantity of DNA within each digested fragment of λ-DNA is listed in Appendix 
1 and was compared with intensities of unknown DNA samples. 
 
2.5 DNA manipulation 
2.5.1   Restriction enzymes 
The restriction enzymes (RE) used throughout the study are listed in Table 2.3. Approximately 1 
μg of plasmid DNA was digested with 1U of enzyme containing 1x buffer in a total volume of 10-
20 μL at 37°C for 2 h. Enzymes were heat inactivated at 65°C for 15 min when DNA was to be used 
in cloning experiments. All restriction enzymes were purchased from Promega, USA. 
2.5.2   Amplification of DNA 
2.5.2.1  Primers 
Primers were designed with the aid of the software program Sci Ed Central for Windows 95. 
Primers were designed to have a guanine & cytosine (GC) content between 40-60% with a melting 
temperature (Tm°C) in the range of 55-75°C. Primers were obtained as lyophilised samples from a 
number of companies (Table 2.4). 
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Table 2.3: List of restriction enzymes (RE) used in this study. 
Restriction enzyme Recognition sequence 
AluI  AGCT 
BamHI GGATCC 
NsiI ATGCAT 
PstI CTGCAG 
SalI GTCGAC 
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Table 2.4: List of primers used throughout this study. 
Primer name Sequence (5’ → 3’) Description Tm°C* 
plcInv-PstIRev CCGCCGCTGCAGCTTTTATATTAT Reverse primer for amplification of plcInv 69.1 
plcInv-PstIForw CGCCTGCAGCGAAAAGAAAGA Forward primer for amplification of plcInv 70.5 
NSPInvPstI Forw ATACTGCAGCGTGGGATGGAAAGA Forward primer to remove internal signal peptide for 
amplification of plcInv 
60.4 
plc104-NsiIForw CGCATGCATCCGAAAAAGATG Forward primer for amplification of plc104 69.4 
NP104-NsiI Rev GCGGCCGATGCATCTTTTATATTAT Reverse primer for amplification of plc104 67.9 
SEQFpMOhly1 ATTGCACTCAGCAGGAC Forward sequencing primer of pMOhly1 57.1 
SEQRpMOhly1 GAAGCTACCTGCAGCTGA Reverse sequencing primer of pMOhly1 59.4 
    
*Calculated by company of synthesis  
Bases highlighted are enzyme recognition sites with: 
Pink sequence indicating a PstI recognition site  
Green sequence indicating an NsiI recognition site 
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2.5.2.2  Polymerase chain reaction (PCR) 
General PCR was performed according to the polymerase manufacturer’s instructions. The 
general reaction mix and programs used are listed in Table 2.5, 2.6 and 2.7. The annealing 
temperature is specified in the relevant chapters. PCR products for cloning purposes were 
amplified using Pfu polymerase (Promega, USA), Platinum Taq polymerase, or Expand Long 
template PCR system (Roche, Germany) to reduce errors. PCR for general detection of fragments 
was prepared with Platinum Taq polymerase. 
 
The reagents were prepared in the sterility of a Biological Safety Cabinet, Class II. A Perkin- Elmer 
DNA Thermal Cycler or a ThermoHybaid gradient cycler was used to amplify the DNA. 
Approximately 10 ng of template plasmid DNA was used for the reactions. Reactions were 
prepared in a final volume of 25 μL, when a high concentration of amplified DNA was required the 
reaction was prepared in a final volume of 50 μL. 
 
2.5.3   Phosphatase treatment of vector DNA 
Digested vector, up to 1 μg, was treated with 0.04U of CIAP and incubated for 30 min at 37°C. A 
further 0.04U was added and incubated for another 30 min. A 200 μL volume of CIAP Stop buffer 
was added and the DNA solution cleaned with PCI. The DNA was precipitated with 95% w/v 
ethanol and collected by centrifugation at 16,100 x g for 15 min and resuspended in 10 μL of 
molecular grade water. 
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Table 2.5: Standard reaction conditions for amplification of DNA by PCR. 
PCR reagent Final concentration 
DNA template 10-100 ng 
dNTP 0.2 mM 
Primer A 0.2 M 
Primer B 0.2 M 
10 x PCR buffer (supplied with polymerase) 1 x 
MgCl2 (Platinum Taq only) 2.5 mM 
Polymerase: 
Pfu 
Platinum Taq 
Expand Long Template range 
 
1.5U/50 L 
1.0U/50 L 
2.5U/50 L 
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Table 2.6: Standard amplification conditions of PCR with Platinum Taq and Expand Long range 
polymerase. 
Temperature (oC) Time (s) Cycles 
94 120 1 
94 10  
Specific Annealing °C 30  
68 Taq 60/kbp 35 
68 Expand 60/kbp 
68 10 min 1 
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Table 2.7: Standard amplification conditions with Pfu polymerase. 
Temperature (oC) Time (s) Cycles 
94 120 1 
94 45  
Specific Annealing °C 45 35 
72 120/kB  
72 10 min 1 
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2.5.4   Ligation 
Ligations were performed with purified digested DNA at a ratio of 1 vector molecule to 3 
molecules of insert with the addition of 2U T4 ligase and buffer in a total volume of 10-20 μL. The 
reaction was incubated at 14-16°C overnight. In some instances digested DNA was ligated without 
further purification. In these cases the volume of digested DNA never exceeded 1/3 the total 
reaction volume. The ligated DNA was then purified prior to transformation via electroporation, 
or used directly for transformation with chemically competent cells. 
 
2.5.4.1  Purification of DNA from ligation for electroporation 
DNA ligations were precipitated from their buffers in order to prevent arcing during 
electrotransformation. This was done by the addition of 0.1 vol of 3 M sodium acetate, 2.5 vol of 
100% ethanol, and 1 μL dextran (of a 10 μg/μL stock) directly into the ligation. The reaction was 
mixed by vortex and left on ice for 10 min. The DNA was then precipitated by centrifugation at 
16,000 x g for 5 min. The sample was washed in 70% ethanol and the centrifugation process 
repeated. The DNA was resuspended in 10 μL molecular grade water and transformed via 
electrotransformation as described below. 
 
2.5.5   Electrocompetent cell preparation 
Bacterial cells were prepared for electrotransformation by the method supplied with the Gene 
Pulser apparatus user’s manual (BioRad, Laboratories). Briefly, 200 mL of Luria-Bertani broth (LB) 
was inoculated with 1/100 volume of an overnight bacterial culture. The cells were grown with 
vigorous shaking at 37°C to an OD600 of 0.5-0.7 (early to mid-log phase). The culture was chilled on 
ice for 15 to 30 min and the culture pelleted by centrifugation in 50 mL tubes at 5,445 x g for 15 
min at 4°C. The supernatant was drained and the pellet resuspended in an equal volume of ice-
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cold mH2O. The centrifuge process was repeated and the cells resuspended in a total volume of 
100 mL of ice-cold mH2O. The cells were pelleted as above and resuspended in 4 mL ice-cold 10% 
glycerol. The cells were pelleted once again and resuspended with 10% glycerol in a final volume 
of 400 μL. Aliquots of 40 μL were distributed to 1.5 mL tubes and stored at -70°C until required. 
 
2.5.6   Electrotransformation 
The method supplied with the Gene Pulser apparatus user’s manual (BioRad Laboratories) was 
employed for the high efficiency electrotransformation of E. coli and S. Typhimurium. Frozen 
electrocompetent cells were thawed on ice for 15 min and mixed with up to 2 μL of unpurified 
DNA or 10 μL of purified DNA and transferred to an ice-cold electrocuvette with a 0.2 cm gap. The 
pulse settings used to deliver DNA into the cells were 2.5 kV, 25 μF and 200 Ω. 
 
After the pulse, LB was immediately added to the cells to a total volume of 1 mL and were 
incubated at 37°C for 1 h. One hundred microlitres of transformed culture was plated out onto 
Luria-Bertani (LB) agar containing the appropriate selective agents. In some instances the 
remaining contents of the transformation mixture were concentrated by centrifuging at 5,455 x g 
for 5 min and also plated onto LA containing the appropriate selective agents. 
 
2.5.7   Sequence analysis 
DNA was amplified using the ABI Prism BigDye Terminator Cycle Sequencing Ready Reaction kit 
(PerkinElmer). DNA from pRSETA was amplified using primers pRSETRev and T7promoter, and 
DNA from the pMOhly1 plasmid was amplified using primers SEQFpMOhly1 and SEQRpMOhly1. 
The amplified DNA was then collected by precipitation with 2.5 vol of absolute ethanol and 0.1 
vol of 3 M sodium acetate as described in the manufacturer’s protocol and was sequenced using 
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the ABI Prism 377 DNA Sequencer with XL Upgrade (PerkinElmer) at Monash University (Clayton 
Campus), Victoria, Australia. 
 
2.6 Protein methods 
2.6.1   Preparation of whole cell lysates 
Samples of E. coli and Salmonella from broth cultures were pelleted by centrifugation at 16,000 x 
g for 2 min. The pellet was resuspended in 0.1 vol of whole cell lysis buffer and the sample boiled 
for 5 min. Debris was pelleted by centrifugation and the protein content of the supernatant was 
determined using the Lowry method. 
2.6.2   Protein determination 
2.6.2.1  Bradford assay 
Protein content determination in samples containing no traces of detergent was performed using 
the Bradford method (Bradford, 1976; Bollag and Edelstein, 1991). 
 
One millilitre of Bradford reagent was added to 100 μL of sample, or standard, mixed by inversion 
and left to stand for 2 min. When required, samples and standards were diluted in 0.15 M NaCl. 
Bovine serum albumin fraction V (BSA) was used as the standard protein solution. Two hundred 
microlitres of processed sample was added to the wells of a 96-well microtitre plate. The OD of 
samples was determined with a Dynatech ELISA plate reader at 600 nm (OD600), and a standard 
curve constructed by plotting the concentrations of the bovine serum albumin standards (μg) 
versus absorbance was used to determine the protein content of unknowns. 
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2.6.2.2  Lowry assay 
The Lowry assay was performed on samples containing the detergent SDS. Lowry reagent A and 
Lowry reagent B were mixed in a ratio of 100:1 to produce Lowry reagent C. Six hundred 
microlitres of reagent C was mixed with 200 µL of bacterial cell lysate (or BSA protein standards) 
then incubated at room temperature for 20 min. Sixty microlitres of Folin’s reagent (Folin-
Ciocalteau reagent diluted 1:1 in water) was added then mixed rapidly and left to stand for 30 
min. Two hundred microlitres of the mixture was dispensed into wells of a 96- well microtitre tray 
and the OD600 was determined. A standard curve was constructed by plotting the concentrations 
of the bovine serum albumin standards (μg) versus absorbance, and the concentration of 
unknown samples determined. 
 
2.6.3   SDS-PAGE 
SDS-PAGE was performed using a discontinuous buffer system (Bollag and Edelstein, 1991). 
The gels were prepared using SDS stacking gel buffer and SDS separating gel buffer. Proteins were 
mixed with SDS loading buffer and heated to 100°C in a dry heating block for 5 min. The proteins 
were separated by electrophoresis at 80 V for 30 min and then at 200 V for 35 min in an 
electrophoresis unit (BioRad Laboratories) containing SDS running buffer. Two gels were run at 
the same time in this system. Gels that were not transferred onto nitrocellulose membranes for 
immunoblotting were stained with Coomassie blue. The SeeBlue Plus2 protein marker was 
separated alongside protein samples and used for the determination of relative protein mass 
(Appendix 2). 
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2.6.4   Coomassie staining 
SDS PAGE gels were stained in Coomassie blue staining solution for 30 min. Gels were rinsed 
under dH2O and destained in the Coomassie destain solution for up to 2 h. A tissue was folded 
and placed into the destaining solution to assist with the removal of the stain. 
 
2.6.5   Immunoblotting 
2.6.5.1  Protein electrophoretic transfer and immunoblotting 
Proteins resolved by SDS-PAGE gels were transferred by electrophoresis onto a nitrocellulose 
membrane padded with 4 sheets of Whatman chromatography paper and a scotch-brite pad on 
both sides of the cassette. Transfer buffer was added to the tank and the electrophoretic transfer 
was carried out at 70 V for 1.5 h. A container of ice was placed in the buffer to maintain a cool 
temperature to prevent overheating of sample transfer. After electrophoretic transfer, the 
nitrocellulose membrane was blocked by incubation with 5% (w/v) skim milk in TBS for 1 h on a 
rotary shaker. The skim milk solution was removed and the membrane washed twice by gentle 
agitation in TBS for 2 min. The membrane was then incubated overnight at 4°C on a rotary shaker 
with 25 mL of TST containing adsorbed antiserum. The membrane was then washed 2 times in 
TBS buffer for 5 min. Horseradish peroxidase-conjugated (HRP) antibodies diluted 1:5000 or 
alkaline phosphatase-conjugated (AP) antibodies diluted 1:15000 in TBS containing 1% skim milk 
were used as the secondary antibodies and were incubated with the membrane for 1 h shaking at 
22°C. The membranes were washed 3 times in TBS for a total of 5 min and for HRP antibodies, the 
bound peroxidase was visualised by incubating in the Western blot substrate solution for 
approximately 5-15 min. For blots with AP as the secondary antibody, the blot was equilibrated in 
detection buffer for 10 min and then the AP labelled bands developed in BCIP/NBT solution. The 
reaction was stopped by washing the blot in dH2O. 
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2.6.6   Enzyme-linked immunosorbent assay 
Ninety-six well flat bottomed sterile plates (Greiner, Germany) were coated with 100 μL of 5 
μg/mL purified protein or 10 μg/mL of a mixed protein sample diluted in PBS and incubated for 1 
h at 37°C or 4°C overnight. Unbound protein was removed with 3 washes in PBST and the plate 
coated with 200 μL of blocking buffer. After a further hour incubation at 37°C, plates were 
washed as above, patted dry on absorbent paper towelling, and 100 μL of primary antibody two-
fold serially diluted in diluent (1% skim milk, PBST) was added. Plates were incubated at 37°C with 
vigorous shaking on an ELISA shaker platform for 2 h. The solution was discarded, wells washed 4 
times in PBST and patted dry. Secondary antibody conjugated to HRP was diluted 1:5000 in PBST 
(1% skim milk) and 100 μL added to the wells of the ELISA plate. Following a 1 h incubation at 
37°C on a shaking platform, the plates were washed 4 times in PBST followed by a wash in dH2O 
and then patted dry on absorbent paper. Tetramethylbenzidine (TMB) substrate was prepared 
and 100 μL added to all wells. The development of the reaction was allowed to proceed for up 30 
min and the reaction was stopped with 50 μL of 1 M sulphuric acid. The OD450 of the wells was 
determined in a Dynatech ELISA microplate reader. The endpoint was determined as the dilution 
at which the OD450 was 3 times the background level (OD≥0.2). All samples were tested in 
duplicate. 
 2.7 Animal studies 
2.7.1   Mouse studies  
Specific pathogen free (SPF) six to eight week old female BALB/c mice were purchased from the 
Animal Resource Centre, Canningvale, Western Australia. Mice were acclimatised for a minimum 
of 1 week prior to the start of any experimentation. 
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Mice were bled from the retro-orbital vein using a capillary tube coated with heparin. Blood 
samples were separated by centrifugation at 6,000 x g for 10 min and the sera was collected and 
stored at -20°C until required for assays. These mouse studies were approved by the RMIT Animal 
Ethics Committee under AEC# 602 and 729. 
 
2.7.2   Chicken studies 
Newly hatched Cobb 500 broiler chicks were obtained from Inghams Farms, Pakenham, Victoria. 
The chicks were allowed to acclimatise for 2 days prior to the start of any experimentation. Chicks 
were bled from the wing vein using a 25 gauge needle and a 1 mL syringe. Blood samples were 
separated by centrifugation at 6,000 x g for 10 min and the sera was collected and stored at -20°C 
until required for assays. These chicken studies were approved by the RMIT Animal Ethics 
Committee under AEC# 729. 
 
2.8  Bioinformatics 
All the Bioinformatics programs used in this investigation were located at the Australian National 
Genomic Information Service (ANGIS) within WebANGIS and BioManager (www.angis.org.au). The 
program Sci Ed Central was used for the design of primers and vectors. 
 ~ CHAPTER 3 ~ 
CLONING, CHARACTERISATION & 
OPTIMISATION OF EXPRESSION OF 
ALPHA TOXIN CONSTRUCTS 
3.1 Introduction 
The alpha toxin gene is highly conserved among C. perfringens isolates and is known as plc or cpa 
in published literature, and hereafter will be referred to as plc. Despite that conservation, there 
are 28 different published variants of plc genes (Sheedy et al., 2004; Abildgaard et al., 2009) 
which all retain their toxicity. Purified alpha toxin can be neutralised by formalin treatment and 
used as a vaccine (Amimoto et al., 2002), however care must be taken to remove all traces of the 
formalin as it is also displays toxicity. The plc gene translates into a 370 amino acid protein with 
an α-helical N-terminus domain and a β-sandwich C-terminus domain as shown by x-ray 
crystallisation studies (Naylor et al., 1998). The key features of this protein are: the presence of 
the N-terminus domain providing phospholipase catalytic activity; the C-terminus domain where 
calcium ions bind to activate haemolytic and sphingomyelinase activities; and the three 
catalytically essential zinc ions in the active site (Naylor et al., 1998; Naylor et al., 1999; Titball et 
al., 1999). The alpha toxin protein also has a signal peptide which are the first 28 residues of the 
N-terminus region that are cleaved upon release into the supernatant (a 3 kDa signal sequence), 
or in the case of E. coli into the periplasmic space (Leslie et al., 1989). 
 
In order to eliminate the toxicity so that the toxin could be used as a vaccine candidate without 
harming the vaccination target, areas of the toxin were removed or altered as described in the 
following studies (Figure 3.1). The main alteration target is the active site and the carboxyl end 
which has been demonstrated to be immunogenic in previous studies (Williamson and Titball, 
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1993; Hoang et al., 2008; Zekarias et al., 2008). The first construct, plcInv, is based on the deletion 
of nucleotides 250 to 309 which removes a section encoding part of the catalytic domain and 
inactivates the active site of the alpha toxin (Figure 3.2). The second construct, plc104, is the 
carboxyl domain of the alpha toxin and the third, plc2, is based on a two point mutagenesis at 
two strategic points of the active site (Figure 3.3 and 3.4). These clones were constructed prior to 
the current study. 
 
The constructed inserts were amplified and cloned into another vector, pMOhly1 (Gentschev et 
al., 1996). This vector has the hly operon which consists of four genes, hlyA’, hlyB, hlyC, hlyD, 
responsible for the hemolysin system used by E. coli to synthesise and transport proteins directly 
out of the cell (Koronakis et al., 1988). The pMOhly1 vector has the full sequence of the structural 
genes hlyC, hlyB and hlyD and the modified version of the hlyA gene, hlyA’ (Figure 3.5). The full 
hlyA gene is not required as the N-terminus 34 amino acids and the C-terminus 61 amino acids 
are the regions that direct translocation of the protein through the cytoplasm to the extracellular 
space (Gentschev et al., 1996). This vector expresses protein constitutively without the need for 
induction (Gentschev et al., 1996). As the alpha toxin has its own signal peptide, two constructs 
were assembled: one with the alpha toxin signal peptide and the hlyA’ signal peptide (clones 
names pMOxxx – for details refer to Table 2.2) and one with only the hlyA’ signal peptide (named 
pMNxxx - for details refer to Table 2.2). This was performed for both the plcInv and plc2 
constructs as they both possess the internal signal peptide, however was not necessary for the 
plc104 clone due to its removal during the original cloning process. The clones that were designed 
were pMOInv, pMNInv, pMO104, pMOplc2 and pMNplc2 and their stability in the cloning E. coli 
strain DH5α and the vaccine strain STM1 were ascertained. 
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Figure 3.1: Representation of the three alpha toxin constructs used in this study.  
White filled areas indicate a deletion of nucleotide sequence; yellow filled areas indicate 
substitution mutagenesis. 
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Figure 3.2: Graphical representation of plcInv deletion as indicated by red section on a tertiary 
structure representation of alpha toxin. 
 
  
CHAPTER 3
 
 
 
~ 79 ~ 
 
 
 
 
 
 
 
 
Figure 3.3: Graphical representation of plc104 protein on a tertiary structure representation of 
alpha toxin.  
Red highlighted section indicates that the N-terminus has been deleted. 
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Figure 3.4: Graphical representation of plc2 substitution modification.  
Amino acid changes indicated by the yellow circles on a tertiary structure representation of alpha 
toxin: pink – aspartic acid to alanine; green – histidine to serine.  
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Figure 3.5: Map of pMOhly1 vector. 
Inserts are cloned in-frame into the NsiI site.  
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Vaccination by administration of bacterial antigens and toxoids is a successful strategy in 
preventing disease. The construction of these alpha toxin constructs was performed to determine 
which one will provide protective responses against C. perfringens infection. In order to do this, 
the proteins must be purified so that they can be tested in an immunogenicity trial. The alpha 
toxin constructs that were cloned using an inducible vector will be purified using the 6xHis-tag 
that was added to make IMAC possible. This would be the basis of a subunit vaccine used in 
Chapter 4. Other existing toxoid based vaccines are the diphtheria toxoid vaccine and tetanus 
toxoid vaccine which are both continually being investigated to reduce adverse reactions after 
use (Relyveld et al., 1998; Lee et al., 2009). 
  
The other method of vaccination being investigated is the use of live attenuated vectors 
expressing heterologous antigens. Over 13 different heterologous antigens have been expressed 
using different hemolysin expression vectors all with different expression levels in different 
bacterial vectors (Hahn and von Specht, 2003; Gentschev et al., 2004; Zhu et al., 2006; Hotz et al., 
2009).The pMOhly1 plasmid was chosen for this reason as it is a suitable vector that can be used 
in both E. coli and Salmonella strains as the hemolysin expression system is active in both. The Hly 
operon (Figure 3.6) consists of the following genes: hlyA’, hlyB, hlyC and hlyD (Koronakis et al., 
1988) and the pMOhly1 plasmid contains the entire operon with an restriction site NsiI in the 
middle of the hlyA’. The hlyA’ was derived from the cytotoxic hemolysin gene but has been 
modified to act as a transporter. The hlyA’ gene consists of two sections of the original gene. 
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Figure 3.6: The hly operon and the fusion construct. 
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The first is 34 amino acids at the N-terminus region which assists with the activation of the 
hemolysin system. The second section is the hlyA’s secretion signal which is the 61 amino acids 
located at the end of the hlyA gene; this is then added to the C-terminus of the inserted coding 
region which will then export the protein across the cellular membrane.  
 
 HlyC assists in the synthesis of the fusion constructs and is an acetylase required for post-
translational activation of the hemolysin system.  The other proteins, hlyB and hlyD, encoded in 
the operon are responsible for the transport of the fusion constructs through the bacterial 
membranes. The hlyB gene is a translocase protein that will be located at the C-terminus of the 
fusion construct and works in conjunction with the hlyD protein. HlyD is a membrane-fusion 
protein which interacts directly with outer membrane proteins and Tol-C receptors as well as hlyB 
translocase to form the conduit through the cytosol to the extracellular space (Koronakis et al., 
1988; Balakrishnan et al., 2001; Hahn and von Specht, 2003). The inclusion of these proteins can 
add up to 11 kDa in size to the fusion constructs if they remain after the translocation of the 
constructs across the bacterial membranes (Li et al., 2002; Hahn and von Specht, 2003). This may 
occur when the cleavage site becomes inaccessible to proteases during exportation due to 
changes in the proteins conformation. 
 
Having successfully cloned the alpha toxin constructs into pMOhly1, the clones were further 
investigated for protein expression. The objectives of this part of the study is to a) purify sufficient 
quantities of the plcInv, plc2 and plc proteins using IMAC with minimal contamination whilst 
investigating possible sugar supplements to increase yield, and b) demonstrate that the 
hemolysin vector, pMOhly1, is capable of extracellularly expressing fusion products that react 
with anti-alpha toxin serum.   
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3.2 Materials and methods 
3.2.1 Background development of constructs 
Early studies on the design and development of the alpha toxin constructs were carried out by Dr 
Xenia Gatsos and Abdulkareem Elbaz. The plc gene, a 1.24 kb amplified fragment, from the 
chromosomal DNA of C. perfringens 61 was amplified using Pfu polymerase (Promega, USA) with 
a 6xCAT (coding for 6xHis) at the 5’ end, cloned into pCR2.1 using TA cloning kit (Invitrogen). This 
plasmid pCRplc (Figure 3.7: A)) was the template for all subsequent clones described in this study. 
The plasmid pCRplcInv (Figure 3.7: B)) was constructed using inverse PCR with Pfu polymerase 
(Promega, USA) with blunt ended self ligation and pCRplc2 (Figure 3.7: D)) by the same method 
using primers with the double base pair substitution site designed to change the aspartate amino 
acid to an alanine at position 56 and histidine to serine at position 68. The insert plc104 (Figure 
3.7: C)) was developed with Pfu polymerase (Promega, USA) amplification using specific primers 
and then ligated into the PstI and EcoRI sites of pRSETA (Invitrogen). All of these plasmids 
incorporated a 6x Histidine tag onto the insert and as these studies focus on expression from a 
vector strain, not purification using IMAC, the primers were designed to omit the 6x Histidine tag. 
The presence of an NsiI site at base position 263 of the alpha toxin sequence resulted in the use 
of another restriction enzyme site for the plcInv and plc2 primers. This NsiI site was not present in 
the plc104 sequence as bases 1-881 were already deleted. In the plcInv and plc2 primers, the NsiI 
restriction site of ATGCAT was substituted for CTGCAT which is recognised and cut by PstI. This 
resulted in complementary overhangs of ACGT for the ligation.  
 
  
CHAPTER 3
 
 
 
~ 86 ~ 
 
 
 
Figure 3.7: Maps of alpha toxin construct plasmids- A) pCRplc, B) pCRplcInv. 
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Figure 3.7 continued: Maps of alpha toxin construct plasmids- C) pRplc104, D) pCRplc2. 
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3.2.2 Cloning of plcInv and NSPplcInv into pMOhly1 
The primers plcInv-PstIRev and plcInv-PstIForw were used to amplify full length plcInv. The 
primers plcInv-PstIRev and NSPInv-PstIForw were used to amplify the plcInv insert without the 
internal signal peptide (nucleotides 1-84), NSPplcInv. The amplifications were carried out as 
described in Section 2.4.2.2 using Platinum Taq polymerase with both carried out at an annealing 
temperature of 40.5˚C and elongation for 2 min, with a final elongation time of 5 min. Ten 
microlitres of each amplified product was analysed on a 1% agarose gel, and the remaining used 
for digestion and ligation into pMOhly1 (Section 2.4.4). The PCR product was then digested with 
PstI for 2 h whilst pMOhly1 was digested with NsiI. After the ligation, the DNA was purified 
(Section 2.4.4.1) and 2 µL was used for electroporation (Section 2.4.6) into electrocompetent E. 
coli DH5α cells. Colonies containing putative clones that grew on the LB agar with 100 µg/mL 
ampicillin were chosen for further analysis.  
 
3.2.3 Cloning of plc104 into pMOhly1 
The primers NPplc104-NsiIRev and plc104-NsiIForw were used to amplify the plc104 insert. The 
amplifications were carried out as described in Section 2.4.2.2 using Pfu polymerase with an 
annealing temperature of 42.7˚C and elongation for 1 min, with a final elongation time of 5 min. 
Ten microlitres of each amplified product was analysed on a 1% agarose gel, and the remaining 
used for digestion and ligation into pMOhly1 (Section 2.4.4). The PCR product was then digested 
with NsiI for 2 h whilst pMOhly1 was digested with NsiI. After the ligation, the DNA was purified 
(Section 2.4.4.1) and 2 µL was used for electroporation (Section 2.4.6) into electrocompetent E. 
coli DH5α cells. Colonies containing putative clones that grew on the LB agar with 100 µg/mL 
ampicillin were chosen for further analysis.  
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3.2.4  Cloning of plc2 and NSPplc2 into pMOhly1 
3.2.4.1   Direct cloning strategy 
The primers plcInv-PstIRev and plcInv-PstIForw were used to amplify full length plc2 insert. The 
primers plcInv-PstIRev and NSPInv-PstIForw were used to amplify the plc2 fragment without the 
internal signal peptide (nucleotides 1-84), NSPplc2. The amplifications were carried out as 
described in Section 2.4.2.2 using Expand polymerase with both at an annealing temperature of 
54.5˚C and elongation for 2 min, with a final elongation time of 7 min. Ten microlitres of each 
amplified product was analysed on a 1% agarose gel, and the remaining used for digestion and 
ligation into pMOhly1 (Section 2.4.4). The digested vector was used both with and without 
phosphatase treatment (Section 2.4.3) during the cloning studies. The PCR product was then 
digested with PstI for 2 h whilst pMOhly1 was digested with NsiI. After the ligation, the DNA was 
purified (Section 2.4.4.1) and 2 µL was used for electroporation (Section 2.4.6) into 
electrocompetent E. coli DH5α cells. Clones that grew on the LB agar with 100 µg/mL ampicillin 
were chosen for further analysis.  
 
3.2.4.2   TA cloning strategy 
The Expand PCR product was also cloned directly into the TA cloning vector pCR2.1 according to 
the manufacturer’s instructions (Invitrogen). Briefly, 30 ng of PCR product was mixed with 50 ng 
of pCR2.1 vector along with 4U of T4 DNA ligase and ligase buffer. This was incubated overnight 
at 14˚C in waterbath. Two microlitres of the ligation product was then transformed into 
chemically competent E. coli TOP10F’ cells, supplied with the TA cloning kit.  
 
These clones were then grown and the plasmid isolated via alkaline lysis plasmid extraction 
(Section 2.3.1). The PCR fragment was then digested out of pCR2.1 using PstI or EcoRI, and run on 
a 0.5 % agarose gel and the appropriate fragment excised from the gel and purified using the 
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Geneclean kit as per the manufacturer’s instructions. The fragment was then directly ligated into 
the previously NsiI digested pMOhly1 (Section 2.4.4). The digested pMOhly1 vector was used 
both with and without phosphatase treatment (Section 2.4.3) during the cloning studies. After the 
ligation, the DNA was purified (Section 2.4.4.1) and 2 µL was used for electroporation (Section 
2.4.6) into electrocompetent E. coli DH5α cells. Colonies containing putative clones that grew on 
the LB agar with 100 µg/mL ampicillin were chosen for further analysis.  
 
3.2.5 Screening of clones  
Plasmids were isolated from the clones using the alkaline lysis plasmid extraction (Section 2.3.1) 
after being grown overnight shaking at 200 rotations per min at 37˚C. The plasmids were then 
linearised via digestion with SalI and analysed on a 1% agarose gel. Plasmids showing an increase 
in size were then subjected to a screening PCR. When the difference in size was difficult to 
determine visually, the plasmids were subjected to a multiple site digestion using either AluI or 
BamHI. Plasmids showing a different restriction profile from the original empty plasmid were 
subjected to further screening.  To determine the presence of the inserts and to confirm 
directionality, PCR was carried out using the following combinations of primers (Table 3.1). Once 
orientation was confirmed, the clone was then subjected to sequence determination (Section 
2.4.8) to confirm the insert had no PCR introduced errors. 
 
3.2.6 Passage of plasmids  
The construct plasmid was isolated from the cloning strain of E. coli (either TOP10F’ or DH5α) 
using alkaline lysis extraction method (Section 2.3.1) and electrotransformation (Section 2.4.6) 
was used to transform the plasmid into the intermediate vector strain, S. Typhimurium LT2-9121 
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Table 3.1: Screening PCR primer combinations for confirmation of orientation. 
Primer combination 
Inferred Insert Orientation if 
PCR product is detected 
  
plcInv  
 SEQFpMOhly1 + plcInv-PstIRev  Correct  
 SEQFpMOhly1 + plcInv-PstIForw  Incorrect 
 SEQRpMOhly1 + plcInv-PstIForw  Correct 
 SEQRpMOhly1 + plcInv-PstIRev  Incorrect 
  
NSPplcInv 
 
 SEQFpMOhly1 + plcInv-PstIRev  Correct 
 SEQFpMOhly1 + NSPInvPstI Forw  Incorrect 
 SEQRpMOhly1 + NSPInvPstI Forw   Correct 
 SEQRpMOhly1 + plcInv-PstIRev  Incorrect 
  
plc104   
 SEQFpMOhly1 + NP104-NsiI Rev  Correct 
 SEQFpMOhly1 + plc104-NsiIForw  Incorrect 
 SEQRpMOhly1 + plc104-NsiIForw  Correct 
 SEQRpMOhly1 + NP104-NsiI Rev  Incorrect 
  
plc2  
 SEQFpMOhly1 + plcInv-PstIRev  Correct 
 SEQFpMOhly1 + plcInv-PstIForw  Incorrect 
 SEQRpMOhly1 + plcInv-PstIForw  Correct 
 SEQRpMOhly1 + plcInv-PstIRev  Incorrect 
  
NSPplc2  
 SEQFpMOhly1 + plcInv-PstIRev  Correct 
 SEQFpMOhly1 + NSPInvPstI Forw  Incorrect 
 SEQRpMOhly1 + NSPInvPstI Forw  Correct 
 SEQRpMOhly1 + plcInv-PstIRev  Incorrect 
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The plasmids were then isolated a second time using the alkaline lysis extraction method (Section 
2.4.1) from the S. Typhimurium LT2-9121 and electrotransformation (Section 2.5.6) was used 
again to incorporate these passaged plasmids into the STM1 vaccine strain. 
 
3.2.7 Plasmid stability assays 
Stocks of STM1 harbouring the pMOhly1 based vectors were streaked onto LB agar with 100 
µg/mL ampicillin to obtain single colonies. Three to four well isolated colonies were selected for 
plasmid stability assays and incubated in 10 mL of LB broth with 100 µg/mL ampicillin at 37˚C on 
an orbital shaker for 18 h. The culture was 10-fold diluted from 10-1 to 10-6 in LB broth and 100 μL 
of each dilution spread plate onto LB agar with 100 µg ampicillin in duplicate, to determine the 
initial plate count. The 10-6 dilution (10 mL) was incubated for 24 h at 37˚C in the absence of 
ampicillin. This culture was again serially 10-fold diluted to 10-6 and 100 μL of each dilution spread 
onto LB agar with 100 µg/mL ampicillin and without ampicillin, in duplicate. The 10-6 dilution (10 
mL) was incubated at 37˚C for 24 h and the process of dilution and spread plating repeated. The 
process was repeated for a minimum time of 5 days (approximately 100 generations) or until less 
than 0.05-0.002% of the culture retained the plasmid. 
 
3.2.8  Alpha toxin assays 
3.2.8.1  Lecithinase reaction 
Nagler plates were inoculated with a single streak of E. coli colonies transformed with vector 
containing plc constructs. The plates were incubated at 37˚C overnight and the diameter of the 
zone of turbidity measured. Samples with no observable signs of hydrolysis were left at 37˚C for 
up to 24 h. 
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3.2.8.2  Haemolysis assay 
Sheep blood agar was prepared as described in Section 2.1.2.1 with the addition of 100 μg/mL 
ampicillin to the molten agar. Fifty microlitres from a stock solution of 100 mM IPTG was spread 
onto the SBA plates and E. coli colonies transformed with vector containing plc constructs were 
streaked onto the agar and incubated for 18 h at 37˚C. Plates were then incubated at 4˚C for 2 h 
prior to determining the presence of incomplete haemolysis surrounding the colonies. 
 
3.2.9   Protein purification 
3.2.9.1  Media supplement evaluation 
One percent (v/v) of an overnight culture of E. coli harbouring pCRplc or pCRplcInv was used to 
inoculate 10 mL LB broth containing 100 μg/mL ampicillin supplemented with 0.5% (w/v) glucose, 
0.5% (w/v) fructose, 0.5% (w/v) sucrose or 0.5% (w/v) maltose. The broth was incubated at 37˚C 
with vigorous shaking until mid-log phase of growth was reached (an OD600 of between 0.4-0.6). 
IPTG, to a final concentration of 1 mM, was added to the culture and incubated for a further 16 h. 
One millilitre hourly samples of culture were taken pre and post induction, cells collected by 
centrifugation and lysed using the whole cell lysis method (Section 2.6.1). Protein concentration 
of the supernatant was measured and 15-30 micrograms of lysed cell supernatant was analysed 
using SDS-PAGE and immunoblotting (Section 2.6.3 – 2.6.5). Cell supernatant was also incubated 
for 18 – 48 h at 4˚C to check the stability of the proteins.  
 
3.2.9.2  Pilot intracellular expression of -toxin and -toxin constructs 
One percent (v/v) of an overnight culture of E. coli harbouring plc constructs was used to 
inoculate 10 mL LB broth containing 100 μg/mL ampicillin. The broth was incubated at 37˚C with 
vigorous shaking until mid-log phase of growth was reached (an OD600 of between 0.4-0.6). IPTG 
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to a final concentration of 1 mM was added to the culture and incubated for a further 16 h. One 
millilitre hourly samples of culture were taken pre- and post-induction, pelleted by centrifugation 
and lysed using the whole cell lysis method (Section 2.6.1). Fifteen to thirty micrograms of lysed 
cell supernatant was analysed using SDS-PAGE and immunoblotting (Section 2.6.3 – 2.6.5). 
 
3.2.9.3  Isolation of proteins 
One percent of an overnight culture (v/v) was used to inoculate 100-500 mL fresh LB broth 
containing 100 μg/mL ampicillin. The culture was grown until an OD600 of 0.4-0.6 was reached 
and protein expression induced with 1 mM IPTG. The culture was incubated for a further 3 h and 
then pelleted by centrifugation. The bacteria were resuspended in 1/25th the volume of protein 
lysis buffer I and incubated at 4˚C for 30 min on a rocking platform. The bacteria were then 
treated with a repeated freeze/thaw cycle up to 4 times, with the addition of 5U of DNase 
following the first thaw cycle. Debris was separated by centrifugation at 5,445 x g for 40 min at 
4˚C. The supernatant was filter sterilised through a 0.2 µm membrane and loaded onto an IMAC 
gravity flow column. 
 
3.2.9.4  Immobilised Metal Affinity Chromatography (IMAC) 
Chelating fast flow sepharose was prepared according to the manufacturer’s instructions 
(Amersham Biosciences) using 1 and 5 mL gravity flow columns (QIAGEN). Once packed and 
washed with H2O, the column was charged using half a column volume (CV) of a 0.2 M solution of 
the transitional metal nickel sulphate (NiSO4) (BDH, USA). The column was washed with at least 5 
CV of 0.45 µm filtered mH2O and equilibrated with 5 CV of binding buffer. Up to 60 mL of 
supernatant containing his-tagged protein was applied to the column. The column was washed 
with 10 CV of wash buffer containing between 60 - 80 mM imidazole depending on the 
optimisation, following protein binding and eluted with 10 CV of elution buffer. One millilitre 
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fractions were collected during the elution step, and analysed using SDS-PAGE. The flow through 
from the column was then placed into a second 1 mL IMAC column and the process repeated to 
purify any recombinant protein that flowed through the first column.  
 
3.2.9.5  Cleaning in place and regeneration of column 
Gravity flow columns were re-used up to 5 times and cleaned between each use to remove 
hydrophobic and ionic bound contaminants. Cleaning in place involved the application of 10 CV of 
2 M NaCl, followed by 10 CV of 1 M NaOH, and finished with 10 CV of 70% ethanol (v/v). Columns 
were washed with dH2O between each solution and Ni
2+ was stripped with 2 CV 0.05 M EDTA, 0.5 
M NaCl, pH 7.0. A 20% ethanol solution was added to the sepharose when stored for later use. 
 
3.2.9.6  Buffer exchange of proteins 
Eluted proteins were concentrated using Centricon centrifugal devices (Millipore) of cut-off pore 
size 3 kDa and 10 kDa according to the manufacturer’s instructions. Buffer exchange of proteins 
was also performed using Centricon devices. Salts and metals were removed by continual 
concentration and dilution of the protein sample in the new buffer. 
 
3.2.9.7  Quantification of protein fractions 
Quantification of purified proteins was done using both Bradford (Section 2.6.2.1) and Lowry 
assay methods (Section 2.6.2.2) and using a spectrophotometric measurement at 280nm on an 
Eppendorf Biophotometer. After quantification, the proteins were run on a SDS-PAGE gel to 
confirm integrity of the protein.  
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3.2.10 Trichloroacetic acid (TCA) precipitation of extracellularly 
expressed proteins 
A volume of 1 mL from a 5 mL overnight culture was pelleted at 16,000 x g for 5 min. The cell 
pellet was discarded and the supernatant transferred to a new microcentrifuge tube. A volume of 
200μL of 100% w/v TCA was added to the supernatant and the tube inverted. The tube was 
incubated on ice for a period of 30 min and the precipitated proteins collected by centrifugation 
at 16,000 x g for 15 min. The precipitated pellet was washed with 100% w/v acetone, recovered 
by centrifugation at 16,000 x g for 15 min and dried at RT for 30 min. The pellet was then 
dissolved in protein sample buffer, boiled at 100°C for 10 min and subjected to SDS-PAGE and 
immunoblotting (Section 2.6.3 – 2.6.5). 
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3.3 Results 
3.3.1 Cloning of plcInv and plcNSPInv and construction of pMOInv and 
pMNInv plasmids 
 
The Platinum Taq PCR amplification of plcInv using an annealing temperature of 40.5˚C resulted in 
a single strong band at the expected size of 1.144kbp (Figure 3.8 A)). This was subsequently 
digested with PstI and ligated into the NsiI digested pMOhly1 vector using T4 DNA ligase. The 
resulting plasmid was named pMOInv (Figure 3.8 B)). The Platinum Taq polymerase PCR 
amplification of plcNSPInv using the same annealing temperature of 40.5˚C resulted in a single 
band at the expected size of 1.060kbp (Figure 3.9 A)). This PCR product was then digested with 
PstI and ligated into the NsiI digested pMOhly1 vector using T4 DNA ligase.  The resulting plasmid 
was named pMNInv (Figure 3.9 B)). Quite a number of colonies obtained from both ligations 
showed the presence of the inserts. The orientation of the inserts was determined using a 
restriction digest profile using the four base cutter AluI (Figure 3.10). The clones that showed a 
different profile from the pMOhly1 digest were sent for sequencing. The sequencing results 
showed that both clones were: missense-error free, in the correct orientation, and in-frame with 
the hlyA’ gene and the rest of the hly operon.  
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Figure 3.8: Development of pMOInv plasmid.  
A) PCR amplification of the plcInv using Taq. Lane 1: PstI/Lambda DNA marker, Lane 2: Negative 
PCR control, Lanes 3 & 4: plcInv at an annealing temperature of 40.5˚C.  B) Map of the completed 
plasmid.  
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Figure 3.9: Development of pMNInv plasmid.  
A) PCR amplification of the plcNSPInv using Taq. Lane 1: NSPplcInv at annealing temperature of 
40.5˚C, Lane 2: PstI/Lambda DNA marker. B) Map of the completed plasmid.  
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Figure 3.10: Screening for insert orientation using AluI restriction profiles. 
Lane 1: PstI/Lambda DNA marker, Lane 2: pMOhly1, Lane 3-12: Unsuccessful clones, Lane 13: 
pMNInv, Lane 14: pMOInv. 
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3.3.2 Cloning of plc104 and construction of pMO104 plasmid 
The Pfu polymerase PCR amplification of plc104 using an annealing temperature of 42.7˚C 
resulted in a strong band at the expected size of 0.322 kbp (Figure 3.11 A)). This was subsequently 
digested with NsiI and ligated into the NsiI digested pMOhly1 vector using T4 DNA ligase. The 
resulting plasmid was named pMO104 (Figure 3.11 B)). Resulting clones were screened for the 
direction of the insert using PCR using the primer combinations outlined in Table 3.1. As shown in 
Figure 3.12, Clone 1 had bands for both the primer combinations for the correct orientation 
whilst also having one band from an incorrect combination of primers. Clone 3 showed two bands 
for the incorrect orientation primers combinations however also had a band of same intensity for 
a correct orientation combination. Both of these clones were sequenced and it was shown that 
Clone 1 was in the correct orientation without errors and Clone 2 was in the reverse orientation.  
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Figure 3.11: Development of pMO104.  
A) PCR amplification of the plcNSPInv using Pfu. Lane 1: plc104 at annealing temperature of 
42.7˚C, Lane 2: PstI/Lambda DNA marker. B) Map of the completed plasmid. 
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Figure 3.12: PCR screening using four combinations of primers (refer to Table 3.1 for each 
reaction) for pMO104, Clone 1 upon sequencing was determined to be pMO104.  
Four PCR reactions were set up for each clone according to the primer combinations listed in 
Table 3.1. Ticks indicate a PCR product is expected if the insert is in the correct orientation, 
crosses indicate a PCR product is expected if the insert is in the incorrect orientation.  
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3.3.3 Cloning of plc2 and NSPplc2 and construction of pMOplc2 and 
pMNplc2 
3.3.3.1  PCR amplification of plc2 and NSPplc2 inserts 
 
PCR amplification of the plc2 insert and NSPplc2 insert was accomplished using Expand Long 
Template system at an annealing temperature of 54.5˚C as shown in Figure 3.13 A). The PCR 
products generated during these reactions were ample and specific without any other 
contaminating bands.  Once the products were digested using the enzyme PstI, they retained 
their size compared to the original products and did not appear to degrade (Figure 3.13(B)).  
 
3.3.3.2  Direct method: Ligation of products into pMOhly1  
 
The first cloning strategy used was a direct method where the PCR products were digested, 
cleaned (Section 2.5.4.1) then immediately used in the ligation. Ligations using a digested 
phosphatase-treated vector and a digested only vector were tested with varying results. The 
ligation frequency was quite low and many of the colonies screened contained the empty vector 
when the vector was not phosphatase treated. The ligation frequency increased slightly with the 
use of the phosphatase-treated pMOhly1. Increasing the vector to insert ratios from 1:3 to 1:15 
and 1:50 for both reactions did not increase the frequency of positive colonies obtained from the 
ligation, nor did altering the ligation timeframe or incubation temperature. 
 
All colonies found to have an insert in the pMOhly1 were screened using PCR with various primer 
combinations to show the orientation of the insert (Table 3.1). The PCR results showed a product 
at the expected size of approximately 1.2 kbp for the primer combination for the incorrect 
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orientation, yet there were also multiple bands in the correct orientation primer combination 
(Figure 3.14 A)). This pattern occurred for every clone tested from the transformations and upon 
sequencing, the orientation of the inserts were shown to be in the incorrect orientation. Over five 
hundred clones were screened and each one of them was in the incorrect orientation, hence the 
production of pMOplc2 and pMNplc2 was unsuccessful using this method.   
 
3.3.3.3  Indirect method: Ligation of products into pMOhly1 via pCR2.1 
 
The alternative indirect strategy was used to increase the probability of the insert going into 
pMOhly1 in the correct orientation; by ensuring all ends of the insert would have the correct 
overhang (a certain proportion of PCR products that were directly digested may not have been 
digested). Both inserts were ligated into the pCR2.1 vector, transformed into TOP10F’ cells via 
electroporation according to the manufacturer’s instructions and then isolated using the alkaline 
lysis method. The insert was then digested out of the pCR2.1 using EcoRI, the fragments excised 
from an agarose gel and further digested using PstI and used for the ligation. This resulted in 
more colonies on the transformation plates than the direct method. 
 
The PCR screening for the directionality using the primer combinations in Table 3.1 showed the 
same distinct pattern that occurred with the direct method of cloning. The PCR results showed a 
product at the expected size of approximately 1.2 kbp for the primer combination for the 
incorrect orientation, and again there were also multiple bands in the correct orientation primer 
combination (Figure 3.14 (B)).  
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Figure 3.13: Development of pMOplc2 and pMNplc2.  
A) PCR amplification of the plc2 and NSPplc2 using Expand template system. Lane 1: plc2 at 
annealing temperature of 54.5˚C, Lane 2: NSPplc2 at an annealing temperature of 54.5˚C, Lane 3: 
PstI/Lambda DNA marker. B) Digestions of products and plasmid, Lane 1: PstI/Lambda DNA 
marker, Lane 2: Empty, Lane 3: NsiI digested pMOhly1, Lane 4: plc2 at annealing temperature of 
54.5˚C, Lane 5: NSPplc2 at an annealing temperature of 54.5˚C. C) Map of the proposed pMOplc2 
plasmid. D) Map of the proposed pMNplc2 plasmid. 
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A) 
 
B) 
 
Figure 3.14: Directional screening of potential clones.  
Four PCR reactions were set up for each clone according to the primer combinations listed in 
Table 3.1. Ticks indicate a PCR product is expected if the insert is in the correct orientation, 
crosses indicate a PCR product is expected if the insert is in the incorrect orientation.  
A) plc2 screening with all clones showing the insert in the incorrect orientation. B) NSPplc2 
screening with all clones showing the insert in the incorrect orientation.   
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Sequencing of these clones (data not shown) revealed that the majority of them that showed the 
inclusion of the insert had the correct insert of either plc2 or NSPplc2 in the reverse direction. 
This left a small portion of the clones that had another unknown insert of similar size that did not 
match with either of the plc2 insert or the NSPplc2 insert. When these unknown fragments were 
sequenced they were found to be contaminating pCR2.1 fragments. Over three hundred colonies 
were screened from this method and not one successful clone of pMOplc2 or pMNplc2 was ever 
found.  
 
3.3.4 Stability of the plasmids in the vaccine strain STM1 
The successful clones of pMOInv, pMNInv and pMO104 were passaged through the intermediate 
strain of S. Typhimurium LT2-9121 into STM1 so that transformation would occur at a higher 
frequency between two related bacterial strains. The stability of each of these was measured 
over a period of 6 days which is over 100 generations of the host strain. The stability of the 
plasmids were tested in both E. coli and STM1 strains as the hemolysin secretion system 
originated from the E. coli and the STM1 strain is the vaccine strain that will be used in later 
studies. Overall, the plasmids were retained by at least 50% of the STM1 over the six day 
timeframe in the absence of any selective pressure normally supplied by the presence of 100 
µg/mL ampicillin. 
 
The plasmid pMOInv was most stable in the E. coli with an average retention of 103% (i.e. no loss) 
while in STM1 the average was 84% (Figure 3.15). In E. coli, the pMOInv plasmid had the highest 
retention at Day 4 whilst the other two plasmids, pMNInv and pMO104, experienced theirs on 
Day 1 in both strains. Carriage of the plasmid steadily declined over the six day period with only 
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58% of STM1 retaining it on Day 6, whilst in E. coli it rose between Day 5 and 6 from 88% to more 
than 100%.  
 
The plasmid pMNInv was more stable in STM1 with an average retention of 86% than in the E. coli 
at 60%. In STM1, the plasmid was retained at 80% on Day 6 whilst in the E. coli it had rapidly 
declined to only 16% (Figure 3.16). Similar to the pMOInv plasmid, there was a rise in retention by 
E. coli on Day 4 from 61% to 69% before declining sharply to 32%. The plasmid pMNInv was 
maintained by STM1 very well and only had a very slow decline over the six days. The final 
plasmid pMO104 was quite stable over the six days in both E. coli and STM1 with averages of 80% 
and 81%, respectively. In both strains there was an increase in retention on Day 3 with STM1 
going from 91% to 98% and E. coli improved from 85% to 89% (Figure 3.17). On the final day, 
STM1 retained 66% of the plasmid whilst E. coli retained only 42%.   
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Figure 3.15: Stability assays for the clone pMOInv in E. coli and STM1. 
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Figure 3.16: Stability assays for the clone pMNInv in E. coli and STM1. 
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Figure 3.17: Stability assays for the clone pMO104 in E. coli and STM1. 
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3.3.5    Translational changes in the alpha toxin constructs   
Mature alpha toxin is destructive due to its haemolytic and enzymatic activities which ruptures 
cell membranes (Sakurai et al., 2004).  The molecular cloning changes to prevent this toxicity 
were confirmed by sequence analysis and the following proteins were purified. The first protein, 
plcInv, has a 20 amino acid deletion from position 56 – 75 removing the amino acids, aspartic acid 
(56) and histidine (68) which are important to zinc binding, and tyrosine (57, 64) and threonine 
(73) which assist in binding of the active site to host membranes (Nagahama et al., 1995; Flores-
Díaz et al., 2004).  The second protein is plc2 which has 2 point mutations with two amino acid 
changes at position 56, aspartic acid to alanine, and position 68, histidine to serine (Figure 3.18). 
The aspartic acid at position 56 was chosen as it is an essential amino acid which interacts with an 
essential zinc cation in the catalytic site whilst the conformation of the binding site of the alpha 
toxin is dependent on the histidine at position 68. Each of these changes was done with two 
nucleotide substitutions to minimise the possibility of spontaneous reversion to wildtype. These 
two proteins along with mature alpha toxin were used for immunogenicity trials.  
 
The clones pMOInv, pMNInv and pMO104 were not designed for high level protein purification 
but as low expression vaccine plasmids that could be delivered via STM1. The plasmid pMO104 
contains the coding region for protein plc104 which is 104 amino acids of the C domain of the 
mature alpha toxin. pMOInv has the plcInv coding region in its entirety whilst pMNInv has the 28 
amino acid signal peptide removed. As these clones were not designed for purification, this 6 
histidine tag was removed for constructs ligated into pMOhly1. The presence of the hlyA’ signal 
peptide along with the inserts altered the expected size of the expressed constructs. Table 3.2 
shows the expected sizes and the features of the proteins explored in this chapter. 
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plcInv          MKRKICKALICAALATSLWAGASTKVYAWDGKIDGTGTHAMIVTQGVSILENDLSKNEPE 60 
plc104          ------------------------------------------------------------ 
plc             MKRKICKALICAALATSLWAGASTKVYAWDGKIDGTGTHAMIVTQGVSILENDLSKNEPE 60 
plc2            MKRKICKALICAALATSLWAGASTKVYAWDGKIDGTGTHAMIVTQGVSILENDLSKNEPE 60 
                                                                             
 
plcInv          SVRKNLEILKENMHELQLGSTYP--------------------NNFSKDNSWYLAYSIPD 100 
plc104          ------------------------------------------------------------ 
plc             SVRKNLEILKENMHELQLGSTYPDYDKNAYDLYQDHFWDPDTDNNFSKDNSWYLAYSIPD 120 
plc2            SVRKNLEILKENMHELQLGSTYPAYDKNAYDLYQDSFWDPDTDNNFSKDNSWYLAYSIPD 120 
                                                                         
 
plcInv          TGESQIRKFSALARYEWQRGNYKQATFYLGEAMHYFGDIDTPYHPANVTAVDSAGHVKFE 160 
plc104          ------------------------------------------------------------ 
plc             TGESQIRKFSALARYEWQRGNYKQATFYLGEAMHYFGDIDTPYHPANVTAVDSAGHVKFE 180 
plc2            TGESQIRKFSALARYEWQRGNYKQATFYLGEAMHYFGDIDTPYHPANVTAVDSAGHVKFE 180 
                                                                             
 
plcInv          TFAEERKEQYKINTAGCKTNEDFYADILKNKDFNAWSKEYARGFAKTGKSIYYSHASMSH 220 
plc104          ------------------------------------------------------------ 
plc             TFAEERKEQYKINTAGCKTNEDFYADILKNKDFNAWSKEYARGFAKTGKSIYYSHASMSH 240 
plc2            TFAEERKEQYKINTAGCKTNEDFYADILKNKDFNAWSKEYARGFAKTGKSIYYSHASMSH 240 
                                                                             
 
plcInv          SWDDWDYAAKVTLANSQKGTAGYIYRFLHDVSEGNDPSVGKNVKELVAYISTSGEKDAGT 280 
plc104          -----------------------------------------------------GEKDAGT 7 
plc             SWDDWDYAAKVTLANSQKGTAGYIYRFLHDVSEGNDPSVGKNVKELVAYISTSGEKDAGT 300 
plc2            SWDDWDYAAKVTLANSQKGTAGYIYRFLHDVSEGNDPSVGKNVKELVAYISTSGEKDAGT 300 
                                                                      
 
plcInv          DDYMYFGIKTKDGKTQEWEMDNPGNDFMTGSKDTYTFKLKDENLKIDDIQNMWIRKRKYT 340 
plc104          DDYMYFGIKTKDGKTQEWEMDNPGNDFMTGSKDTYTFKLKDENLKIDDIQNMWIRKRKYT 67 
plc             DDYMYFGIKTKDGKTQEWEMDNPGNDFMTGSKDTYTFKLKDENLKIDDIQNMWIRKRKYT 360 
plc2            DDYMYFGIKTKDGKTQEWEMDNPGNDFMTGSKDTYTFKLKDENLKIDDIQNMWIRKRKYT 360 
                 
 
plcInv          AFPDAYKPENIKIIANGKVVVDKDINEWISGNSTYNIK 378 
plc104          AFPDAYKPENIKIIANGKVVVDKDINEWISGNSTYNIK 104 
plc             AFPDAYKPENIKIIANGKVVVDKDINEWISGNSTYNIK 398 
plc2            AFPDAYKPENIKIIANGKVVVDKDINEWISGNSTYNIK 398 
                 
 
 
 
Figure 3.18: Amino acid sequence alignment for alpha toxin with alpha toxin constructs.  
Grey shaded area represents the N-terminus α-helical domain and the open-boxed area the C-
terminus β-sheet domain. The first 28 amino acids are a signal peptide. The yellow highlighted 
amino acids are the two site mutagenesis changes in the pCRplc2 plasmid.  
↑ ↑ 
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Table 3.2: Description of alpha toxin variants. 
Expression 
vector 
Protein No. of aa in 
protein 
Deletion (Δ) or 
Change 
Estimated MW (kDa) 
pCRplc plc 370 — 46.90 
pCRplc2 plc2 370 Change Positions 
56 (D→A) & 68 
(H→S). 
46.80 
pCRplcInv plcInv 350 Δ Position 56 – 75 44.00 
    Without hlyA With hlyA 
pMO104 plc104 104 Δ Position 1 – 266 12.21 23.22 
pMOInv plcInv 350 Δ Position 56 – 75 43.00 53.01 
pMNInv plcNSPInv 322 Δ Position 1 – 28  
 Δ Position 56 – 75 
40.00 50.01 
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3.3.6  Enzymatic properties of the alpha toxin constructs 
Mature alpha toxin shows hemolytic activity when exposed to red blood cells and this was 
assessed using sheep blood agar plates and induction of protein expression using IPTG. This 
assessed the ability of the transformed E. coli strain to produce hemolytic protein. The alpha toxin 
clone showed typical β–hemolytic activity with complete clearing of the media around the 
transformed colonies (Figure 3.19 A)).  The construct plcInv displayed no hemolytic activity 
(Figure 3.19 B)) indicating that the 20 amino acid deletion severely compromises the protein 
function, as expected. The protein plc2 also showed no hemolytic activity on the sheep blood 
agar (Figure 3.19 C)) which demonstrated that the 2 site mutagenesis was adequate in 
deactivating the properties of the toxin. Lecithinase activity is also a well documented feature of 
alpha toxin and was measured using Nagler plates.  This activity is evident for alpha toxin (Figure 
3.20 A)) but absent for both the plcInv (Figure 3.20 B)) and plc2 (Figure 3.20 C)) proteins. 
Therefore, the molecular changes made either via deletion or substitution renders the toxin 
inactive. 
 
3.3.7  Purification studies using sugar supplements 
Purification of the mature alpha toxin and the plcInv construct from E. coli was assessed using 
four different sugar supplements at a consistent concentration of 0.5% (w/v) in LB broth.  Alpha 
toxin and plcInv were examined as higher quantities from the purification would be needed for 
vaccine trials. Purification of alpha toxin on average yielded 3.5 mg/L of E. coli grown in LB broth 
without any supplement over a 5 hour induction.  The purification of plcInv was always lower 
than alpha toxin with an average yield of 1.5 mg/L of culture grown to the same conditions. Four 
sugars were chosen based on their ability to be digested without placing a high metabolic load on 
the E. coli. The first two are glucose and fructose which are monosaccharides followed by maltose 
and sucrose which are disaccharides. Each supplement was tested in duplicate.   
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Figure 3.19: Haemolysis reaction on SBA for alpha toxin constructs.  
A) β-haemolysis from E. coli harbouring pCRplc. B) Lack β-haemolysis of E. coli harbouring pCRplc2 
and C) Lack β-haemolysis of E. coli harbouring pCRplcInv. 
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Figure 3.20: Lecithinase activity on Nagler plates.  
A) Characteristic opaque halo from E. coli harbouring pCRplc showing Lecithinase activity. B) Lack 
of lecithinase activity of E. coli harbouring pCRplc2 and C) Lack of lecithinase activity of E. coli 
harbouring pCRplcInv. 
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3.3.7.1  Alpha toxin purification with sugar supplements 
Over a 5 h induction the amount of protein typically increases over time, with purification done 
shortly after. Each culture was sampled after each hour until 5 samples had been taken and the 
semi-quantitative western blot reflects changes to the expression level at each time point by 
differing reactivity to the anti-serum. Alpha toxin in the whole cell lysate acquired from E. coli 
grown in LB broth after 5 h yielded a single band as visualised by SDS-PAGE (Figure 3.21 A)) with 
minimal breakdown of the protein. In the presence of glucose there is a slight increase in 
expression at 5 h to however there are small amounts of breakdown (Figure 3.21 B)).  
 
With the inclusion of fructose in the media, the lowest expression is observed with the band 
showing less reactivity with breakdown at each induction time point (Figure 3.21 C)). As maltose 
breaks down to two glucose molecules it was expected that there would be an increase in 
expression as was observed for the glucose supplement. However the western blot shows a 
marked decrease in expression across all time points (Figure 3.21 D)). Supplemented sucrose 
increased the expression of alpha toxin after 5 h induction, compared to the whole cell lysate 
grown in LB broth, but there is still a slight amount of breakdown evident at 5 h (Figure 3.21 E)). 
 
3.3.7.2  plcInv purification with sugar supplements 
The purification of plcInv from E. coli consistently gave lower yields than the alpha toxin 
purification and typically over a 5 h induction would give an increasing expression. In this 
experiment, the LB broth whole cell lysate showed decreased expression at 5 h induction (Figure 
3.22 A)) but retained its stability over 18 h at 4˚C. The highest expression was at 4 h induction.   
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Figure 3.21: Western blots of alpha toxin obtained from whole cell lysate grown in LB media 
supplemented with four different sugars.  
A) No supplement, B) 0.5% (w/v) Glucose, C) 0.5% (w/v) Fructose, D) 0.5% (w/v) Maltose and E) 
0.5% (w/v) Sucrose. Numbers (0-5) above blot are h post-induction, M: SeeBlue Plus2 protein 
standard marker. 
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Figure 3.22: plcInv purified from media supplemented with different sugars.  
A) No supplement, B) 0.5% (w/v) Glucose, C) 0.5% (w/v) Fructose, D) 0.5% (w/v) Maltose and  
E) 0.5% (w/v) Sucrose; Numbers (0-5) above blot are h post-induction, M: SeeBlue Plus2 protein 
standard marker. 
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When glucose was added to the media there was an increase in expression over all time points 
with the highest being at 5 h (Figure 3.22 B)). However there was increased degradation after the 
2 h induction sample. The same pattern was observed for the media supplemented with fructose 
(Figure 3.22 C)). E. coli grown in maltose supplemented media expressed plcInv at a higher rate at 
5 h induction (Figure 3.22 D)). There was no breakdown apparent at any of the time points. 
Higher expression rates were observed in LB media supplemented with sucrose with breakdown 
observed after 3 h induction (Figure 3.22 E)). Overall in the presence of any of these sugars, E. coli 
expressed the plcInv at a higher rate over the entire 5 h induction. Glucose was used as a 
supplement for subsequent purification experiments.   
 
3.3.8  IMAC purification for vaccine studies 
Large scale purification was done using IMAC with a Ni+ loaded column using E. coli cultures 
ranging in size from 500 mL to 1.2 L. Soluble protein were recovered from the cell lysate in 
substantial quantities and the cell pellet revealed no inclusion bodies detected by western blot 
(not shown). Optimisation of the wash buffer was carried out using imidazole concentrations 
ranging from 60 mM to 100 mM and the buffer that removed the most contaminating bands with 
the smallest loss of the target protein was used. Large contaminating bands varying in size from 
80 – 85 kDa that were not reactive to the anti-alpha toxin sera were binding to the column. 
Optimisation of the wash buffer showed that concentrations higher than 70 mM imidazole would 
remove more alpha toxin than the contaminating bands (Figure 3.23 A)). Both plc2 and plcInv 
bound to the column more readily, Figures 3.23 B) & C) respectively, hence tolerated a higher 
imidazole concentration at 80 mM with minimal loss of the target protein.  
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After optimisation of the wash buffers, the contaminating bands were no longer appearing in the 
fractions eluted from the columns. The alpha toxin was purified from the column in multiple 
fractions with minimal contaminating bands. Approximately 3.6 mg of plc was obtained per litre 
of E. coli following IMAC purification. Protein plcInv bound well to the column and no 
contaminating bands were found in the fractions eluted using 200 mM imidazole. An average 
yield of approximately 1.6 mg of plcInv was obtained per litre of E. coli following IMAC 
purification. Protein plc2 bound to the column exceedingly well and was eluted from the column 
over multiple fractions using 200 mM imidazole. The highest average yield of plc2 from IMAC 
purification was approximately 4.4 mg per litre of E. coli culture. Fractions were combined and 
subjected to buffer exchange to remove the imidazole prior to use in a vaccine trial.  
 
Although the large contaminating protein bands varying in size from 80 – 85 kDa were removed 
from the individual fractions taken from the column upon combination and concentration they 
were apparent (Figure 3.24 A)) but remained non-reactive to the anti-alpha toxin sera (Figure 
3.24 B)). Attempts were made to separate these proteins from the target proteins using Centricon 
centrifugal filter devices with a cut off of 50 kDa with the flow-through containing the target 
proteins. This was unsuccessful as the target proteins were too close to the cut off resulting in a 
large loss of the target protein. It was also observed that plc2 ran slower on the SDS-PAGE gel 
than expected from its predicted mass of 46.9 kDa (Figure 3.24). Buffer exchange was carried out 
in the Centricon devices of 5 and 10 kDa cut-off and less than 10% of the protein was lost. 
Although not a high percentage in the final protein mixture, the minor contaminating proteins 
were taken into consideration when the alpha toxin proteins were used for the vaccine trials.  
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Figure 3.23: Optimisation of IMAC wash buffers.  
A) Alpha toxin - Imidazole concentrations, Lane 1: 70mM, Lane 2: 80mM, Lane 3: 90mM, Lane 4: 
100mM and Lane 5 & 6: 200mM; B) plc2 - Imidazole concentrations, Lane 1: 60mM, Lane 2: 
70mM, Lane 3: 80mM, Lane 4: 90mM, Lane 5: 100mM and Lane 6 & 7: 200mM; and C) plcInv - 
Imidazole concentrations, Lane 1: 60mM, Lane 2: 70mM, Lane 3: 80mM, Lane 4: 90mM, Lane 5: 
100mM and Lane 6 & 7: 200mM. M: SeeBlue Plus2 protein standard marker.  
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Figure 3.24: Concentrated fractions of plcInv, plc2 and alpha toxin.  
A) Coomassie stained gel - M= SeeBlue Plus2 protein standard marker, Lane 1: plcInv, Lane 2: 
plc2, Lane 3: plc. B) Western blot - M= SeeBlue Plus2 protein standard marker, Lane 1: plcInv, 
Lane 2: plc2, Lane 3: plc. 
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3.3.9 TCA precipitation studies of hemolysin secreted alpha constructs  
 
The detection of the plcInv, plcNSPInv and plc104 fusion proteins from the pMOHly1 vector was 
difficult for two reasons. The first was the deliberate removal of the 6xHis-tag at the genetic level 
as this was for purification means via IMAC and was not essential for the protein expressed in the 
pMOhly1. Hence with the removal of the His-tag the easiest method to concentrate the 
expressed proteins was eliminated so other methods had to be investigated. The second difficulty 
was the level of expression from the hemolysin vector as it has been reported to be as little as 25 
to 100 µg/L (Hahn and von Specht, 2003). Three bacterial vectors, E. coli, S. Typhimurium LT2-
9121 and STM1 harbouring the pMOHly1 constructs were grown in broth culture and the 
supernatant was tested for the expressed constructs.  
 
TCA precipitation studies were carried out on 10 mL cultures. These samples were taken from 
both mid-log phase and overnight cultures.  This method of concentration only yielded a minute 
amount of precipitated protein for both cultures. This was then completely dissolved and used for 
the SDS-PAGE and the western blot. For the mid-log phase cultures no reaction was observed 
from any of the bacterial vectors.  
 
For the overnight cultures, there was a reaction for each of the bacterial hosts with the reactions 
shown for the vaccine vector STM1 (Figure 3.25). The pMNInv fusion construct expressed the 
highest level and showed a band at 50 kDa. There was a second band below the expected one at 
approximately 48 kDa which would indicate that the N-terminus part of the hlyA’ has been 
removed. It would appear that this cleavage is not 100% efficient. The pMOInv fusion construct 
also expressed well and had a single band lower than the expected 53 kDa. It appears to be 
approximately 46 kDa which would indicate that the C-terminus portion of the hlyA’ has been 
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removed. The pMO104 construct was also expressed but not as strongly by the other constructs.  
There was a weak band expressed at the predicted size of 23.22 kDa with a stronger one at 
approximately 12 kDa which is the predicted size of the pMO104 protein without either the N-
terminus or C-terminus hlyA secretion signals. Expression of these fusion constructs was 
confirmed in all bacterial vectors and at two different temperatures. Normal growth and 
expression was observed at 37°C (Figure 3.25) as well as at 42°C (not shown) which is a significant 
temperature as it is the core body temperature of chickens. For the mid-log phase no bands were 
detected (not shown). 
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Figure 3.25: TCA precipitation of extracellular expressed proteins from STM1.  
M: SeeBlue Plus2 protein standard marker, N: Empty STM1 vector. 
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3.4 Discussion 
3.4.1 Cloning difficulties with pMOhly1 
Difficulties were encountered in the construction of some of the recombinant clones. The major 
difficulty encountered was with the vector pMOhly1. In order to utilise the hly operon in its most 
efficient form, the NsiI site is the ideal place to insert a coding region to be expressed. Restriction 
profiling proved useful in determining orientation of the insert in this case where the restriction 
enzyme, AluI, was used for its four-base recognition site. This resulted in clear profiles for the 
empty pMOhly1 and for the clones that had the insert (Figure 3.10). A difficulty encountered for 
pMO104 screening is that as the NsiI sites remained, when the plc104 was digested out using NsiI, 
it confirms the presence of the insert but not the directionality of it.  
 
PCR determination of the orientation (Figure 3.12 and Figure 3.14) was achieved using different 
primer combinations by mixing pMOhly1 sequencing primers and the insert primers (Table 3.1). 
In theory, if the insert was present in either the correct or incorrect orientation there should only 
be two bands present from the four PCR reactions. In the pMO104 screening, each clone 
produced three bands and the one that proved to be the correct clone, after sequencing, 
amplified two bands for the correct orientation and one for the incorrect (Figure 3.12). In the 
screening of pMOplc2 and pMNplc2, there was a single robust band for the incorrect orientation 
and then multiple bands for the correct orientation but none at the expected size of 1.2-1.3 kbp 
(Figure 3.14). These other bands can be attributed to non-specific binding of the primers on the 
pMOhly1 plasmid. Though the PCR screening was at times unpredictable and the restriction 
profiling time consuming, when combined they proved successful in identifying the correct 
pMOInv, pMNInv and pMO104 constructs.  
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Ligation of the plc2 and NSPplc2 inserts into the pMOhly1 vector was not successful. The size of 
the insert should not have impeded the insertion of plc2 and NSPplc2 into pMOhly1 as larger 
inserts have been successfully expressed and reported in the literature (Gentschev et al., 1996; 
Spreng et al., 2000; Gentschev et al., 2004; Zhu et al., 2006; Hotz et al., 2009). The most probable 
reason that the inserts were not compatible with the pMOhly1 plasmid is the fact that expression 
is constitutively controlled. The original plasmid pCRplc2 has an inducible T7 promoter which is 
not activated until the presence of IPTG, whereas the hly operon is activated upon successful 
transformation (Gentschev et al., 1996). The production of the toxoids is unlikely to have proved 
toxic to the host cell as expression in the previous vector accumulated in the cytoplasm of the 
host cell without being toxic. So as the toxoids were being exported directly to the outer 
membrane with hemolysin expression, it should not have killed the host cell.  The expression of 
the toxoid-hemolysin complex may have been excessive and caused the host cell to die when the 
interaction of the HlyD and Tol-C receptors formed too many trans-periplasmic export channels 
causing leakage of the cytoplasm (Thanabalu et al., 1998; Balakrishnan et al., 2001). If this was 
the case, the metabolic load of this expression system was the most probable cause of the host 
cells demise when the insert was in the correct orientation.  
 
3.4.2 Stability assays 
Due to the metabolic load that the hemolysin secretion system can impose on a host cell, it was 
important to verify that the host cell can retain the plasmid without the assistance of selective 
pressure. The more stable the plasmid is in the vector strain the more likely it is to persist in a 
vaccinated animal increasing the host immune response. Retention rates of more than 100% can 
be attributed to sampling during log-phase growth and standard pipetting error. As the plasmids 
range in size from 11.966 kbp to 12.783 kbp (i.e. relatively large), the retention of the plasmids 
could be decreased in the STM1 vaccination strain. Overall the pMNInv plasmid was retained by 
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STM1 the longest with an average of 86% over the six day period. The pMOInv construct was 
comparable with an average of 84% but had a lower STM1 retention rate of 58% on Day 6 (Figure 
3.15) where pMNInv was still high at 80% (Figure 3.16). These two constructs are very similar and 
the presence of two signal peptides in pMOInv may be responsible for the slight decrease in 
stability in STM1. The pMO104 was not as stable as the other constructs with an average of 81% 
which is surprising as it is the smallest expressed protein yet had the steepest decline in retention 
(Figure 3.17). However, these levels of retention of plasmid are relatively high, and as the 
expression is constitutive should enable good amounts of recombinant protein to be secreted and 
available to the host immune system.  
 
3.4.3 Expression and purification of the alpha toxin constructs  
The purpose of this study was to construct non-toxic stable proteins based on the alpha toxin 
which while inactive will still retain immunogenic epitopes. This has been achieved by a) partial 
deletion of the active site or b) site mutagenesis of two amino acids at the DNA level. These 
molecular changes resulted in inactivation of the toxin’s two main activities – haemolysis (Figure 
3.19) and lecithinase (Figure 3.20). Variants of alpha toxins have been designed in previous 
studies with site mutagenesis changing one amino acid to an alternative one (for a complete 
summary of refer to (Flores-Díaz et al., 2004)). Individual changes to the histidine at position 68 
and aspartic acid at position 56 reduced lecithinase activities to 0.2% of that of the original toxin, 
and no activity, respectively (Nagahama et al., 1995; Guillouard et al., 1996; Nagahama et al., 
1997).  By having these two amino acids changed to serine and alanine, respectively (changing 
two nucleotides in each codon), this ensured that the protein plc2 would be highly unlikely to 
revert to full toxicity as four mutation events would be required in the plasmid pCRplc2. The 
protein plc2 displayed full inactivation of haemolysis and lecithinase activities yet was fully 
reactive to the anti-alpha toxin serum. This demonstrated that whilst the protein was inactivated 
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the key immunogenic epitopes were retained. The immunogenicity of plc2, along with plcInv and 
inactivated alpha toxin will be further explored in Chapter 4.  
 
The use of supplements in media to increase growth of bacterial vectors is well known for large 
scale batch cultures (Yee and Blanch, 1992). The same idea was applied to these small scale 
cultures to increase expression of the recombinant protein. The sugars were chosen as either 
monosaccharides (glucose and fructose) or disaccharides (maltose and sucrose) due to the ease 
of digestion. As a simple carbon source all of these sugars had an effect on the expression of 
alpha toxin and plcInv. Glucose was used as a supplement in subsequent purification 
experiments. 
 
For the expression of alpha toxin, supplemented sucrose had the most positive effect by 
increasing the expression over the 5 h induction period (Figure 3.21 (E)). Degradation of the alpha 
toxin was unexpected as when purified from culture grown in LB broth breakdown was rarely 
observed. For the protein plcInv, degradation was often observed after purification hence why 
supplements were investigated to see if a more stable product could be purified. The glucose 
supplemented culture produced more protein overall however a small proportion of this was 
degraded plcInv (Figure 3.22 (E)).  
 
The higher migration of the plc2 protein than the predicted size of 46.8 kDa was unexpected. This 
had not been experienced with the other constructs as the deletion of sections of the proteins 
resulted in the clear reduction of the predicted size of protein. In other published studies, 
substitutions of one amino acid at similar positions in the alpha toxin have also shown a similar 
occurrence (depicted in Figure 3.24) using western blot analysis with anti-alpha toxin serum 
(Nagahama et al., 1995; Guillouard et al., 1996; Nagahama et al., 1997). In those studies, as here, 
this minor size difference did not adversely affect the purification or the stability of the variants.  
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3.4.4 Expression of alpha toxin constructs using a hemolysin expression 
system 
The expression of the plcInv, plcNSPInv and plc104 was successful from the pMOhly1 plasmid and 
was observed from all of the bacterial vectors. The expression from STM1 vector is the most 
important as this is the vector which will be used for vaccination trials. Although it is an efficient 
recombinant expression system, it has been observed that expression levels can vary from 25 to 
100 µg/L of culture supernatant (Hahn and von Specht, 2003).  
 
Hahn and colleagues (2003) found that culture size greatly affected the protein expression rate in 
the hemolysin expression system due to the reduction in oxygen saturation levels in small culture 
volumes. This activation of the hemolysin system under reduced molecular oxygen might be 
beneficial under in vivo conditions as the gastrointestinal tract is a low oxygen environment. It 
could result in a higher level of expression of the fusion products which potentially could increase 
the potency of the immune responses.  
 
All of the fusion-constructs were expressed successfully from the STM1 vector and were reactive 
with the anti-alpha toxin sera (Figure 3.25). The maintenance of the immunogenic epitopes on 
the fusion constructs is essential if these plasmids were to be used to stimulate protective 
immune responses in mice and chickens against C. perfringens. This will be explored in the 
subsequent experiments using a vaccine trial using a mouse model and immunological studies in 
chickens.  The protective responses invoked by the IMAC purified proteins will also be tested in a 
gas gangrene mouse model. 
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VACCINATION STUDIES IN MICE 
4.1 Introduction 
The bacterium Clostridium perfringens can cause gas gangrene in humans (Flores-Diaz and Alape-
Giron, 2003) and necrotic enteritis in poultry (Al-Sheikhly and Truscott, 1977).  Both of these 
diseases are difficult to treat due to the location of the infection, hence why an efficacious 
vaccine is required. The mouse lethal dose of alpha toxin has been previously reported as  
<0.1 µg/mouse which makes it a highly potent toxin (Titball et al., 1989). As discussed in Chapter 
1, alpha toxoid has been demonstrated to be immunogenic in previous studies (Amimoto et al., 
2002; Zekarias et al., 2008; Cooper et al., 2009), with varying levels of protection achieved. 
 
Although the ultimate objective is to find a vaccine for use in poultry, the vaccine candidates were 
first tested in a commonly used gas gangrene model carried out in mice. Gas gangrene is 
characterised by the production of gas within the tissues as a result of metabolic activities of the 
multiplying C. perfringens and the production of numerous toxins (Shimizu et al., 2002). The 
clostridial toxins reduce the oxygen saturation in the infected area which increases proliferation 
of C. perfringens resulting in further spreading of the infection and more extensive tissue damage 
(Shimizu et al., 2002). Alpha toxin assists by causing intravascular coagulation, reduced perfusion 
of neutrophils and the development of thrombosis (Bunting et al., 1997; Flores-Díaz et al., 2004; 
Sakurai et al., 2004), which maintains the anaerobic conditions required for the infection to 
continue. Cyanosis ensues followed by necrosis of the deoxygenated tissues, leaving the area 
swollen, necrotic and black and without treatment the infection will be fatal (Stevens, 2000). 
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Two different types of vaccines were evaluated in these mouse model studies. The first was the 
protein constructs in purified sub-unit form described in Chapter 3. The second vaccine type is an 
attenuated STM1 harbouring the hemolysin expression vector encoding three different toxin-
constructs.  The hemolysin expression operon and its genes have been described in Section 4. The 
main function of this system is to transport the fusion proteins outside of the vaccine strain so 
that host humoral immune responses can be efficiently induced even if only during the 
extracellular phase in vivo (Gentschev et al., 1996). Expression levels of hemolysin fusion proteins 
from the carrier strains has varied from as low as <0.01 µg/mL to 3.5 µg/mL (as reviewed in Hahn 
and Specht, 2003). The hemolysin system will express the majority of hemolysin fusion protein 
into the supernatant however small amounts can be found in the periplasm and the cytoplasm 
(Zhu et al., 2006). The hemolysin secretion system in a heterologous delivery vector, such as 
STM1, is shown in Figure 4.1.  
 
To confirm that the alpha toxin variants are immunogenic when delivered alone or as a fusion 
construct, the two different vaccines were tested in the gas gangrene mouse model. The 
objectives for these animal trials are: a) to determine the effect of the protein vaccine on the 
development of gas gangrene; b) to determine the level of protective immune response induced 
by the protein vaccines; c) to ascertain if the level of expression of the fusion proteins is sufficient 
to provide a level of protection; and d) to establish if the use of a carrier strain influences the 
immunogenicity of the fusion proteins. 
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Figure 4.1: Delivery of heterologous antigens using the E. coli hemolysin expression system. 
In STM1, the fusion proteins are expressed as secreted protein (Figure 3.25). Surface-bound 
fusion protein (which assists in pathogen detection by APC) and cytoplasmic fusion proteins were 
not detected by Western blot on whole cell lysates (not shown). Figure obtained from (Gentschev 
et al., 2002).  
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4.2 Materials and methods 
4.2.1 Protein preparation 
Proteins plc, plcInv and plc2, described in Chapter 3 (Table 4.1) were purified to homogeneity as 
described in Section 3.2.9. Tris was removed from the protein fractions by buffer exchange with 
PBS using Centricon centrifugal devices (Section 3.2.9.6) and the protein fractions concentrated 
using the same devices.  
 
4.2.2 Toxoid preparation  
Formaldehyde (Sigma-Aldrich, Germany) was added directly to a solution of plc (prepared in PBS 
at a concentration of 1 mg/mL) to give a final concentration of 0.4% (v/v) formaldehyde.  The 
mixture was incubated at 37°C overnight on a rotating platform.  Toxin inactivation was 
confirmed by the addition of 40 L of formaldehyde treated sample to wells bored into a Nagler 
and SBA plate in the presence of 10 mM CaCl2.  Residual formaldehyde was removed by buffer 
exchange with PBS in Centricon centrifugal filters and the protein content of the solution was 
reconfirmed by the Bradford method and spectrometry, as protein losses during buffer exchange 
could be quite high. 
 
4.2.3 Adjuvant preparation 
Prior to vaccinations, inactivated plc (toxoid), site deletion protein plcInv, and site mutagenesis 
protein plc2 were prepared in an equal volume of Freund’s incomplete adjuvant (FIA) (Sigma) 
following the protocol outlined in Ausubel (1994). Briefly, an emulsion was prepared by drawing 
up and expelling equivalent volumes of protein and FIA through a 21 gauge needle in a 3 mL glass 
syringe until the fluidic suspension increased markedly in viscosity and was no longer able to  
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Table 4.1: Purified proteins used to vaccinate mice via the intraperitoneal route. 
Protein Description Location of His tag 
plc The complete -toxin of C. perfringens 
(inactivated prior to vaccination) 
C-terminus 
plcInv Plc with an internal deletion of aa residues 56-
75 which encompass two zinc binding residues 
essential for phospholipase C activity. 
C-terminus 
plc2 Plc with a two site mutagenesis of amino acid 
position 56 (aspartic acid to alanine) and 
position 68 (histidine to serine). 
C-terminus 
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disperse when a drop was placed in a glass beaker of cold water.  Vaccines prepared in adjuvant 
were used within 6 h of preparation. 
 
4.2.4 Mouse vaccine trial using protein vaccine candidates 
Four groups, each containing 6 female BALB/c mice (6-8 weeks old), were vaccinated via the 
intraperitoneal route using a 1 mL syringe and 21 gauge needle with 100 L of protein: adjuvant 
emulsion.  The groups consisted of a toxoid plc:FIA, plcInv:FIA, plc2:FIA and PBS:FIA control.  Mice 
were vaccinated on days 1, 15 and 30 with 25 g of protein at each vaccination.  Mice were bled 
prior to each vaccination. 
 
4.2.5 Mouse vaccine trial using STM1 expressing the engineered toxin 
variants 
Four groups, each containing 6 female BALB/c mice (6-8 weeks old), were vaccinated via the 
subcutaneous route using a 1 mL syringe and 21 gauge needle with 100 L of STM1 carrying the 
constructs pMO104, pMNInv, pMOInv along with the empty vector pMOhly1. Another four 
groups, each containing 6 female BALB/c mice (6-8 weeks old), were vaccinated via the oral route 
using a 1 mL syringe and a oral gavage needle with 100 L of STM1 carrying the constructs 
pMO104, pMNInv, pMOInv along with the empty vector pMOhly1. All oral groups were 
vaccinated on days 1, 15, and 30 with 108 CFU of STM1 harbouring each of the vaccine constructs 
at each vaccination. Subcutaneous groups were vaccinated on the same days but with 106 CFU of 
STM1 harbouring each of the vaccine constructs at each vaccination.  Mice were bled prior to 
each vaccination. 
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4.2.6 C. perfringens challenge 
Clostridium perfringens strain 60, a field isolate obtained from a chicken with clinical signs of 
necrotic enteritis was used as the challenge organism (Table 2.1). One percent (v/v) of an 
overnight culture of C. perfringens 60 grown in Thioglycollate broth was used to inoculate bottles 
containing 500 mL of freshly prepared and autoclaved Thioglycollate broth.  To avoid oxygen 
exposure to the bacterium, a lid with a rubber septum was used to seal the bottle, and the 1% 
inoculum was injected into the bottles with a syringe.  The rubber septum was first sterilised with 
80% (v/v) ethanol.  The culture was grown for 4 h at which time approximately 5 x 108 CFU/mL 
was reached.   
 
The culture was separated by centrifugation in sterilised 250 mL autoclave bottles at 10,000 x g 
for 10 min, the supernatant discarded and the pellet washed in sterile saline, pelleted as above 
and resuspended in a final volume of 3 mL saline (including bacterial volume).  Mice received  
50 L containing approximately 109 cells by an intramuscular injection to the left thigh.  The right 
thigh was left unchallenged as an internal control.  Mice were monitored closely for the first 4 h, 
and every 6-8 h for the following 72 h.  Severity of gangrene in the mice was determined using an 
index calculating the severity of infection of challenged mice (Table 4.2). Mice were examined and 
scored according to Table 4.2 every 8 h for the first 48 h post-challenge, or more frequently if 
disease progression was acute. 
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Table 4.2: The index used to score mice infected with C. perfringens.  
The reduced perfusion of vessels and migration of C. perfringens is indirectly observed via the 
swelling (oedema of infected thigh and gas production by C. perfringens) and blackening 
(cyanosis) of the injection site, and eventual gas-gangrene development towards the foot pad. 
 
 
Score Clinical signs 
0 Swelling/limping of infected thigh 
1 Cyanosis (blackening) at the injection site / Swelling 
of the foot pad with pink colouring 
2 Spread of cyanosis to the thigh surrounding injection 
site 
3 Spreading of cyanosis to ankle / Swelling of foot pad 
with dark red colouring 
4 Blackening of complete foot pad (sacrifice) / Mouse 
found dead 
 
  
CHAPTER 4
 
~ 142 ~ 
4.2.7 ELISA protocols 
Humoral antibody responses of vaccinated mice were measured using the ELISA as outlined in 
Section 2.6.6 with some modifications.  Wells were coated with 3 g/mL of purified alpha toxin 
(plc).  Doubling dilutions of sera obtained from vaccinated mice were used as the primary 
antibody, and goat anti-mouse IgG-HRP (diluted 1:5000 in PBST/1% skim milk) was used as the 
secondary conjugated antibody.  Following the addition of the substrate TMB, plates were 
incubated for 15 min before the addition of 50 L of a 1 M solution of sulphuric acid.  The 
endpoint was determined as the dilution at which the optical density (OD) at a wavelength of 450 
nm (OD450), was 3 times the background level. 
 
4.2.8 Adsorption of sera to STM1  
Four millilitres of TE buffer were used to flood an agar plate confluent with STM1 grown for 18 h 
at 37°C. The cells were harvested and separated by centrifugation for 10 min at 5,445 x g. The 
cells were washed in TE buffer and were ruptured on ice using 6 x 20 s bursts of sonication with a 
30 s cooling off period between each cycle. Insoluble matter was separated by centrifugation at 
14,000 x g for 5 min and the supernatant filtered through a 0.45 μm filter. Two millilitres of the 
supernatant was used to adsorb 15 μL of anti-sera previously diluted in 1 mL TST. This was left 
shaking at room temperature for 4 h or at 4°C for 24 h. The adsorbed anti-serum was then stored 
at -20°C until required. 
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4.2.9  Tissue sampling 
At necropsy, spleens were removed and stored in sterile tubes on ice. Spleens were then 
homogenised with 1mL sterile PBS and spread onto LB plates and LB plates with 100 μg/mL 
ampicillin with serial dilutions of each homogenate. Plates were then grown overnight at 37°C 
and the colonies enumerated. Colonies grown on LB plates with 100 μg/mL ampicillin were then 
subjected to alkaline lysis plasmid extraction (Section 2.3.1) and the plasmids screened for 
constructs (Section 3.1.5). Homogenates were stored at 4°C for no longer than 48 h whilst the 
screening took place. 
 
4.2.10 Statistical analysis 
All statistical analysis was calculated using the program Microsoft Excel 2007 using the Data 
Analysis add-in. The results of all ELISA assays for the detection of anti-alpha toxin antibodies 
were analysed for equal variance within the data set. If unequal variances were encountered this 
was taken into account and a Welch’s T-test was used. Results displaying a normal distribution 
and equal variances were analysed using Student’s T-test and ANOVA methods. 
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4.3 Results 
4.3.1 Clostridium perfringens challenge against protein vaccinated mice 
Prior to challenge, sera was taken from all mice and analysed for the presence of anti-alpha toxin 
antibodies. All mice vaccinated with the purified protein vaccines of alpha toxoid, plc2 and plcInv 
developed an anti-alpha toxin antibody response, whilst the mice vaccinated with PBS:FIA did not 
develop a detectable response above the background (Figure 4.2). The group with the highest IgG 
titres was the plcInv vaccinated group; with the plc2 inducing a lower level and alpha toxoid was 
the least immunogenic of the three proteins. Each of the protein vaccinated groups induced 
significantly higher titres than negative control of PBS, the plcInv and the plc2 groups also induced 
significantly higher titres (p<0.05) than the toxoid. 
 
The index used to score the development of gas gangrene was based on previous challenge trials 
(Awad et al., 2000; Awad et al., 2001) and is outlined in Table 4.2. All mice including the toxoid 
vaccinated mice displayed localised swelling at the site of challenge injection and limping in the 
injected thigh so these clinical symptoms were excluded from the index. Mice that developed 
cyanosis from the thigh to the footpad (Figure 4.3) were euthanized due to animal welfare 
considerations.  
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Figure 4.2: Elicited IgG response after three vaccinations with purified protein vaccines. 
 Bars with * indicate significant difference at p <0.05 in comparison to the PBS control group. 
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Figure 4.3: Clinical signs of C. perfringens gas gangrene in mice. 
A) Swelling of the thigh, ankle and foot caused by gross vasodilation of blood vessels, cyanosis is 
visible on the upper thigh and abdomen indicative of a score of 3 according to the index (Table 
4.3). B) Cyanosis of the footpad indicative of a score of 4 according to the index (Table 4.3).  
C) Comparison of left and right thighs of a mouse infected with C. perfringens. Inflammation and 
swelling is prominent in the infected thigh on the left. 
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Development of gas gangrene was observed in all vaccinated groups. In the current study, two 
mice displayed cyanosis on the affected thigh and an open wound from the injection site at 77 h 
post-challenge. A third mouse developed an open wound at the conclusion of the observation 
period and was euthanized. In the plcInv group, four mice developed a black foot pad indicating 
an index score of 4 after 40 h post-challenge. Mice that were not vaccinated with protein but 
PBS:FIA developed signs of gangrene similar to that of plcInv vaccinated mice (Figure 4.4).  The 
plcInv group did not have a delayed onset of gas gangrene despite having high anti-alpha toxin 
antibodies prior to challenge (Figure 4.5). 
 
The plc2 vaccinated group did display a delay in onset of gas gangrene with no mice displaying 
higher than a CI score of 2 for the first 32 h post-challenge (Figure 4.4).  This was despite having a 
lower detected level of anti-alpha toxin antibodies than the plcInv group which had a higher 
antibody titre but a higher cumulative CI score over the 88 hour observation period. In the plc2 
vaccinated groups there were 4 mice out of 6 that displayed no signs of gas gangrene (CI score 0) 
until the conclusion of the trial. 
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Figure 4.4: Progression of gas gangrene over 88 h in mice vaccinated with purified toxin proteins. 
Group name with * indicates significant reduction (p<0.01) from the PBS control group.  
% CI Score is the sum of CI Index scores for all mice in the group over the maximum CI Score 
possible (i.e. 5 x n) expressed as a percentage.  
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Figure 4.5: IgG response in BALB/c mice (grouped data, n=6) to purified alpha toxin vaccines. 
All groups displayed a significantly higher titre (p<0.05) that the PBS control group (not shown) 
which displayed no reactivity to the alpha toxin specific ELISA. 
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4.3.2 Clostridium perfringens challenge against STM1 carrying pMOhly1 
constructs vaccinated mice  
Prior to challenge, sera was collected from all groups and tested for reactivity against both STM1 
and alpha toxin. It was found that after adsorption of the sera to STM1 (Section 4.2.8) no 
reactivity was observed against the alpha toxin. The same was observed when the sera were 
adsorbed with alpha toxin instead. As will be seen, this compounds the analysis; therefore it was 
proposed that STM1 contains epitopes cross-reactive with alpha toxin. As this cross reactivity 
masks the specific antibodies against alpha toxin, all the ELISAs were carried out on normal sera 
with no adsorption. 
 
The humoral response induced by oral vaccinations with pMO104, pMOInv and STM1 carrying 
pMOhly1 were relatively higher than with their subcutaneous vaccinations (Figure 4.6). The 
pMO104 construct elicited the highest IgG antibody response with pMNInv eliciting the lowest 
response. However, none of the vaccinated groups, neither oral nor subcutaneously delivered, 
displayed a significantly increased response when compared to the STM1 carrying pMOhly1 
(p>0.05). All groups had induced IgG responses against the vector strain, STM1 (Figure 4.7). The 
IgA response was higher in the orally vaccinated mice than the subcutaneous vaccinated group 
but they did not differ significantly (p>0.05) (Figure 4.8).  
 
The challenge culture was grown to an estimated 5 x 108 CFU/mL to give challenge inoculums of 
109 CFU. Retrospective plate counting of the challenge inocula on SBA revealed that mice were 
given 4.6 x 108 CFU/mL instead of the calculated dose of 109 CFU per mouse. The reduced 
inoculum was adequate in producing severe signs of gas gangrene. Mice that developed cyanosis 
from the thigh to the footpad (Figure 4.3) were euthanized due to animal welfare considerations.  
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Figure 4.6: IgG responses (obtained from pooled sera, 1:25 dilution) against alpha toxin from oral 
and subcutaneous STM1 vaccination carrying the following constructs.  
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Figure 4.7: IgG responses against STM1 from oral and subcutaneous STM1 vaccinated mice. 
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Figure 4.8: Alpha toxin specific IgA after vaccinations Days 1, 14 and 28.  
No significant differences were observed between any of the groups.   
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After the challenge, progression of gas gangrene was rapid (Figure 4.4). Both the oral and 
subcutaneous groups that were vaccinated with STM1 carrying the pMOhly1 vector developed a 
CI score of 4 within 14 h of challenge (Figure 4.8). The group with the lowest CI score at the 
conclusion of the observation period was the orally vaccinated pMOInv group at 83.33%. There 
was no significant difference in overall progression of the disease at 31 h post-challenge as all 
groups followed the same trend. Upon necropsy, spleens were recovered and tested for the 
presence of STM1. STM1 was recovered from one third of the mice and of these, 31.25% 
harboured the construct plasmids. The most recovered plasmid from the spleen was pMNInv 
from two mice in the oral group and one in the subcutaneous group, with only one mouse 
positive for the pMO104 construct and one for the pMOhly1 construct (Figure 4.9). The best 
group for recovery of STM1 alone was the oral pMNInv where all 6 of the mice in the group 
tested positive for the STM1 in their spleens (Figure 4.10). 
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Figure 4.9: Progression of CI scores over 31 h post-challenge after oral or subcutaneous 
vaccinations. 
No significant differences were observed between any of the groups. SC – subcutaneous route, 
Oral – oral route. % CI Score is the sum of CI Index scores for all mice in the group over the 
maximum CI Score possible (i.e. 5 x n) expressed as a percentage. 
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Figure 4.10: Recovery of plasmids and STM1 from spleens.  
Mice from the oral pMNInv vaccinated group were positive for STM1 in significantly higher 
numbers (p<0.05) than the other groups (denoted by *). 
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4.4 Discussion 
Two alpha toxin variants, one a deletion mutant and the other a substitution mutant were 
developed, expressed and purified as described in Chapter 3, were examined for their potential as 
vaccines against C. perfringens. Immunogenicity was determined using BALB/c mice when 
administered intraperitoneally with FIA. Both of the vaccines, plcInv and plc2, as well as the 
positive control alpha toxoid produced a significant titre of anti-alpha toxin IgG (Figure 4.2). The 
plcInv vaccine did induce a significantly higher IgG titre than the alpha toxoid which was 
unexpected as the alpha toxoid may have been expected to induce the highest titre as it is the 
same sequence as the native alpha toxin. It also had a disease progression similar to the 
unvaccinated PBS control group (Figure 4.4). This reduction in titre is probably caused by the 
formaldehyde in the inactivation incubation. The alpha toxins physical state is affected by the 
formaldehyde resulting in denatured protein with a subsequent loss of conformational epitopes. 
Therefore, some antibodies induced by the inactivated toxoid may not recognise epitopes on the 
native toxin in the ELISAs. 
 
The challenge inoculum was lower than the anticipated 109 CFU/dose; however it was adequate 
in reproducing the signs of gas gangrene.  Mice that survived longer than 48 h either displayed a 
CI score of 3 over many h or showed no symptoms at all. Two thirds of the plc2 vaccinated group 
(4/6) demonstrated full protective responses as they did not develop any symptoms of gangrene. 
This indicates that the substitution mutant retains the same immunogenic level of alpha toxoid, 
even though the IgG levels were lower than the plcInv vaccine. This indicates the presence of 
alpha toxin neutralising antibodies which can result in the significant delay in developing a high CI 
score.  The plcInv protein, which has part of the α-helical region of the active site removed, is not 
as effective at eliciting neutralising protective responses, although the IgG titre was relatively 
high. 
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In the second challenge trial, three constructs pMO104, pMNInv and pMOInv, that were 
developed and confirmed for expression as described in Chapter 4, were tested in BALB/c mice 
for the induction of protective immune responses against alpha toxin from C. perfringens.  These 
constructs were stable in the vaccine strain STM1 and were able to express detectable levels of 
the alpha toxin variants (Chapter 3). The main difficulty encountered was the lack of specific 
reactivity of the induced antibodies to the native alpha toxin as shown by the lack of reactivity 
when the serum was adsorbed with STM1 lysate. This lack of reactivity was observed in both the 
IgG (Figure 4.6) and IgA (Figure 4.7) ELISAs.  
 
This lack of antigen specificity indicates one of three problems: non-specific binding, cross 
reactive binding or undetectable levels of responses. The relatively high levels of humoral 
responses to the control pMOhly1/STM1 compared to the toxin constructs indicate that there is 
non-specific induction of humoral responses. To determine if there is cross-reactive binding the 
alpha toxin protein sequence was compared against the Salmonella genome. A hypothetical 
protein (GenBank: BAE20151.1) demonstrated some sequence identity (44%) with alpha toxin. So 
there is a possibility that between these similar proteins the specific antibodies against alpha 
toxin are lost in the adsorption due to cross-specific binding. In other recent studies cross-
reactivity has not been reported however these studies do not adsorb their sera against the 
carrier strain before testing for specific antibody responses (Gentschev et al., 2004; Zhu et al., 
2006; Hotz et al., 2009). Finally, it may be that the expressed amount of fusion constructs is not 
substantial enough to induce a detectable level of humoral responses.  
 
Despite there being difficulties identifying specific immune responses the ELISAs did show that 
the route of administration is important. For the IgG responses, the mice that were orally 
vaccinated showed a relatively higher level of alpha toxin specific and STM1 specific IgG than 
when the vaccine was delivered in a subcutaneous manner. This can be attributed to the STM1 
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being delivered in a manner akin to its natural infection route and the higher dose delivered to 
the mucosa-associated lymphoid tissue (MALT). For orally vaccinated mice it was expected that 
alpha toxin-specific IgA levels would be higher than in the subcutaneously vaccinated mice as the 
STM1 colonise the mucosal surfaces of the intestinal tract when delivered orally. However there 
was no significant difference in the alpha toxin-specific IgA levels measured from either the oral 
or subcutaneous vaccinated groups. 
 
The progression of gas gangrene in the second challenge trial was more rapid than that of the first 
trial showing that the two different vaccine types induce different immune responses. As the 
ELISAs showed specific anti-alpha toxin antibodies could not be detected, it was unlikely that 
there would be a significant effect on the onset of symptoms. Both control groups that were only 
vaccinated with STM1 carrying pMOhly1 developed gas gangrene in all of the mice by 11.5 h 
 post-challenge, which was the same for the subcutaneous vaccinations of pMO104 and pMOInv. 
The other test groups were somewhat more delayed with the majority of the mice having a CI 
score of 3 at 14 h for the pMNInv and pMOInv orally vaccinated and the subcutaneous 
vaccination with pMNInv. The last group to develop a mean CI score of 3 was the orally pMO104 
vaccinated showing that the highest titre measured for the IgG  (Figure 4.6) and IgA (Figure 4.7) 
may be true anti-alpha toxin antibodies that partially neutralised the active toxin. 
 
The spleen is an important lymphoid organ in terms of vaccination as both innate and adaptive 
immune responses can be mounted in this one organ. The white pulp of the spleen houses APCs 
and undifferentiated T cells whereas the marginal zone has a large population of macrophages 
and B-cells (Mebius and Kraal, 2005). Consequently, when the STM1 is recovered from the spleen 
it is probable that both innate and adaptive immune responses are being elicited. The recovery of 
STM1 was significantly higher in pMNInv vaccinated mice than any of the other groups (p<0.05) as 
STM1 was recovered from each mouse. Overall, STM1 (with or without plasmid) were found in 
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one third of the mice in the trial. In terms of plasmid, pMNInv was recovered from 3 mice, two 
from the oral group and one from the subcutaneous group. This was expected as the stability of 
this construct was the highest at 86% after 6 days of non-selective culture (Figure 3.13). The 
pMO104 and pMOhly1 constructs were recovered just once each and pMOInv was not recovered 
at all. Both pMO104 and pMOInv were stable in the STM1 with 81% (Figure 3.17) and 84% (Figure 
3.15) retention, respectively. This suggests that stability in vivo does not correlate with how the 
constructs will be recovered and disseminated throughout the body after vaccination. 
 
The first mouse trial showed that the induction of partial protection by antigen-specific humoral 
responses could be achieved using the purified recombinant proteins. Partial protection was 
observed in the plc2 vaccinated group (Figure 4.4) and significantly high antibody levels were 
observed for the other variant, plcInv (Figure 4.2). However in the second trial, where the 
constructs were delivered via STM1, the lower expression levels by the hemolysin system negate 
this prophylactic potential against gas gangrene (Figure 4.8). In terms of protection against gas 
gangrene these STM1 vectored vaccines are not successful. However, the use of the gas gangrene 
mouse model to test for protective responses is not entirely appropriate as it is believed that 
necrotic enteritis is caused by prolonged exposure to small doses of C. perfringens (Kaldhusdal et 
al., 1999; Lovland and Kaldhusdal, 2001; Hofacre et al., 2003). So, what may be an inadequate 
neutralising immune response against gas gangrene in mice may be a sufficient neutralising 
immune response against alpha toxin and necrotic enteritis in chickens.  Both diseases also affect 
completely different regions of the hosts anatomy – gas gangrene is a deep fascia infection 
whereas necrotic enteritis occurs in the intestinal tract. Hence these vectored vaccines will be 
tested in immunogenicity trials in the target animal, chickens.  
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IMMUNOGENICITY TRIALS IN 
CHICKENS 
5.1 Introduction 
 
Poultry is one of the largest naturally occurring animal reservoirs for Salmonella (Zhang-Barber et 
al., 1999). The presence of Salmonella species in broiler and layer flocks has a devastating effect 
on the quality and price of the product. In 2010, the USA experienced its largest consumer egg 
recall when there was a four-fold increase in reported Salmonella Enteritidis infections nationally 
over the period of May to July (CDC, 2010). The recall was for any eggs produced by two Iowa 
farms and accounted for approximately 500 million eggs that had been sold nationally under 
multiple brand names (BBC, 2010). The use of attenuated Salmonella vaccines to eliminate 
Salmonella infections and reduce colonisation rates has been quite successful in other countries 
and eliminates the risk of such recalls occurring.  
 
Several live attenuated commercial vaccines exist, including STM1, which when used in chickens 
cause no signs of illness and can provide heterologous protection (Barrow et al., 1990; Copper et 
al., 1992; Coloe et al., 1995; Mohler et al., 2006; Bohez et al., 2008). Modification of these 
attenuated vaccines into delivery vectors has been widely investigated utilising a diverse 
assortment of heterologous pathogen antigens (Coulson et al., 1994; Bachtiar et al., 2003; 
Garmory et al., 2003; Stokes et al., 2007; Pan et al., 2009; Bartolomé et al., 2010). There have 
been various degrees of success using Salmonella as a delivery vector depending on the host 
animal and the disease, including targeting necrotic enteritis in chickens using alpha toxin as a 
potentially protective antigen (Kulkarni et al., 2008; Zekarias et al., 2008).  The method of 
heterologous delivery or DNA vaccines has also been investigated leading to the theory that 
CHAPTER 5
 
~ 162 ~ 
 
prokaryotic expression in the Salmonella vector (from cryptic bacterial promoters in the CMV 
promoter) is equally important as eukaryotic expression after transfection for inducing immune 
responses (Gahan et al., 2009).  
 
Although the complete mechanism of pathogenesis of necrotic enteritis has yet to be fully 
elucidated, targeting of potential vaccines to the MALT and the gut associated lymphatic tissue 
(GALT) is the most logical choice as this is where lesions occur during the infection. This was taken 
into consideration when selecting the hemolysin expression system to used in STM1 so that 
induction of humoral responses in the MALT and GALT could be achieved. The first trial aimed to 
establish immunogenicity levels in chickens against both the STM1 vector and the C. perfringens 
alpha toxin via two vaccination routes, oral and subcutaneous injection. A necrotic enteritis 
challenge model was not conducted as repeated efforts to have a reproducible model at the 
university proved unsuccessful (personal communication, Jason Chang). 
 
One potential impediment for the use of live attenuated Salmonella vaccines is pre-existing 
immunity as a result of pre-exposure to either a heterologous or homologous strain. For chickens 
Salmonella exposure can occur via both horizontal and vertical transmission and many different 
strategies have been utilised to reduce such transmission including feed and drinking water 
acidification, immune strategies based on passive and active immunity, nutrient composition to 
reduce susceptibility to Salmonella and improved hygiene practices (Vandeplas et al., 2010). It 
was reported that a bivalent killed vaccine in laying hens significantly reduced vertical in ovo 
transmission of S. enterica serovars Enteritidis, Typhimurium and Gallinarum biovar Pullorum 
(Okamura et al., 2007). However, the consequence of in ovo transmission, where the chicks will 
already be colonised prior to Salmonella vaccination is not yet clear. 
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In Australia, Salmonella enterica serovar Sofia is the most prevalent strain found in poultry and 
one study recently demonstrated that S. Sofia was the dominant isolate found in carcasses before 
processing with 45/89 (51%) isolations and 51/69 (74%) isolations after processing (Mellor et al., 
2010). This serovar is also found dominantly in the litter of poultry farms which would assist 
transmission between chickens (Chinivasagam et al., 2010). This prevalence of S. Sofia could 
influence the efficacy of live Salmonella vectored vaccines, especially if vertical transmission 
occurs by in ovo transmission as well as horizontal transmission from other birds and 
environmental exposure.  
 
Currently there is much speculation over the effect of pre-existing immunity on heterologous 
delivered antigens. There has been various reports that draw the conclusion that pre-existing 
immunity leads to an up-regulation of the immune response magnitude to the delivered antigen 
(Bao and Clements, 1991; Whittle and Verma, 1997; Kohler et al., 2000; Kohler et al., 2000; 
Jespersgaard et al., 2001; Metzger et al., 2004; Sevil Domenech et al., 2008; Saxena et al., 2009). 
However, there has been convincing reports that pre-existing immunity diminishes heterologous 
antigen-specific immune responses and that this effect is a restrictive limitation of this delivery 
system as exposure to Salmonella is common (Attridge et al., 1997; Roberts et al., 1999; 
Vindurampulle and Attridge, 2003; Vindurampulle and Attridge, 2003; Sevil Domenech et al., 
2007; Gahan et al., 2008). These reports draw their conclusions from mouse models which is why 
this study was designed to test the effect of S. Sofia colonisation in a chicken immunogenicity trial 
to determine if either the humoral or cell-mediated immune responses to subsequent vaccines 
are affected.  
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5.2 Materials and methods 
Throughout this chapter, STM1 is left out of the vaccine nomenclature for brevity.  
 
5.2.1 Chickens and bacterial strains 
Newly hatched Cobb 500 broiler chicks were obtained from Inghams Farms, Pakenham, Victoria. 
The strain of S. Sofia used in the colonisation study was kindly provided by Dr Margaret McKenzie, 
Inghams Enterprises Pty Ltd., Springwood, Queensland. 
 
5.2.2 Immunogenicity trial via subcutaneous and oral vaccination routes  
The immunogenicity of the pMO104/STM1, pMNInv/STM1, pMOInv/STM1 and pCRplc2/STM1 
vaccines was determined in a chicken model. Four groups of six chickens were vaccinated via the 
oral route and four groups of six chickens were vaccinated via the subcutaneous route. Each 
vaccination consisted of 108 CFU in a total volume of 1 mL for oral vaccinations and 0.5 mL for 
subcutaneous vaccinations. Chickens were vaccinated three times in a period of 28 days. Blood 
samples were taken from the wing vein prior to the first vaccination and at necropsy. Faecal 
samples were taken prior to the first vaccination and one day prior to necropsy for IgA analysis. 
Necropsy occurred two weeks after the final vaccination. Samples from the caecal contents, 
spleen, liver and cloaca were collected at necropsy (Section 6.1.4). Plates were incubated at 37°C 
for 18-24 h. 
 
5.2.3 Immunogenicity trial using chicken colonised with S. Sofia prior to 
vaccination 
Two vaccines were selected to determine if immune responses could still be induced in the 
presence of a common commensal, S. Sofia. The vaccines were pMO104/STM1 and 
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pCRplc2/STM1 with the empty vector pMOhly1 as a negative control. Three groups of five 
chickens (5 days old) were colonised with S. Sofia five days prior to the first oral vaccination and 
three groups of five chickens were left un-colonised. Faecal samples were collected for five 
consecutive days from all chickens and enumerated, and chickens observed twice daily for signs 
of abnormal behaviour and/or malaise. Briefly, the faecal matter was suspended in sterile LB 
broth and dilutions were made of the faecal suspension and plated out onto Hektoen and XLD 
media in duplicate. Plates were incubated at 37°C for 18-24 h. Subsequently, two vaccinations 
consisting of 108 CFU in a total volume of 1 mL were administered over a period of 14 days. One 
week post-vaccination two chickens were euthanized and their organs analysed for the presence 
of S. Sofia and STM1 (Section 6.1.4) and the final three chickens two weeks post vaccination. 
Blood samples were collected at necropsy. Faecal samples were collected prior to the first 
vaccination and one day prior to necropsy for IgA analysis.   
 
5.2.4 Recovery of Salmonella from the organs.  
Standard microbiology methods were used to recover bacteria from the chicken organs (Copper 
et al., 1992; Cox et al., 2007). Each organ was removed aseptically at necropsy and stored at 4°C 
until processed. Samples were streaked onto selective media Hektoen Enteric agar and XLD agar 
(Oxoid). STM1 could be distinguished from S. Sofia from the lack of hydrogen sulphide production 
on both the Hektoen agar and XLD agar. Cloacal swabs were obtained and streaked onto selective 
media Hektoen Enteric agar and XLD agar. Cecal contents were diluted in LB broth and spread 
onto Hektoen Enteric agar and XLD agar plates. Vaccine constructs were isolated on ampicillin 
supplemented media (100 μg/mL) and confirmed by PCR amplification once isolated by Qiagen 
Miniprep (Qiagen, Australia). 
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5.2.6 ELISA protocols 
Antibody responses of vaccinated chickens were measured using the ELISA as outlined in Section 
2.5.7 with a few modifications. Wells were coated with 3 g/mL of purified alpha toxin (plc).  
Doubling dilutions of sera obtained from vaccinated chickens were used as the primary antibody, 
and goat anti-chicken IgG-HRP (Sapphire Bioscience, Australia) diluted 1:5000 in PBST/1% skim 
milk, was used as the secondary conjugated antibody.  Following the addition of the substrate 
TMB, plates were incubated for 15 min before the addition of 50 L of a 1 M solution of sulphuric 
acid.  The endpoint was determined as the highest dilution at which the OD at a wavelength of 
450 nm (OD450) was 3 times higher than the background level.   
 
5.2.7 Preparation of faecal samples for IgA analysis 
Faecal samples were collected within minutes of defecation over a period of an hour. Samples 
were weighed and then frozen at -20°C until processed. Standard faecal preparations of 1:10 
dilutions (w/v) were made in PBS, and the samples were vortexed vigorously for 5 min and 
allowed to stand at room temperature for 1 h (Holt et al., 1999 ). After centrifugation at 15,000 
 x g for 15 min, the supernatant was decanted and added to the ELISA plate in triplicate. The 
ELISA protocol was carried out as per Section 6.1.6 with the secondary conjugated antibody of 
rabbit anti-chicken IgA – HRP diluted 1:5000 in PBST/1% skim milk (Sapphire Bioscience, 
Australia). 
 
5.2.8 Chicken splenocyte preparation 
The chicken splenocytes were homogenised by squashing the spleen using the back of a 3 mL 
syringe.  The homogenised cells were resuspended in 5 mL of RPMI and filtered through a cell 
strainer (BD Falcon).  The splenocytes were pelleted by centrifugation at 1,600 x g for 5 min at 
4°C, the RPMI solution decanted and cells resuspended in 5 mL of ACK lysing buffer to lyse any 
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erythrocytes present.  Following 5 min incubation on ice, 5 mL of RPMI was added to the lysing 
solution and the cells pelleted by centrifugation (1600 x g, 5 min, 4°C).  The cells were washed 3 
times in RPMI and resuspended in 1 mL of RPMI.  Cell viability was calculated using Trypan Blue 
exclusion.  Ten microlitres of cell suspension, 10 L of Trypan blue (Sigma) and 80 L of PBS were 
mixed and viable cells counted in a haemocytometer chamber using an inverted microscope.  Cell 
concentration was adjusted to 106 cells/ 90L in RPMI.  The splenocyte suspension was used to 
determine chicken IFN-γ levels (Section 6.1.7)  
 
5.2.9 Determination of IFN-γ levels 
Chicken IFN-γ levels were determined using the Chicken IFN-γ Cytoset kit (CAC1233, Biosource-
Invitrogen, USA). A 96 well plate was coated overnight at 4°C with 100 l anti-chicken IFN-γ 
antibody (1.0 g/mL) in Coating Buffer (137 mM NaCl, 8 mM Na2HPO4, 1.5 mM KH2PO4, 2.7 mM 
KCl, pH 7.4); the wells washed twice with 400 μL Wash Buffer (1.5 mM KH2PO4,, 8.3 mM K2HPO4, 
1.4 mM EDTA, 0.05% v/v Tween 20, pH 7.4) and patted dry with autoclaved paper towelling. 
Unbound capture antibody was discarded and the plates rinsed once with 400 μL Wash Buffer. 
Excess liquid was removed from the plate by patting the bottom of the plate onto sterilised dry 
absorbent paper, and wells were blocked with 300 μL Assay Buffer (137 mM NaCl, 8 mM 
Na2HPO4, 1.5 mM KH2PO4, 2.7 mM KCl, 0.5 w/v BSA – fraction V, pH 7.4) for 1 h at room 
temperature. A volume of 100 L of RPMI was added to each well whilst the chicken IFN-γ 
standards using RPMI and splenocyte samples were prepared (Section 6.1.6).  The RPMI was 
discarded, plates were patted dry and 90 L of splenocytes added to each well (containing  
106 cells/ 90 L). All standard and sample wells were seeded in triplicate, as well as three wells 
per control. The addition of 10 l of a stock (10 g/mL) of concanavalin A (Sigma-Aldrich, 
Germany), a mitogen would serve as a positive control, 100 g per well BSA would serve as a 
negative unrelated protein control and 10 L of RPMI to confirm that there was no contamination 
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of the tissue culture media.  Alpha-toxin was prepared in RPMI at a concentration of 250 g/mL 
and 10 L added to each sample well.   
 
Subsequently, 50 μL of Detection Biotin antibody at a concentration of 0.5 g/mL was added to 
each well and the plate incubated at room temperature shaking at 700 rpm. The plates were 
washed 5 times with 400 μL Wash Buffer and patted dry with autoclaved paper towelling. To each 
well 100 μL of working Streptavidin-HRP was added and the plate incubated at room temperature 
for 30 min shaking at 700 rpm. The plates were washed 5 times again with 400 μL Wash Buffer 
and patted dry with autoclaved paper towelling. To develop the assay, 100 μL of TMB (BD) was 
added to each well and incubated at room temperature with continual shaking at 700 rpm for  
30 min. The assay was stopped with the addition of 100 μL 1.8 N sulphuric acid to each well and 
the absorbance at 450 nm measured. The amount of chicken IFN-γ was derived from a log-log 
standard curve. The independent Student’s t-test was used to determine any statistical 
differences between vaccine groups. 
 
5.2.10 Statistical analysis 
All statistical analysis was calculated using the program Microsoft Excel 2007 using the Data 
Analysis add-in. The results of all ELISA assays for the detection of anti-alpha toxin antibodies 
were analysed for equal variance within the data set. If unequal variances were encountered this 
was taken into account and a Welch’s T-test was used. Results displaying a normal distribution 
and equal variances were analysed using Student’s T-test and ANOVA methods. 
 
  
CHAPTER 5
 
~ 169 ~ 
 
5.3 Results 
5.3.1 Immunogenicity trial via subcutaneous and oral vaccination routes  
Samples of blood were taken prior to vaccination with STM1 to ensure that the chickens were 
immunologically naive to Salmonella at hatching and were not exposed by in ovo transmission. All 
pre-bleed sera and pre-vaccination faecal samples were negative (below background level) for the 
presence of Salmonella specific humoral responses (data not shown). Vaccination doses were 
confirmed by retrospective plate count and none were found to be over the 108 CFU in the 
volume of 1 mL given for oral vaccinations and 0.5 mL dose given for subcutaneous vaccinations. 
They were not significantly less than the required dosage. 
 
5.3.1.1  Humoral and cell mediated responses 
The sera collected at necropsy was analysed for the presence of IgY humoral responses specific to 
both the alpha toxin and the STM1 vector in all chickens. All orally and subcutaneously vaccinated 
groups showed humoral IgY responses above the background levels of the prevaccination sera 
including the pMOhly1/STM1 vaccinated control group (Figure 5.1). The highest IgY alpha-toxin-
specific immune response was obtained from the subcutaneously vaccinated pMOInv and this 
was a significant increase (p<0.05) when compared to the pMOhly1/STM1 vaccinated control 
group. The lowest IgY response from the subcutaneously vaccinated chickens was the 
pMOhly1/STM1 vaccinated control group. For the orally vaccinated groups there were no 
significant differences between any of the groups or with the pMOhly1/STM1 control group. 
 
The presence of IgY humoral responses specific to STM1 was also determined (Figure 5.2). The 
highest IgY STM1-specific immune response was obtained from the subcutaneously vaccinated  
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Figure 5.1: Anti-alpha toxin IgY humoral responses detected after three vaccinations via two 
different routes.  
The pMOInv/STM1 induced humoral responses at a significantly higher level via the subcutaneous 
route (denoted by *) compared to the control construct of pMOhly1/STM1. 
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Figure 5.2: Anti-STM1 IgY humoral responses detected after 3 vaccinations via two different 
routes.  
All constructs administered via the subcutaneous route induced a significantly higher humoral 
response than their oral counterpart (denoted by *). 
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chickens in the pMOhly1/STM1 vaccinated control group. All of the subcutaneously vaccinated 
groups demonstrated significantly higher (p<0.05) IgY STM1-specific immune responses than their 
orally vaccinated equivalent group. However, the IgY STM1-specific immune responses from the 
pMOInv/STM1 and pCRplc2/STM1 vaccinated groups were not above control levels. None of the 
orally vaccinated chickens showed IgY STM1-specific immune responses above the level observed 
in pMOhly1 vaccinated chickens.  
 
Faecal IgA responses were determined against both the alpha toxin (Figure 5.3) and the STM1 
vector (Figure 5.4). The alpha-toxin-specific IgA responses were below control level for the 
subcutaneously vaccinated groups with the exception of the pCRplc2/STM1 vaccinated group. 
This group had a significant increase (p<0.05) compared to the other test groups and the 
pMOhly1/STM1 vaccinated control group. The orally vaccinated test groups all had significant 
increased responses (p<0.05) when compared to the pMOhly1/STM1 vaccinated control group. 
The highest alpha-toxin-specific IgA responses occurred in the pMO104/STM1 groups and this 
was a significant increase when compared to the other test groups and the pMOhly1/STM1 
vaccinated control group.  
 
STM1-specific IgA responses were determined to be significantly higher in the orally vaccinated 
groups than the subcutaneously vaccinated equivalent which were below background level and 
showed no significant differences between the groups (p>0.05) (Figure 5.4). The highest STM1 
specific IgA response was from the pMO104/STM1 orally vaccinated group and this was 
significantly higher (p<0.05) than in the pMNInv/STM1, pMOInv/STM1 and pCRplc2/STM1 
vaccinated groups. When compared to the pMOhly1/STM1 vaccinated control group, all orally 
vaccinated test groups IgA responses were significantly higher (p<0.05). 
  
CHAPTER 5
 
~ 173 ~ 
 
 
 
 
 
 
Figure 5.3: Anti-alpha toxin IgA humoral responses detected after 3 vaccinations via two different 
routes.  
A significant increase in IgA responses compared to the control was observed by all constructs 
delivered by oral vaccinations and pCRplc2 via the subcutaneous route (p<0.05, denoted by *). 
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Figure 5.4: Anti-STM1 IgA humoral responses detected after 3 vaccinations via two different 
routes.  
All constructs delivered orally demonstrated significant increase in the IgA response when 
compared to the control (p<0.05, denoted by *). 
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Cell mediated responses were measured by the production of IFNγ by splenocytes in response to 
stimulation by alpha toxin and BSA as a negative control (Figure 5.5). Orally and subcutaneously 
delivered pMO104/STM1 induced a significantly higher IFNγ level than the counterpart pMOhly1 
controls (p<0.05).  Of the subcutaneously delivered groups the highest IFNγ response was 
induced by from the pCRplc2/STM1 vaccine. There was no difference in the induced IFNγ 
responses between the pMNInv/STM1 and pMOInv/STM1 vaccines and the pMOhly1 control 
delivered by either the oral or subcutaneous routes.  
 
5.3.1.2  Presence of constructs and vector strain from tissue samples 
The presence of the vaccine constructs and strains was determined at necropsy from the ceca, 
cloaca, liver and spleen (Table 5.1). This part of the study reports on the number of chickens 
whose particular organs contain STM1 with construct and also the number without the construct. 
This indicates how successfully the construct is retained and delivered by STM1 in organs where 
virulent wild-type Salmonella upon infection would invade. Recovery of STM1 could not be 
determined for some samples due to the presence of other bacterial and fungal species in the 
samples (particularly the cloacal swabs) which outgrew the STM1 on the plates. For the ceca, all 
vaccine constructs from both vaccination routes were able to be detected, the lowest being 7/8 in 
the subcutaneous pMO104/STM1 group. The vaccine strain alone without construct was also 
isolated although not to the same degree with the lowest being 2/8 chickens that were orally 
vaccinated with pMOhly1/STM1, and the highest being 6/7 orally vaccinated chicken with 
pMO104/STM1. This suggests that there is good persistence of the constructs when the STM1 
disseminates to the organs. 
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Figure 5.5: Induced IFN-γ from vaccinations with STM1 carrying alpha toxin construct.  
For oral delivered vaccines, pMO104 demonstrated a significant increase compared to the control 
group (p<0.05, denoted by *). In terms of subcutaneous delivery, the pCRplc2 construct 
significantly induced a higher IFN-γ response than the control group (p<0.05, denoted by *). 
Negative control splenocytes were stimulated with BSA as an unrelated protein control with 
minimal IFN-γ induced. 
 
 
* 
* 
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Table 5.1: Recovery of vaccine constructs and vaccine strain alone from individual chickens in each vaccination group.  
 
 CECA  CLOACA  LIVER  SPLEEN  
 Construct 
with STM1 
STM1 alone  Construct 
with STM1 
STM1 alone  Construct 
with STM1 
STM1 alone  Construct 
with STM1 
STM1 alone  
Oral Vaccination 
            
 pMO104/STM1a 7/7 6/7  6/7 7/7  2/7 3/7  5/7 6/7  
 pMNInv/STM1 8/8 4/8  8/8 6/8  3/8 4/8  4/8 5/8  
 pMOInv/STM1 8/8 2/8  8/8 4/8  3/8 5/8  5/8 3/8  
 pCRplc2/STM1 8/8 4/8  8/8 7/8  3/8 5/8  6/8 7/8  
 pMOhly1/STM1 8/8 2/8  8/8 4/8  4/8 5/8  4/8 5/8  
             
Subcutaneous Vaccination 
           
 pMO104/STM1 7/8 2/8  7/8 3/4b  4/8 5/8  2/8 3/8  
 pMNInv/STM1 8/8 5/8  6/7b 4/5b  4/8 4/8  3/8 5/8  
 pMOInv/STM1 8/8 5/8  6/7b 6/8  3/8 3/8  4/8 2/8  
 pCRplc2/STM1 8/8 5/8  7/8 6/6b  3/8 4/7b  6/8 6/8  
 pMOhly1/STM1 8/8 3/8  7/7b 3/7b  0/8 0/8  0/8 0/8  
             
 
a One chicken died during acclimatisation of a congenital defect prior to the commencement of the vaccinations. 
b Recovery of STM1 could not be determined in some chickens (see Section 5.2.1.2) 
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From the cloacal swabs, the majority of the orally vaccinated chickens showed the presence of 
both the construct and the vector strain with the exception of the pMO104/STM1 group (6/7). 
The vector strain without the construct was recovered in lower numbers with the lowest being 
the pMOhly1 group (4/8). For the subcutaneously vaccinated groups, the recovery was still high 
with the construct and vector strain not dropping below half of the chickens in the group (lowest 
– 6/7, pMNInv/STM1 and pMOInv/STM1 groups).  For the vector strain alone, the lowest recovery 
was 3/7 for the pMOhly1/STM1 group with the other groups remaining above three quarters of 
the individuals were positive for the vector strain. Again this indicated that the vector strain with 
plasmid is more prudent that the vector which has lost the plasmid.  
 
The liver samples demonstrated some variation in the recovery rates. For the oral groups, the 
highest recovery of the construct was 4/8 in the pMOhly1 group and the lowest in the pMO104 
group (2/7). For the vector strain alone, most groups were at 5/8 with the lowest being pMO104 
group (3/7). In the subcutaneous groups, neither the pMOhly1 control construct nor the vector 
strain was isolated from any chicken livers. The highest recovery was of the vector strain in the 
pMO104 group (5/8) then the recovery of pMO104 and pMNInv constructs at 4/8 for both 
groups. 
 
Recovery of the constructs from the spleen was still relatively high with the highest at 6/8 for 
pCRplc2 in both the orally and subcutaneous vaccinated groups, and the lowest was 4/8 for the 
pMNInv and pMOhly1 groups. Even the recovery of the vector alone was 7/8 and 6/8 for the 
pCRplc2 for the oral and subcutaneously groups, respectively and the lowest at 3/8 for pMOInv 
group for the oral group. Once again the pMOhly1 construct with vector strain and the vector 
strain alone could not be isolated from any of the spleen samples in the subcutaneous vaccinated 
group.   
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5.3.2 Immunogenicity trial using chickens colonised with S. Sofia prior to 
vaccination 
Samples of blood were collected prior to colonisation with S. Sofia to ensure that the chickens 
were immunologically naive to Salmonella at hatching and were not exposed by in ovo 
transmission. All prevaccination sera and faecal samples were negative (below background level) 
for the presence of Salmonella specific humoral responses. Vaccination doses were confirmed by 
retrospective plate count and none were found to be over the 108 CFU in the volume of 1 mL 
given for oral vaccinations and were not significantly less than the required dose.  
 
5.3.2.1  Recovery of S. Sofia from faeces after colonisation 
S. Sofia colonies were not recovered over the five day period from the faecal samples of the 
chickens that were not inoculated. All of the chickens that were colonised showed slight signs of 
salmonellosis in the first two days with their faecal matter having a more watery appearance and 
consistency than prior to colonisation. However, normal feeding behaviour and activity was 
observed from all subjects after inoculation. The highest level of faecal S. Sofia recovered was at 
24 h post-inoculation at 1.32x108 CFU/g with the lowest being on the fifth day (120 h) post-
inoculation at 1.24x108 CFU/g.  
 
5.3.2.2  Humoral and cell mediated responses to vaccination  
The sera collected at necropsy was analysed for the presence of IgY humoral responses specific to 
both the alpha toxin and the STM1 vector in all chickens. The IgY responses specific against alpha 
toxin did not register higher than the pMOhly1 control level for either the colonised or non-
colonised groups (Figure 5.6). Each of the vaccine groups elicited an IgY response against STM1 
higher than the prevaccination control level in chickens that were not colonised with  
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Figure 5.6: IgY responses induced in chickens specific to alpha toxin detected after two 
vaccinations at Days 12 and 26.  
Responses measured were not significantly above control pMOhly1 levels.  
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S. Sofia prior to vaccination (Figure 5.7). The groups that were colonised prior to vaccination had 
significantly increased IgY responses to STM1 (p<0.05). The responses elicited from the two 
vaccines pMO104/STM1 and pCRplc2/STM1 were not significantly different (p>0.05) when 
compared to each other, as expected. 
 
Faecal IgA responses were also determined against alpha toxin and STM1. Specific IgA responses 
to alpha toxin were elicited by both vaccines (Figure 5.8). The pMO104 group did not significantly 
vary between the colonised and the non-colonised groups (p>0.05). For the pCRplc2 vaccine there 
was a significant decrease (p<0.05) in the colonised group compared to the non-colonised group. 
The STM1 specific responses from the pMO104 construct was significantly increased (p<0.05) in 
the colonised group compared to the non-colonised group (Figure 5.9). The pCRplc2 construct 
elicited a significantly lower IgA response in the colonised group (p<0.05) compared to the non-
colonised group.  
 
Cell mediated responses were measured by the production of IFN-γ by splenocytes in response to 
stimulation by alpha toxin and BSA as a negative control (Figure 5.10). The levels of chicken IFN-γ 
were significantly different for each construct used between the colonisation and non-
colonisation groups (p<0.05). The construct pMO104 induced a significantly lower level of IFN-γ 
when the chickens were colonised with S. Sofia (297 pg/mL; non-colonised at 421 pg/mL) whilst 
the pCRplc2 construct induced a significantly higher level of IFN-γ in the colonised group (417 
pg/mL; non-colonised 269 pg/mL). The pMOhly1 control group demonstrated a significantly lower 
level of IFN-γ when the chickens were colonised with S. Sofia however this is not antigen-specific 
(207 pg/mL; non-colonised 660 pg/mL). 
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Figure 5.7: IgY responses induced in chickens specific to STM1 detected after two vaccinations at 
Days 12 and 26.  
Significant differences were observed for the groups colonised with S. Sofia (p<0.05, denoted  
by *). 
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Figure 5.8: Faecal IgA responses specific to alpha toxin after two vaccinations at Days 12 and 26. 
The pCRplc2 group showed a significant decrease in the colonised chickens (p<0.05, denoted  
by *).  
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Figure 5.9: Faecal IgA responses to STM1 after two vaccinations at Days 12 and 26.  
The pMO104 group both showed a significant increase in responses when colonised with S. Sofia 
(p<0.05, denoted by *). The pCRplc2 group showed a significant decrease in IgA responses when 
colonised (p<0.05, denoted by *). 
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Figure 5.10: Cell-mediated responses as deduced by chicken IFN-γ production.  
Each group is significantly (p<0.05) different from its colonisation counterpart (denoted by *), 
with reduction for the pMO104 construct and an increase for the pCRplc2 group. Negative control 
splenocytes were stimulated with BSA as an unrelated protein control with only 15 pg/mL IFN-γ 
induced which is below the recommended limits of the assay. 
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5.3.2.3  Recovery of constructs, vector strain and S. Sofia from tissue samples 
Recovery of the vaccine constructs with and without the vector strain and S. Sofia was 
determined at necropsy from the ceca, cloaca, liver and spleen (Table 5.2). Chickens that were 
not inoculated with S. Sofia before vaccination were negative for S. Sofia strain in organs or 
tissues samples at necropsy. This was despite all groups being housed in the same room (but in 
separate pens). The colonisation strain S. Sofia was isolated overall from all colonised chickens 
most frequently from the spleens (73.33%, 11/15), then the livers (66.67%, 10/15), followed by 
the cloacal swabs (46.67%, 7/15), and the least in the ceca (27%, 4/15).  
 
The ceca had relatively high recovery rates for the constructs for all three vaccines in the non-
colonised groups: pMO104 – 3/5, pCRplc2 – 3/5 and pMOhly1 – 4/5. This was decreased 
significantly (p<0.05) in the S. Sofia colonised groups which had pMO104 vaccination (0/5) but not 
for the pCRplc2 (1/5) and pMOhly1 (2/5) groups. The same trend was observed for the isolation 
of the vector strain alone in the chickens that were colonised: significant decrease (p<0.05) for 
pMO104 group – 1/5, non-colonised 4/5; no significant difference for pCRplc2 – 1/5, non-
colonised 3/5; and pMOhly1 – 2/5, non-colonised 4/5.  
 
The constructs were isolated from the cloacal swabs from all non-colonised groups with the 
pMOhly1 group being identical (2/5, colonised: 2/5) and no significant difference for the pCRplc2 
group (2/5, colonised: 4/5). There was a significant reduction for the pMO104 vaccinated group 
(p<0.05) in isolation from 3/5 of the non-colonised group versus 0/5 of the colonised group. For 
the isolation of the STM1 vector strain alone, there was a significant decline in the isolation from 
the colonised chickens (p<0.05). The biggest significant difference in the cloacal swabs was in the 
pMO104 group which was 3/5 for the non-colonised group compared to the colonised group at 
no isolations (0/5).  Similarly, for both the pCRplc2 and pMOhly1 groups 2 out of 5 chickens were 
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Table 5.2: Recovery of vaccine strains and vaccine constructs when the chickens are colonised with S. Sofia. 
 
  
  
Without S. Sofia colonisation  With S. Sofia colonisation 
  
Construct and 
STM1 
STM1 alone S. Sofia  
Construct and 
STM1 
STM1 alone S. Sofia 
Ceca         
 pMO104/STM1  3/5 4/5 0/5  0/5 1/5 3/5 
 pCRplc2/STM1  3/5 3/5 0/5  1/5 1/5 1/5 
 pMOhly1/STM1  4/5 4/5 0/5  2/5 2/5 0/5 
        
         
Cloaca        
 pMO104/STM1  3/5 3/5 0/5  0/5 0/5 2/5 
 pCRplc2/STM1  2/5 2/5 0/5  4/5 0/5 3/5 
 pMOhly1/STM1  2/5 3/5 0/5  2/5 0/5 2/5 
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Table 5.2 continued: Recovery of vaccine strains and vaccine constructs when the chickens are colonised with S. Sofia. 
 
 
  
Without S. Sofia colonisation  With S. Sofia colonisation 
  
Construct and 
STM1 
STM1 alone S. Sofia  
Construct and 
STM1 
STM1 alone S. Sofia 
Liver         
 pMO104/STM1  5/5 5/5 0/5  1/5 1/5 4/5 
 pCRplc2/STM1  3/5 5/5 0/5  3/5 0/5 4/5 
 pMOhly1/STM1  5/5 5/5 0/5  2/5 2/5 2/5 
         
         
Spleen         
 pMO104/STM1  3/5 3/5 0/5  0/5 0/5 4/5 
 pCRplc2/STM1  5/5 4/5 0/5  3/5 3/5 3/5 
 pMOhly1/STM1  4/5 4/5 0/5  3/5 1/5 4/5 
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positive for the STM1 strain alone when not colonised, but in the colonised groups no chickens 
tested positive (0/5).  
 
In the liver, the constructs were isolated from all chickens with the exception of the pCRplc2 
groups where 3/5 had the construct recovered. In the pCRplc2 group this recovery rate did not 
vary in the colonised group which remained at 3/5. The two other constructs had a significant 
reduction in the recovery in the colonised group (pMO104 – 5/5 versus 1/5; pMOhly1 – 5/5 
versus 2/5). Similarly, this was also observed for the STM1 alone. All the groups had a significant 
decrease (p<0.05): pMO104 – 5/5 versus 1/5; pCRplc2 – 3/5 versus 0/5; and pMOhly1 – 5/5 
versus 2/5. 
 
For the spleen, significant reductions in the isolation of the vaccine constructs in the colonised 
chickens were observed for the pMO104 group (0/5; non-colonised 3/5) and the pCRplc2 group 
(3/5; non-colonised 5/5). The pMOhly1 group had no significant difference in recovery (3/5; non-
colonised 3/5). Isolation of the STM1 vaccine strain was significantly reduced in the pMO104 
group (0/5; non-colonised 3/5) and the pMOhly1 group (1/5; non-colonised 4/5). The pCRplc2 
group had 4/5 isolations from the non-colonised chickens and 3/5 from the colonised chickens.  
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5.4 Discussion 
5.4.1 Immunogenicity trial via subcutaneous and oral vaccination routes  
Four vaccine constructs, pMO104, pMNInv, pMOInv and pCRplc2 were tested for immunogenicity 
in chickens using STM1 as a vector delivery strain via two different vaccination routes, oral and 
subcutaneous. In the following discussion, STM1 is left out of the vaccine nomenclature for 
brevity. The delivery of the hemolysin system was also being compared to a cytoplasm 
accumulation vector, pCRplc2 vaccine construct, where the plc2 was expressed into the 
cytoplasm unlike the hemolysin constructs which expressed extracellularly. Prior to any 
vaccination, the chickens were confirmed to be immunologically naive to Salmonella which 
confirmed that the source of our chickens had effective measures in place to prevent Salmonella 
colonisation and in ovo transmission. After three vaccinations via the two routes of delivery each 
of the vaccine constructs induced differing levels of responses for both humoral and cell 
mediated.  
 
For IgY humoral responses specific to the alpha toxin all groups showed responses. As previously 
discussed in Section 4.3, humoral immune responses were detected in mice vaccinated with the 
control pMOhly1 that reacted with alpha toxin in the immunoglobulin ELISAs. These responses 
were considered to be either cross-reactive or non-specific by standard ELISA method. The same 
trend was observed in both chicken immunogenicity trials for the humoral responses; however 
the use of BSA in the chicken IFN-γ assays (Figure 5.5 and 5.10) as a negative control 
demonstrated that these responses in the pMOhly1 control chickens are most likely 
 cross-reactive with alpha toxin, as splenocytes were not induced to produce IFN-γ in the 
presence of BSA. 
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The vaccine construct pMOInv delivered by the subcutaneous route elicited significantly higher 
IgY responses (p<0.05) in an alpha toxin ELISA than the other groups and was the highest elicited 
response of either vaccination routes (Figure 5.1). The pMOInv vaccine construct did not have the 
highest expression in the STM1 vector (Figure 4.9) so it was not expected to produce the highest 
elicited IgY response. However, it did appear to have complete cleavage of the hemolysin signal 
peptides which may have contributed to its immunogenicity by revealing more epitopes. The 
other construct of pMO104 which also had complete cleavage but was not expressed to the same 
degree, but it also induced moderate responses in both the oral and subcutaneous groups. This 
indicates that although the expression was not as high as the other constructs the plc104 
construct is a strong immunogen even though it was only the C-terminus of the full length toxin.  
 
The IgY responses against alpha toxin (Figure 5.1) were similar for both vaccination routes which 
indicate that the use of oral vaccination in the poultry industry is effective at eliciting the same 
magnitude of humoral responses as a subcutaneous vaccination. However, for STM1 specific IgY 
responses (Figure 5.2) the subcutaneous route was significantly higher (p<0.05) than the oral 
route for all vaccinated groups. This is to be expected as the subcutaneous route is more effective 
at eliciting systemic humoral and cell mediated responses (Muir et al., 2000). The oral route is not 
as effective at eliciting IgY responses but can elicit strong IgA mucosal responses which may be 
sufficient to protect against pathogens at the site of entry, in this case the intestinal tract.   
 
The IgA responses specific to alpha toxin (Figure 5.3) were significantly higher for each of the 
orally delivered vaccine constructs compared to the subcutaneous groups. The highest response 
was from pMO104 demonstrating that the carboxyl terminus of the alpha toxin was being 
successfully delivered to the MALT and eliciting a strong IgA response despite the expression not 
being lower than the other two vaccine constructs (Figure 4.9). The IgA response elicited from the 
subcutaneously delivered pCRplc2 was inconsistent with the expectations of this vaccination 
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route as subcutaneous delivery has no direct contact with the mucosal surfaces; however, this 
effect has been reported previously in chickens (Widders et al., 1996; Muir et al., 2000). The 
STM1-specific IgA elicited by the oral vaccinations were substantially higher (p<0.05) than that of 
the subcutaneously vaccinated groups which can be attributed to the higher magnitude of 
exposure of the GALT.  
 
Cell mediated responses were measured by the induction of IFN-γ by splenocytes in the presence 
of alpha toxin (Figure 5.5). The most consistent result for both the oral and the subcutaneous 
routes was obtained from the pMO104 vaccinated group which were 217.24 pg/mL and 223 
pg/mL respectively. Both of these were significantly higher (p<0.05) than their respective control 
groups. The pCRplc2 orally vaccinated group induced the highest response; however the oral 
group was the lowest of the vaccinated groups. The recovery of both of these constructs from the 
spleens of the chickens also showed that they were processed by the chickens’ lymphoid tissue 
and were colonising the chickens at a substantial level in the cloaca and ceca to induce both 
humoral and cell mediated immune responses.  
 
Whilst the humoral responses in the mouse trials (Chapter 4) were clearly cross-reactive between 
a native STM1 protein and the alpha toxin variants, in the chicken trials there are instances where 
the level of non-specificity has subsided. For example, there are non-specific responses in the 
case of IgY (Figure 5.1 and 5.2) but in the case of IgA (Figure 5.3 and 5.4) there appears to be 
more specific responses to both alpha toxin and STM1. Due to this inconsistency, the responses 
measured in this chicken trial are not considered to be definitive indications of specific responses. 
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The two vaccine constructs of pMO104 and pCRplc2 were chosen to be tested in a chicken model 
where the chickens were colonised with S. Sofia prior to vaccination. The two constructs of 
pMOInv and pMNInv were not examined in this trial. The vaccine construct pMO104 was chosen 
as it gave consistent humoral responses and a good IFN-γ response compared to the control 
groups (p<0.05). The pCRplc2 vaccine was chosen as it could induce significantly high levels of 
IFN-γ in the chickens demonstrating strong immunogenicity and a potential for stronger cell 
mediated responses if up-regulation occurred. An effect of either up-regulation or down-
regulation of the specific immune responses, either humoral or cell mediated, should be 
determined with these two vaccine constructs.  
 
5.4.2 Immunogenicity trial using chickens colonised with S. Sofia prior to 
vaccination 
Colonisation with S. Sofia was easily achieved and demonstrated no long term effects besides 
minor short term diarrheal signs in the litter. The colonisation levels remained relatively high and 
stable over the period of five days post-inoculation with it not dropping below 108 CFU/g. This 
shows how successful S. Sofia is at colonising a naive chicken and contaminating the environment 
through the high levels of S. Sofia shed in the faecal matter.  
 
Alpha toxin specific IgY in both the colonised and non-colonised groups (Figure 5.6) did not rise 
above background levels which was unlike the previous trial (Figure 5.1) which showed a higher 
magnitude humoral response. The cause of this is unknown but does show that oral vaccinations 
can be inconsistent for induction of humoral IgY responses. However this may be compensated by 
the higher level of IgA induced as IgA-mediated phagocytosis of Salmonella would occur much 
faster and prevent adhesion and invasion of the tissues.  
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The elicited IgY responses against STM1 (Figure 5.7) significantly increased in the presence of 
colonisation for both of the vaccine constructs, pMO104 and pCRplc2 and the pMOhly1 control 
(p<0.05). The responses measured for the constructs and the control were almost the same 
magnitude despite there being two different vaccine constructs being delivered by STM1. This 
indicates that the delivery method of the heterologous antigen is not contributing to the overall 
immunogenicity of the STM1 although it may diminish slightly compared to the pMOhly1. Once 
STM1 is sampled by APC in the GALT and T helper cells are activated, IgY will be generated with a 
higher magnitude than in chickens that are not colonised by S. Sofia. This up-regulation of the 
serum IgY is the prime-boost response that some vaccines rely on to generate lifelong immunity. 
The colonisation of chickens by S. Sofia at a young age is priming the immune system for a higher 
magnitude and avidity response which is shown by the increased response of IgY when the 
chickens are subsequently exposed to STM1. These induced IgY responses are cross-reactive 
against both strains of Salmonella. 
 
For an intestinal pathogen like Salmonella, the production of IgA can greatly assist in preventing 
colonisation and infection as shown in studies with heterologous-delivered Campylobacter jejuni 
antigens by Salmonella (Wyszynska et al., 2004; Buckley et al., 2010), hence why heterologous 
antigen delivery to the GALT and MALT is of great importance. For this study it was shown that 
prior colonisation can directly modulate the induced faecal IgA response against a heterologous 
antigen from a similar vector strain as the colonising serovar. The faecal IgA response specific to 
alpha toxin in the colonised group was significantly decreased (p<0.05) for the vaccine construct 
pCRplc2 (Figure 5.8). As this vaccine construct accumulates in the cytoplasm and is released upon 
lysis, a more rapid and effective clearance of the vaccine would account for the reduction in 
faecal IgA response to alpha toxin, as there would be less accumulation at the time of 
phagocytosis. No significant difference in the specific-alpha toxin IgA responses was observed in 
the pMO104 colonised group compared to the non-colonised group. This indicates that the 
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extracellular expression of this heterologous antigen and recognition by the chickens’ immune 
system is not affected by prior colonisation by a similar vector strain.  
 
The IgA responses to the vector strain showed a similar outcome for the pCRplc2 group (Figure 
5.9). Again the IgA responses specific to STM1 was significantly (p<0.05) down-regulated in the 
pCRplc2 vaccinated group that was colonised. The elicited IgA response specific to STM1 was up-
regulated in pMO104 vaccinated group that was colonised, as well as the pMOhly1 control group. 
The increase in the response for both the pMO104 construct and pMOhly1 control constructs can 
be attributed again to the prime-boost effect that is an established outcome of exposing the 
immune system to the same immunogen multiple times and getting a higher magnitude response 
on the second exposure. However the pCRplc2 vaccine construct did not exhibit this effect in the 
colonised chickens.   
 
Cell mediated responses as indicated by the expression of IFN-γ did change with the presence of 
colonisation. The IFN-γ induced from the splenocytes of colonised chickens was significantly 
decreased for the pMO104 and pMOhly1 vaccinated groups (p<0.05) but significantly increased in 
the pCRplc2 group (p<0.05). This suggests that the expression system for the heterologous 
expression does affect what immune responses are elicited. Extracellularly expressed plc104 from 
the pMO104 vaccine construct induced higher IgA but less IFN-γ whilst cytoplasm accumulated 
plc2 from the pCRplc2 vaccine construct had a decreased IgA response but an increased IFN-γ 
response. The effectiveness of the immune responses induced by both of these vaccine 
constructs would have to be tested in a challenge trial in order to demonstrate how protective 
they are; however as discussed previously necrotic enteritis models are extremely difficult to 
replicate in laboratory settings as the full disease pathology has not been elucidated.  
 
CHAPTER 5
 
~ 196 ~ 
 
Recovery of vaccine constructs (Table 6.2) was successful from all of the organs but the most 
dramatic reductions were observed in the ceca of the colonised chickens. Once the chickens were 
colonised with S. Sofia the presence of the vaccine, both construct and vector strain alone, were 
unrecoverable in the ceca. This could be accredited to an invasion-inhibition effect by S. Sofia 
against the STM1 vector strain. This effect has only recently been described where homologous 
and heterologous strains can result in a lower influx of phagocytes to the caecal tissue and 
completely prevent invasion during a secondary exposure of a related Salmonella strain (Methner 
et al., 2010).   In the liver and spleen, there were also reductions but not to the same degree as in 
the ceca. The importance of the spleen has been discussed previously and the presence of S. Sofia 
in the spleens of the majority of the chickens shows that although the strain does not cause 
disease, the level at which it colonised the tissue is quite high.  
 
This study has shown that whilst the presence of a related strain of Salmonella serovar can have 
an effect on the magnitude of humoral and cell mediated responses, delivery of the heterologous 
antigen to the host system is more important.  As shown by the two contrasting vaccine 
constructs, when the antigen is delivered extracellularly there is no modulation of the IgA 
response but a down-regulation of cell mediated responses and the opposite is true if the antigen 
is accumulated in the cytoplasm of the vector strain. The effectiveness of these different response 
profiles would need to be tested in a necrotic enteritis model to assess if they are protective 
against the ongoing exposure to low levels of C. perfringens; however as those models are 
difficult to maintain and reproduce perhaps alternative animal models should be investigated.  
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CONCLUDING REMARKS 
 
Necrotic enteritis is a subtle but devastating disease in the global poultry industry (Parish, 1961; 
Al-Sheikhly and Truscott, 1977; Songer, 1996; Kaldhusdal et al., 1999). The success rate of 
antimicrobials in affected flocks has been debatable with antimicrobial resistance observed in 
some countries (Gharaibeh et al., 2010) but alternative treatments such as competitive exclusion 
and probiotics feed products to promote balanced intestinal health have been only partially 
successful in field trials (Hofacre et al., 2003; Thanissery et al., 2010). The development of an 
efficacious vaccine to protect against the onset of necrotic enteritis would improve the husbandry 
of poultry and increase the productivity of poultry farms (Kaldhusdal and Lovland, 2000; Lovland 
and Kaldhusdal, 2001). 
 
This study focused on using variants of the alpha toxin delivered by attenuated Salmonella 
vectors to elicit immune responses that would be protective against a related clostridial disease in 
mice, gas gangrene and necrotic enteritis in broiler chickens which is the most commonly affected 
species in poultry (Lovland and Kaldhusdal, 2001). When used as a subunit vaccine against gas 
gangrene in mice all recombinant protein variants elicited immune responses; however the plc2 
variant was the only protein vaccine to significantly delay the onset of gas gangrene. Both the 
plc104 and plcInv proteins elicited detectable humoral responses, however these were not 
protective.  
 
Incorporation of the two deletion variants of plc104 and plcInv into a hemolysin expression 
system using the pMOhly1 vector was successful and expression was demonstrated. It was 
unfortunate that the plc2 variant could not be ligated into this system as this variant showed the 
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most potential from the gas gangrene challenge trial. This outcome is probably caused by over-
expression of the hemolysin operon causing either a high metabolic load for the host organism to 
sustain or excessive pore formation by the interaction of HlyD with Tol-C receptors during 
expression leading to cell death (Thanabalu et al., 1998; Balakrishnan et al., 2001). This could be 
examined further by introducing mutations into the HlyD gene to reduce the number of pores 
formed or into the other genes to reduce the level of expression. This has been successfully done 
to the HlyB gene to increase expression levels (Low et al., 2010), so a reduction in expression 
could theoretically be achieved. It has also been reported that expression levels of heterologous 
antigen from Salmonella vectored vaccines do not affect the magnitude and diversity of immune 
response levels generated by the expressed heterologous antigen (Pathangey et al., 2009) so 
decreasing the expression efficiency of the hemolysin operon will not decrease its effectiveness 
as a vaccine. Alternatively, inducible promoters could be used, as done by Saxena and colleagues 
(2009). 
 
The inability to generate protective responses in mice against gas gangrene does not necessarily 
mean there will not be efficacy against necrotic enteritis, as the diseases are quite different in 
both their pathology and progression. In particular, the conditions that lead to the establishment 
of necrotic enteritis are not fully elucidated, and therefore the required array of immune 
responses needed to target the disease may be more complex that for gas gangrene, where 
neutralising antibody is proposed to be the effector mechanism. Alpha toxin is a protective 
antigen for gas gangrene and it has not been elucidated yet if there is a sole protective antigen for 
necrotic enteritis. Although alpha toxin was a good candidate for over twenty years, the 
variability of the literature regarding its role in necrotic enteritis indicates that a multifaceted 
approach to vaccination is required, including targeting strong T cell responses to selected 
antigens. 
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The chicken immunogenicity trial demonstrates that delivery by the STM1 vector is targeted to 
the MALT and GALT as shown by the IgA responses achieved (Figures 5.3) which could be 
protective against intestinal invasion by C. perfringens. Cell mediated responses were also 
generated by the pMO104 and pCRplc2 that were significantly higher than the pMOhly1 control 
(Figure 5.5) suggesting that with the right variant both strong humoral and cell mediated 
responses can be generated. STM1 was successful at delivering the construct not only to the 
gastrointestinal tract but to the spleen, ceca, cloaca and liver in the chickens confirming that this 
attenuated bacterial vector is an excellent delivery option for heterologous antigens.  
 
Pre-existing immunity is a burgeoning issue for veterinary and medical vaccine development and 
unfortunately it affects all bacterial and viral vectors. The prevalence of avirulent S. Sofia was 
observed rising from approximately 5% in the chicken population in 1980 (Harrington et al., 1991) 
to currently 51% (Mellor et al., 2010) which reveals that as the levels are increasing over time a 
larger number of chickens will be exposed. The recovery of S. Sofia from the organs was much 
higher than anticipated considering that it is deemed to be an avirulent commensal. However 
others have found that similarly avirulent Salmonella species can also be recovered from organs 
(Desin et al., 2009; Wisner et al., 2010). The down-regulation of the cell mediated responses for 
the extracellularly expressed construct and up-regulation for the cytoplasmic-accumulated 
construct without modulation of the IgA responses implies that early detection of S. Sofia in 
commercial flocks is critical. If the cell mediated responses are down-regulated resulting in failure 
of the vaccine this leads to higher production costs and waste of the flock as they will be 
condemned at slaughter if infected with a human pathogen. Early detection and education of 
commercial farmers to the implication of pre-existing immunity will lead to more efficacious 
vaccine usage in poultry.  
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In conclusion, the responses generated by the alpha toxin variants delivered by STM1 were not 
protective in mice against gas gangrene and did not elicit high specific responses in chickens. This 
failure does not preclude the use of the hemolysin system as a heterologous delivery system in 
Salmonella vectors. This system is particularly appropriate for any gastrointestinal pathogens as 
targeted delivery was achieved with the high levels of IgA detected in the trials. Even though the 
responses were cross-reactive, there were significant differences which suggest that further 
examination is required. For this to occur, a consistent and reproducible necrotic enteritis model 
would have to be used to establish if the responses are protective, and consideration should be 
made for the inclusion of antigens other than, or in addition to, alpha toxin. 
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Appendix 1 
Lambda DNA digested with PstI run on a 1.5% agarose gel.  
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Appendix 2 
SeeBlue Plus2 protein standard marker by Invitrogen, Australia 
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